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1. Introduction 
The complement system has been shown to have a role in various systemic 
autoimmune (AI) diseases which have a renal component. This includes systemic 
lupus erythematosus (SLE), goodpastures syndrome and anti-neutrophil 
cytoplasmic antibody (ANCA) associated vasculitides. In particular the classical 
pathway (CP) of complement is involved in SLE, with the exact mechanism 
of how these SLE autoantigens along with their autoantibodies interact with 
complement in the glomerulus remaining ambiguous. Furthermore, recent 
studies have demonstrated the expanding role of the alternative pathway (AP) 
of complement activation in steady state or in aspects of ANCA associated 
vasculitides or anti-GBM disease. The precise means of activation of the AP in 
these immune complex mediated disease settings remains unclear. Regulation 
is imperative in the AP due to its inherent ability to autoactivate. Factor H and 
properdin are both key opposing regulators in the AP with novel emerging roles in 
initiation and control of the AP. Deciphering the specific modes of AP activation 
and involvement is an ever expanding field requiring further elucidation, with 
previously unexpected roles for AP components revealing the diversity and 
complexity of this ancient pathway.       
   
1.1 The Complement system
The complement system has long been viewed as a key member of innate 
immunity. Its biological activities range from defense against pathogens, 
regulation of self-tolerance and shaping of the adaptive immune response (1-4). 
The complement system consists of approximately thirty soluble and membrane 
proteins which are mainly produced in the liver along with white blood cells acting 
as an extrahepatic source. The system is divided into three pathways based on 
their mode of recognition, activation and regulation, the classical pathway (CP), 
lectin pathway (LP) and alternative pathway (AP). The pathways all converge on 
the central complement component C3 which if activated and deposited can lead 
to assembly of the membrane attack complex (MAC) and resulting lysis of the 
target cell (5)(Figure 1).       
The classical pathway is activated by binding of its recognition molecule C1q 
to various ligands including antigen bound IgM and IgG, acute phase proteins, 
apoptotic or necrotic material. The binding of C1q to its ligand induces a 
conformational change which allows the associated serine protease C1r and C1s 
located on the collagen-like tail region to become activated. The activated C1s 
cleaves C4 and C2 assembling the classical pathway C3 convertase (C4bC2a 
complex). The C3 convertase cleaves C3 into C3b and C3a. The resulting 
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cleavage exposes an internal highly reactive thioester bond which covalently 
links C3b to its target. The bound C3b acts as opsonin while the C3a functions as 
an anaphylotoxin (5-7).  
The lectin pathway is activated in a similar manner to the CP. It can be initiated by 
the recognition of certain carbohydrate ligands by mannan binding lectin (MBL) 
as well as H-ficolin or L-ficolin. MBL can bind mannose residues on pathogens 
leading to activation of MBL associated serine protease (MASP), in a similar 
manner as C1r and C1s activation (8). The MASPs associated with MBL are 
MASP-1, MASP-2 and MASP-3 (9, 10). MASP 2 once activated cleaves C4 and 
C2 generating the C4bC2a complex which is identical to the CP C3 convertase 
(11).
The AP is the oldest phylogenetically of all the complement pathways. The AP is 
unique in that its activation can occur spontaneously or more recently it has been 
proposed that it can be directed in a pattern recognition manner via properdin. 
The pathway comprises of C3, factor B, factor D and properdin. With the 
pathway being capable of activating spontaneously, regulation is key to prevent 
uncontrolled activation on the surface of self. A series of cell surface and fluid 
phase negative regulators are instrumental in controlling the AP (7, 12-14). With 
the alternative pathway being one of the major topics in this thesis it will be 
discussed later in more detail.
Figure 1: Complement system overview
General introduction   •   13
   1
1.2 Complement system and autoimmunity
The complement system is involved in a variety of biological activities. This 
includes the recognition and clearance of foreign pathogen via direct lysis, 
opsonisation and phagocytosis (5, 15, 16). Complement is also involved in the 
removal of self-antigens including immune complexes and apoptotic cells (17). 
In recent times, complement studies have focused on its ability to bridge innate 
and adaptive immunity in either lowering the threshold for B cell activation 
or activating T cells (3, 18). It comes as no surprise that both complement and 
autoimmunity are intimately interweaved which is clearly evident in conditions 
such as ANCA associated vasculitides and SLE. The targeting of the kidney 
in such autoimmune disease may be in part due to its ability to filter 120ml of 
plasma per minute. The complement arm in such autoimmune renal disease could 
be accounted for by complement in circulation along with the production of 
complement components locally in the kidney. Classical pathway (CP) activation 
has always been recognised as a feature of immune complex mediated diseases, 
however there has been an increasing array of data demonstrating a role for the 
alternative pathway (AP) in such systemic disease states (19, 20).    
1.2.1 Systemic lupus erythematosus 
SLE is an incurable systemic autoimmune disease characterised by loss of self-
tolerance. This dysregulation of self-tolerance is exhibited by B cell hyperactivity, 
autoantibody production and immune complex formation (21, 22). The aetiology 
remains largely unknown with genetic, environmental and hormonal factors 
involved (23). SLE can target various organs including skin, central nervous 
system, serosa, joints and kidney (24, 25).                                                                   
A central characteristic of SLE is the breakdown in self-tolerance resulting in 
autoantibody production which targets antigens that are widely expressed. 
These antigens include nuclear components such as DNA, histones and 
ribonucleoproteins with the believed source of autoantigens due to failure in the 
clearance of apoptotic cells, with the nucleosome being the driving autoantigen 
(26-30). Anti-nuclear antibodies are found in the majority of SLE patients with 
anti-dsDNA regarded as being highly specific for the disease (31, 32).                                          
Lupus nephritis (LN) (renal disease found in up to 50% of SLE patients) is a 
major cause of morbidity and mortality for these SLE patients (33, 34). Patients 
with LN experience a rise in anti-dsDNA antibodies and a reduction in serum 
complement levels. Immune complexes become deposited in the glomeruli and 
induce complement activation both of which are involved in the pathogenesis of 
LN (35, 36). Complement is involved in the effector phase of LN in SLE however, 
the complement system can also be the target of autoantibody response (31, 37). 
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Anti-C1q autoantibodies may be predictive of LN flares in SLE patients however 
they can also be found in healthy individuals with no renal pathology (37-40). 
Studies by Trouw et al found that anti-C1q antibodies alone were not sufficient 
to induce full blown renal injury (i.e proteinuria) in-vivo. The work indicated that 
additional triggers were required, with the addition of a sub threshold amount of 
anti-glomerular basement membrane which binds C1q, followed by anti-C1q, 
induced renal injury (41). Intriguingly, further links with complement exist as 
deficiency in C1q and C1r/C1s are associated with increased susceptibility to 
develop SLE (42). Deficiencies in complement are believed to be a prominent 
cause of defective clearance of apoptotic cells leading to the “waste disposal” 
hypothesis becoming a proposed mechanism of disease induction. However, the 
presence of the complement system can lead to activation of the system during 
active SLE which may lead to tissue injury (43). These findings demonstrate the 
paradoxical role of the complement system in this disease setting.
1.2.2 Anti-neutrophil cytoplasmic antibody (ANCA) associated 
vasculitides
ANCA associated vasculitides (AAV) consist of a group of systemic AI diseases 
including granulomatosis with polyangiitis, microscopic polyangiitis, Churg-
Strauss syndrome, “renal-limited” vasculitis and certain drug-induced vasculitis 
syndromes (44). They are characterised by necrotising inflammation of small 
vessel walls frequently targeting the kidneys. ANCA are predominantly used as 
serological markers of small vessel vasculitides, with proteinase 3 (PR3) targeted 
in granulomatosis with polyangiitis or mainly myeloperoxidase (MPO) in the 
remaining AAV (19, 45). In AAV, primed neutrophils express ANCA antigens 
on their cell surface followed by adherence of the neutrophil to susceptible 
endothelium. Following interaction of ANCA antibodies with the exposed 
antigens the neutrophil becomes activated. The activated neutrophil releases 
soluble factors to activate the complement system and damage the endothelium 
resulting in necrotising vasculitis (46). The hypothesised source of these 
autoantigens include TNF primed neutrophils and neutrophil extracellular traps 
(47, 48). 
Recent studies have demonstrated that ANCA activated neutrophils can activate 
the complement system. Neutrophils act as potent source of various complement 
components such as C3, factor B and properdin (49-51). The proteases stored 
within the neutrophil granule have been shown to activate complement C5 
with oxidants demonstrating a similar capability (52-54). Studies by Xiao et al 
illustrated that activation of human neutrophils with ANCA antibodies releases 
factors which can activate complement leading to the generation of C3a (55). 
Further work by Schrieber et al revealed that supernatants from ANCA activated 
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neutrophils activated the complement system in normal serum generating C5a. 
The presence of C5a can prime the neutrophil allowing for ANCA induced 
respiratory burst in the neutrophil, releasing free oxygen radicals and proteases 
(56). 
With various in-vitro data demonstrating the role of complement in the induction 
or effector phase of the disease, the in-vivo studies focused mainly on elucidating 
which complement pathway was involved. A mouse model of the disease using 
anti-MPO IgG demonstrated that C4 deficient mice developed comparable disease 
as to wild type, while factor B or C5 deficient mice were protected from damage, 
indicating a role for the AP (55). Recent studies in the ANCA field demonstrated 
the presence of AP components at the site of injury as well as activation of the AP 
in the circulation of patients with active ANCA vasculitis (57, 58). Cumulatively 
the data illustrates the role of the AP in ANCA vasculitis as well as highlighting 
the varied interactions between various neutrophil components and the AP, which 
will be discussed further in this thesis. 
1.2.3 Anti-glomerular basement membrane (GBM) disease
Anti-GBM disease refers to what was originally called goodpastures syndrome 
or goodpastures disease. Recently, anti-GBM disease has been classified in the 
new nomenclature of immune complex small vessel vasculitides (59). Anti-
GBM disease is an autoimmune disease characterised by the role of B cell and 
T cells in the pathogenesis. HLA-DRB1*1501 and DRB1*1502 are associated 
with the disease however it is also believed to have environmental triggers. It 
is characterised by the presence of autoantibodies targeting typically the non-
collagenous domain of the α3-chain of type IV collagen. The α3-chain of type IV 
collagen is a component of alveolar basement membrane and GBM, which are 
the principle targets in the condition. The autoantigen is a cryptic epitope which 
can be exposed upon oxidant damage. Patients suffering from anti-GBM disease 
would present with anti-GBM autoantibodies with glomerulonephritis and/or 
alveolar bleeding. The anti-GBM autoantibody is integral to the disease based 
on elution studies and transfer to primates (60). With the anti-GBM antibody 
a central characteristic and driving force in the disease it is the focus of many 
murine models of anti-GBM disease. Histopathologically, the glomeruli of 
patients with anti-GBM present with a linear deposition of IgG on the GBM 
generally accompanied by C3 deposition, with recent studies demonstrating the 
extent of complement activation in circulation and urine of patients with anti-
GBM disease, including AP activation (61, 62). In particular a murine model of 
anti-GBM disease, demonstrated a role for the AP, through the ability to induce 
significant disease in C1q and C4 knockout mice (63).
Anti-GBM antibodies are crucial for diagnosis, however approximately 20-35% 
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of patients with anti-GBM antibodies also have ANCA, generally targeting MPO 
(61). This demonstrates the close overlap between both ANCA and anti-GBM, 
both autoantibody mediated diseases with complement and renal components. 
The exact role of the AP in anti-GBM disease remains unclear and continues to 
be an area requiring further elucidation.
  
1.3 Alternative pathway initiation and activation
Activation of the AP can occur to the best of our knowledge by two described 
mechanisms. The traditional model of AP activation involves a process known as 
“tickover”. Tickover describes the ability of fluid phase C3 to undergo spontaneous 
conformational changes to generate C3(H2O) or C3i. This C3(H2O) or “C3b like 
molecule” is formed by interaction of the internal thioester bond with water. This 
“C3b like molecule” has the C3a fragment still attached, however it can associate 
with the inactive serine protease factor B in the presence of Mg2+. The factor B 
attached to C3(H2O) is cleaved by factor D (serine protease) into a Bb fragment 
and a Ba segment. The Ba fragment is released while the Bb fragment remains 
attached to the C3(H2O). The active C3(H2O)Bb complex is then stabilised by 
properdin forming the “initiation C3 convertase”. The stabilised “initiation C3 
convertase” can cleave additional fluid phase C3 into metastable C3b (lacks C3a 
fragment) which can covalently attach to its target surface using its thioester 
bond. The newly formed metastable C3b can in the presence of factor B, Mg2+ 
and factor D assemble the AP C3 convertase (C3bBb) which can be stabilised 
by properdin (Figure 2). This stabilised multimeric complex can generate more 
metastable C3b feeding back into the AP activation (7, 12-14).
Figure 2: C3 initiated alternative pathway activation
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Recently, another method of AP activation has been described termed the 
properdin-directed model. This mechanism is dependent on the pattern recognition 
ability of properdin to initially recognise and bind its target surface. Properdin 
can recognise ligands such as zymosan, bacteria and glycosaminoglycans 
acting as a focal point for complement activation (64, 65). Once properdin has 
bound the target surface it can bind C3b followed by factor B and Mg2+, with 
the inactive factor B cleaved by factor D to form the fully stabilised and active 
AP C3 convertase (C3bBb) as described earlier. Both mechanisms lead to the 
generation of the same AP C3 convertase with the initiation molecules being the 
only variation (64)(Figure 3).
One of the unique features of the AP is the “amplification loop C3 convertase”. 
This loop is initiated when C3b generated from any of the three pathways then 
binds factor B and assembles the AP C3 convertase leading to augmentation of 
C3 activation. The “amplification loop” can play a major role in AP activation in 
particular in settings of local injury where infiltrating cells can act as source of C3 
and properdin or where regulatory mechanisms are impaired or due to a reduction 
in the expression of complement regulators (66-68). The loop can deposit 107 C3b 
molecules on a target in less than five minutes (69). Furthermore, autoantibodies 
termed C3 nephritic factors can stabilise the C3 convertase inhibiting them from 
degradation allowing for propagation of AP activation (70). The ability of the 
AP to become initiated spontaneously allowing for continuous C3 activation 
demonstrates the importance the cell surface and fluid phase regulators play in 
the AP, preventing complement depletion and uncontrolled deposition on host 
cells.
Figure 3: Properdin directed alternative pathway activation
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1.3.1 Alternative pathway regulation
The regulators involved in limiting AP activation can be sub-divided into cell 
surface or fluid phase regulators. The plasma regulators of the AP include factor 
H, factor H-like protein 1 (FHL-1), factor H-related proteins (FHRs) and factor I. 
Factor H is a major fluid phase regulator of the AP including the “amplification 
loop”. Factor H acts as a co-factor for factor I mediated cleavage of C3b and has 
decay accelerating activity for the AP C3 convertase. Furthermore factor H can 
exhibit surface inhibitory effects based on its ability to interact with C3b or sialic 
acid on target surfaces (71). Also FHL-1 can act as a co-factor for factor I while 
FHR members can bind C3 controlling its fate. Factor I is a serine protease with 
proteolytic degrading activity which requires co-factors for cleavage of C3b and 
C4b, which is imperative to controlling the classical and alternative pathway (71, 
72). 
Cell surface regulators: membrane co-factor protein (MCP, CD46) and decay-
accelerating factor (DAF, CD55) are both involved in AP regulation. MCP acts as 
a co-factor for factor I mediated cleavage of C3b and C4b while DAF accelerates 
the decay of the AP and CP C3 and C5 convertase (7). CR1 (CD35) expressed 
on red blood cells functions as a co-factor for factor I mediated cleavage of C3b 
while CD59 inhibits C9 polymerisation and assembly of the membrane attack 
complex (MAC) (73). A novel aspect of the AP is that it contains the only positive 
regulator of the complement system, properdin which promotes complement 
activation. The delicate balance between properdin and the various negative 
regulators of the AP in particular factor H is an integral axis for determining the 
fate of the AP activation.     
1.4 Properdin
Properdin was discovered by Louis Pillemer in 1954 and was the first AP 
component to be found (74). The name properdin originates from the latin word 
perdere “to destroy” which fittingly describes many aspects of this serum protein. 
Properdin is known as the only positive regulator in the complement system. It 
stabilises the short lived AP C3 convertase (C3bBb) by approximately five to ten 
fold (75). Properdin bound more readily C3bB and C3bBb as compared to C3b 
(76).
1.4.1 Genetics
The human properdin gene is located on the short arm of the X chromosome at 
Xp11.23 - Xp11.3 encoding for the thrombospondin repeats (TSR), the basic 
subunit of properdin (77, 78). The properdin gene is composed of ten exons 
encompassing 6kb of the genome. Exon 1 is transcribed however it is not 
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translated with the translation start site located in the second exon. The 49 amino 
acid N-terminal domain is encoded for by exon 3. Exon 4-8 codes for TSR 1-5 
with exon 9 encoding for the initial 38 amino acid of TSR 6 with the remainder 
of TSR 6 encoded for by exon 10, which also encodes for the C-terminal domain 
(79). 
A deficient state does exist in humans, with properdin deficient individuals at 
3000 fold greater risk of meningococcal disease caused by Neisseria meningitides. 
The properdin deficient individuals are generally male as the properdin gene is 
encoded on the X chromosome (77). Properdin deficiency is categorised into 
three subtypes: Type 1 deficiency is the complete absence of properdin in the 
plasma. Type 2 deficiency is categorised as plasma properdin of less than 10% 
of the normal range. Type 3 deficiency presents with normal plasma levels of 
properdin however the protein is aberrant (80).
1.4.2 Structure
Properdin consists of rod like subunits of 53kDa which form head to tail 
associations, forming dimers, trimers, tetramers and the recently described 
pentamers respectively (Figure 4) (81-83). In plasma the approximate ratio of 
dimers: trimers: tetramers is 26:54:20 (82). Properdin function increases with 
size as tetramers are ten times more active compared to dimers (84). Each 53kDa 
subunit consists of seven type 1 thrombospondin repeats (TSR), numbered from 
TSR 0-6 in order from the N-terminus (85). TSR 4 is involved in stabilisation of 
the C3 convertase with TSR 5 involved in binding C3b while TSR 6 is involved 
in the oligomerisation of properdin subunits (86). Properdin can interact with the 
C345C domain of C3b and the von Willebrand factor type-A (vWA) domain in 
Bb allowing it to stabilise the AP C3 convertase by holding the two components 
Figure 4: Properdin Isoforms
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of the complex together. Furthermore, properdin promotes stability of the C3 
convertase by inhibiting the ability of C3b to interact with DAF or factor I 
mediated co-factors thus prolonging activation (83). 
1.4.3 Biosynthesis
In contrast to the majority of complement factors which are produced in the liver, 
properdin is synthesised mainly by white blood cells. Properdin is synthesised by 
monocytes, T lymphocytes, neutrophils and is stored in dendritic cells and the 
granules of mast cells (51, 87-90). Limited data is available on the regulation of 
production or secretion by white blood cells, with data from neutrophils indicating 
that TNF, C5a and IL-8 can induce properdin secretion (51). Intriguingly, 
activated neutrophils can release properdin from it granules which then becomes 
bound to the neutrophil cell surface independent of any C3, allowing for C3 
convertase assembly (91). Normal properdin levels in plasma (approx. 25 μg/ml) 
are relatively low compared to various other AP components such as C3 (1000-
1500μg/ml) and factor B (74-286 μg/ml), demonstrating its potent effects on the 
AP even as a minority (92). This is of particular interest when you focus on the 
local complement production at a site of injury or the immunological synapse. 
Previous studies have demonstrated a key role for the alternative pathway in the 
APC T cell synapse, whereby the AP is produced locally and enhances T cell 
proliferation and APC cytokine release (93). Infiltrating cells such as dendritic 
cells acting as a source of properdin at the site of injury, can dramatically alter 
the ability to induce AP activation in the local environment. The exact source of 
plasma derived properdin still remains unclear, with murine studies offering us 
some insight into its origin. Studies by Miwa et al, illustrated that tissue specific 
deletion of properdin in myeloid cells of mice resulted in a 95% reduction in 
plasma properdin levels (94), indicating that myeloid cells are the majority 
properdin “shareholder”.
1.4.4 Emerging roles
Next to the ability of properdin to act as stabiliser it can act as a pattern recognition 
molecule. Initially it was described to recognise microbial stimuli including 
Neisseria gonorrhoeae and zymosan, inducing complement activation (64). In-
vitro, properdin can bind LPS coated wells and native forms of properdin can 
bind to Chlamydia pneumonia resulting in C3b deposition (95, 96). Properdins 
pattern recognition capabilities stretch further than its ability to bind exogenous 
ligands. Properdin can bind mammalian cells via glycosaminoglycans (Figure 
3) as was observed with proximal tubular epithelial cells (PTEC). Properdin 
bound viable PTEC by attaching to tubular heparin sulphates (65). Gaarkeuken 
et al demonstrated properdin deposition along the brush border of patients with 
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proteinuric kidneys which was absent in healthy controls. In-vitro purified 
properdin could bind specifically PTEC, which when exposed to serum could 
support complement activation. Indicating that properdin can act as an anchor 
on PTEC and induce AP activation on its surface (97). Properdin can bind viable 
cells however it seems just as capable as a pattern recognition molecule binding 
altered self. Properdin can bind necrotic mouse splenocytes, either in the absence 
or presence of C3, illustrating the properdin directed model of AP activation (98). 
Properdin binding altered self is not limited to just necrotic splenocytes as it 
can also bind apoptotic T cells. The properdin bound apoptotic T cell can direct 
deposition of C3b or induce phagocytic uptake of the apoptotic T cell independent 
of complement activation (99). 
The generation of a properdin knockout mouse has expanded the field of 
investigation and our understanding of properdin in-vivo in AP mediated tissue 
injury. Murine models of arthritis have demonstrated a beneficial effect in 
deficiency of properdin, with neutralisation of properdin also improving arthritis 
development (100, 101). In a model of abdominal aortic aneurysm, properdin 
deficient mice had a better outcome as well as wild type mice treated with an anti-
properdin antibody (102). Also, a mouse model of renal ischemia reperfusion 
injury generating AP mediated tubular injury, demonstrated amelioration of 
the condition in a properdin depleted setting (94). Properdin has exhibited a 
fatal role in various AP mediated tissue injury settings as above, surprisingly 
in C3 glomerulopathy which is characterised by AP activation, the presence 
of properdin can be protective (103-105). The ever diverse roles of properdin 
including its “traditional” and emerging roles are the focus of studies in both 
healthy and disease states, to elucidate the depth of capabilities of this previously 
disregarded protein.
1.5 Scope of the thesis
The scope of this thesis surrounds the role of the complement system in various 
aspects of autoimmunity. Our experiments were targeted towards investigating 
the possible roles of the classical pathway and alternative pathway in various 
AI settings. Properdin is the only positive regulator of the complement system 
by stabilizing the alternative pathway convertase, and both in human and mouse 
it’s precise role in steady state or disease conditions remains to be elucidated. In 
chapter 2 we investigated the causal relationship between autoantibodies and the 
development of lupus nephritis. Our studies focused on endothelial cells which are 
a major target in LN and their interaction with autoantigens C1q and nucleosomes. 
The aforementioned in-vitro studies were performed in the presence or absence 
of autoantibodies against the respective autoantigens, followed by addressing 
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its ability to induce classical pathway activation. In chapter 3 we describe the 
generation of a novel mouse properdin ELISA and histological stain to elucidate 
the contribution of properdin in murine disease models. In chapter 4 we focused 
on generating a method for the purification and functional testing of human 
properdin for in-vitro studies. As the AP has been implicated in many neutrophil-
mediated diseases, in chapter 5 we investigated the interaction of properdin 
with neutrophil components and their role in alternative pathway activation. Our 
studies focused on the interactions between the neutrophil enzymes including 
those which are autoantigens in ANCA vasculitis. Our findings demonstrated 
a novel method of AP activation by human neutrophil enzymes. Recent studies 
have indicated the ability of properdin to act as stabiliser and initiator of the AP, 
however there has never been a physiological inhibitor for properdin described. 
In chapter 6 we describe our findings on a novel inhibitor that can directly 
interact with properdin, inhibiting properdin directed complement activation on 
human cells. With regulation of the AP being particularly important due to the 
amplification loop, we focused in chapter 7 on the role in adaptive immunity of 
the two opposing AP regulators properdin and factor H. Our findings demonstrated 
novel diverging roles of DC derived properdin and factor H production and roles 
in T cell immunity. In chapter 8 we discuss the findings and future lines of 
investigation encompassing the ever expanding role of properdin activation, 
regulation and downstream effects on the alternative pathway.
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Abstract
Various studies indicate a role for anti-nucleosome and anti-C1q autoantibodies 
in glomerulonephritis of patients with systemic lupus erythematosus. However, 
a causal relationship between these autoantibodies and the development of lupus 
nephritis has not been fully established. Since injury of the endothelium is a major 
target in lupus nephritis we assessed the interaction of C1q and nucleosomes with 
glomerular endothelial cells in-vitro in the presence or absence of autoantibodies 
against these antigens. We demonstrate a direct and dose-dependent binding of 
both nucleosomes and C1q to immortalized human glomerular endothelial cells 
(GEnC) in-vitro, which in part is mediated by cell surface heparan sulfate. We 
demonstrate that nucleosomes and C1q serve as targets for monoclonal and 
polyclonal antibodies as well as for anti-nuclear autoantibodies from patients with 
systemic lupus erythematosus. An additive effect of anti-C1q autoantibodies on 
anti-nucleosome mediated complement activation was observed. Furthermore, 
we showed that the activation of complement on glomerular endothelial cells 
is mediated by the classical pathway since the deposition of C3 on GEnC is 
abrogated by MgEGTA and does not occur in C1q-depleted serum. Taken 
together, our studies demonstrate a direct binding of both nucleosomes and C1q 
to glomerular endothelial cells in-vitro. The subsequent binding of autoantibodies 
against nucleosomes in patients with systemic lupus erythematosus is potentially 
pathogenic and autoantibodies against C1q seem to have an additional effect.
Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease 
characterized by B cell hyperactivity, production of a multitude of different 
autoantibodies directed primarily against nuclear antigens, such as nucleosomes, 
and immune complex formation. The initial triggers that lead to the autoimmune 
response in SLE may be explained by a reduced clearance of apoptotic material 
and/or an aberrant apoptotic process (1). SLE affects about 0.04% of the general 
population in developed countries. Nearly 80% of the cases occur in women in 
the childbearing years, and it may affect as many as 1 in 1000 young women (2). 
The etiology of SLE is largely unknown, however it involves genetic, hormonal, 
and environmental factors (3).
Antibodies against double-stranded DNA (dsDNA) are regarded as highly specific 
for the disease (4) and anti-dsDNA antibodies are found in the majority of SLE 
patients (5). It is established now that the nucleosome is the driving autoantigen 
in SLE (6) and it has been suggested that the presence of anti-nucleosome 
antibodies could serve as a better marker for SLE than anti-dsDNA antibodies 
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since anti-nucleosome antibodies are present in up to 90% of lupus patients (7, 
8). In SLE many organs may be affected, including serosa, joints, CNS, skin, and 
kidney. Lupus nephritis (LN) is found in approximately 25–50% of SLE patients 
(9) and is the major cause of morbidity and mortality (10). LN is associated 
with a rise in titer of especially high avidity anti-dsDNA IgG and reduced levels 
of serum complement. Deposited immune complexes in the glomeruli induce 
complement activation and are involved in the pathogenesis of lupus nephritis 
(7, 11). Moreover, elution studies of glomeruli of SLE patients and lupus mice 
have revealed the presence of anti-dsDNA, anti-histone and anti-nucleosome 
antibodies, and their respective antigens (12-14). The molecular mechanisms 
of how these antibodies in conjunction with their antigen activate complement 
within the glomerulus, however, remains unclear.
As mentioned, the complement system plays an important role in the onset as well 
as the effector phase of LN in SLE (4, 15). Complement itself may also be the 
target of an autoantibody response (16). Next to anti-dsDNA antibodies, anti-C1q 
autoantibodies have been found to be closely associated with LN (17). There is 
evidence that a rise in anti-C1q autoantibody titers may predict flares of nephritis 
(17, 18). Additionally there is an accumulation of anti-C1q autoantibodies in 
kidneys from patients with SLE and renal involvement (19, 20). Conversely, 
in the absence of anti-C1q autoantibodies, signs of LN seem to be absent (21). 
Interestingly, anti-C1q autoantibodies can be found in several other disease 
conditions, such as hypocomplementemic urticarial vasculitis (HUVS), and even 
in some healthy individuals (16, 22), but in these instances anti-C1q antibodies 
are not related to renal pathology (23). Anti-C1q autoantibodies also occur in 
murine models of SLE (24-26). In MRL/lpr mice, a rising anti-C1q autoantibody 
titer is observed in parallel with an increase in renal injury. In order to obtain 
insight in the possible causal relationship between anti-C1q antibodies and renal 
injury, Trouw et al. (26) injected naïve mice with mouse monoclonal and rabbit 
polyclonal antibodies directed against C1q, which induced significant renal 
inflammation, as assessed by the glomerular infiltration of polymorphonuclear 
leucocytes. However, a full blown renal injury in the form of proteinuria was 
not observed suggesting that additional triggers are required for significant renal 
damage.
Indeed, combination of anti-C1q antibodies with a sub-threshold dose of anti-
glomerular basement membrane antibodies led to significant proteinuria. Since 
both anti-C1q and anti-dsDNA antibodies seem to be involved in LN, we isolated 
nucleosomes, which are the main target of anti-DNA and anti-nucleosome 
antibodies in the kidney of human as well as murine SLE (13, 14, 27, 28), and found 
that they bind directly to glomerular endothelial cells (GEnC), independently of 
antibodies. Furthermore, we assessed the effects of anti-nucleosome and anti-
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C1q autoantibodies from patients with SLE versus that of healthy controls on 
complement activation using conditionally immortalized glomerular endothelial 
cells (GEnC) in-vitro.
Material and methods
Generation of nucleosomes and interaction with C1q
Jurkat cells were cultured in standard culture medium (RPMI 1640, Invitrogen, 
Breda, the Netherlands) supplemented with 10% of fetal calf serum and penicillin/
streptomycin. Apoptosis was induced with ultra-violet irradiation of 100 J/m2 and 
the cells were subsequently cultured under serum-free conditions for another 10 
days. Supernatants from these apoptotic cell cultures were used for the isolation 
of DNA using the phenol, chloroform and isoamyl alcohol extraction method. 
Nucleosomes in the culture supernatant were further purified by size exclusion 
chromatography on Sepharose S200 (Pharmacia), and fractions were collected 
and subsequently coated on ELISA plates (NUNC, Roskilde, Denmark) (29) and 
assessed for reactivity with a specific anti-nucleosome monoclonal antibody. 
Fractions containing nucleosomes were pooled and analyzed for nucleosome 
components and reactivity with monoclonal antibodies against DNA (mAb #36), 
histones (mAb #34) and nucleosomes (mAb #32)(30).
DNA and histones were commercially obtained (Invitrogen, Breda, the 
Netherlands), respectively (Roche, Mannheim, Germany). Binding of C1q to 
nucleosomes was evaluated on coated nucleosomes in an ELISA plate (NUNC) 
and subsequent incubation with increasing concentrations of purified human C1q, 
in the presence or absence of potential inhibitors (BSA, DNA or nucleosomes), 
was performed in PBS with BSA (1%) and Tween-20 (0.02%), abbreviated 
as PBS–BSA–Tween. Bound C1q was detected with a mouse monoclonal 
antibody against human C1q and a goat anti-mouse IgG conjugated to horse 
radish peroxidase (HRP) (DAKO, Glostrup, Denmark) and 2,2`-Azinodi(3-Ethyl 
Benzthiazoline Sulfonic acid) (ABTS). Data are expressed as optical density 
values at 415 nm (OD415).
Glomerular endothelial cells (GEnC)
Conditionally immortalized human GEnC have been described in detail by 
Satchell et al. (31). Briefly, the GEnC were cultured in 96 wells plates (Costar), 
allowed to proliferate at a permissive temperature of 33˚C, until confluent, and, 
subsequently, cultured at a non-permissive temperature of 37˚C for, at least, 
5 days. GEnC were cultured in EGM-2/bullet kit medium (Lonza, Breda, the 
Netherlands), containing VEGF and other growth factors. In some experiments, 
heparinase III (Sigma–Aldrich, Zwijndrecht, the Netherlands), diluted in  culture 
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medium at a  concentration  of 0.25 U/ml for 60 min at 37˚C, was used to remove 
heparan sulphate chains from GEnC as  was described before (32-34).
After culture or incubation with different reagents, GEnC were washed three 
times with PBS–BSA-azide. GEnC were subsequently incubated with purified 
Jurkat-derived nucleosomes (0–800 ng/ml) and/or purified human C1q (0–100 
µg/ml) diluted in culture medium for 30 min at 4˚C. C1q was purified as described 
previously (35). Human serum samples from either healthy controls or patients 
with systemic lupus erythematosus were heat-inactivated for 30 min at 56˚C and 
diluted (1:2 and 1:4) in culture medium. Before addition to cell cultures, normal 
human serum was used as a source of complement at a concentration of 30% in 
culture medium containing 5mM MgCl2 and CaCl2 for complement activation 
which was then incubated at 37˚C. In some experiments 5mM MgEGTA was 
added to block the classical and lectin pathway of complement. C1q depleted 
human serum (36) was also used to prevent classical pathway of complement 
activation. After incubation with the complement source, cold PBS–BSA was 
added to stop the activation of complement. After incubation with the required 
agents adherent GEnC were detached with PBS–BSA–azide containing lidocaine 
(5 mg/ml) for 30 min at 37˚C. Detached GEnC were then incubated in PBS–BSA–
azide with detecting antibodies. For the detection of GEnC-bound nucleosomes, 
a monoclonal mouse anti-nucleosome IgG (#32) was used. For the detection of 
GEnC-bound C1q, a monoclonal mouse anti-human C1q IgG (36) was employed 
and for the detection of human C3, a monoclonal mouse anti-human C3 (RFK22) 
(37) was used. For the detection of human IgG, a monoclonal mouse anti-human 
IgG (American Type Tissue Culture Collection, HB43) was used. Goat anti-
mouse allophycocyanin (APC) (DAKO) was used to detect the binding of these 
monoclonal mouse antibodies. Polyclonal digoxigenin (DIG)-conjugated rabbit 
(generated in our laboratory) anti-human C1q antibodies and goat anti-DIG FITC 
conjugated antibodies (Roche) were applied to detect binding of human C1q to 
GEnC (38). Cells were analyzed by fluorescent activating cell sorting (FACS) 
on a Becton Dickinson FACS Calibur flowcytometer, using CellQuest software.
Results
Isolation and characterization of nucleosomes from apoptotic Jurkat 
cells
Nucleosomes of human origin were generated from apoptotic Jurkat cells. DNA 
extracted from nucleosomes released into the supernatant of apoptotic Jurkat 
cell cultures typically exhibited bands of approximately 150, 300 and 450 bp 
(Fig. 1a), indicating that mononucleosomes, dimers and trimers of nucleosomes 
(300 and 450 bp) were released in the supernatant. To show that nucleosomes 
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were generated with this method, the pool of nucleosomes after size exclusion 
chromatography on Sepharose S200 were coated in 96-well plates and assessed 
for reactivity with a mouse anti-nucleosome monoclonal antibody. In addition 
DNA and histones were used as a coating, and the reactivity of anti-DNA and 
anti-histone antibodies were tested in ELISA as well (Fig. 1b). The mouse anti-
nucleosome monoclonal antibody only recognizes intact nucleosomes and not 
DNA and or histones indicating that we obtained intact nucleosomes.
Binding of nucleosomes to human glomerular endothelial cells
To determine whether nucleosomes are able to interact with human glomerular 
endothelial cells and thereby potentially serve as a target for anti-chromatin 
autoantibodies, we made use of a conditionally immortalized glomerular 
endothelial cell line (GEnC) (31). Exposure of GEnC to nucleosomes followed 
by FACS analysis, revealed significant and direct binding of nucleosomes (Fig. 
2a). Cells not exposed to nucleosomes (control antibody) have a low mean 
fluorescent index, whereas the monoclonal antibody control without nucleosomes 
shows some background staining. To demonstrate the possible involvement of 
heparan sulfate (HS) in the binding of nucleosomes to GEnC, adherent cells 
were pre-treated with heparinase III or left untreated. Subsequently, the cells 
were incubated with increasing concentrations of nucleosomes, and analyzed by 
FACS. The binding of nucleosomes to GEnC was dose-dependent and the binding 
was significantly reduced following heparinase III pretreatment of the GEnC 
by approximately 60% at all concentrations of nucleosomes, indicating that the 
Fig.1. 
Isolation and characterization of 
nucleosomes. SDS PAGE analysis 
of Sepharose S200 purified 
nucleosomes (panel a). Lane M 
contains a molecular weight marker 
and lane N consists of purified 
nucleosomes. Panel (b) shows the 
reactivity of specific monoclonal 
antibodies against DNA (open 
bars), histones (hatched bars) and 
nucleosomes (dark bars) with 
the purified oligonucleosomes, 
DNA and histones in ELISA. The 
ELISA plates in (b) panels 1,2 and 
3 were coated with DNA, histones 
or with nucleosomes, respectively.
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binding of nucleosomes to GEnC is, at least in part mediated via heparan sulfate 
structures on GEnC (Fig. 2b). From the literature, it is known that nucleosome/
anti-nucleosome immune complexes (IC), but not anti-nucleosome antibodies 
alone, are able to react with glomeruli of rats in-vivo (29). Therefore, GEnC were 
incubated with immune complexes containing nucleosomes and mouse anti-
nucleosome IgG2a as compared to nucleosomes alone for 30 min at 37˚C. The 
presence of mouse antibodies (as a measure of bound IC) was readily detectable 
by FACS, demonstrating that immune complexes bind to GEnC (Fig. 2c), most 
likely via the interaction between highly positively charged histones within the 
nucleosome and negatively charged HS structures.
To find out whether antibody-mediated binding to Fc receptors for IgG isotypes 
(FcγRs) could be involved in the binding of immune complexes to GEnC, we 
assessed the expression of FcγRs on GEnC. No detectable expression of FcγRs on 
GEnC was observed, while peripheral blood-derived cells from a healthy donor 
were clearly positive (data not shown). Furthermore, when aggregated human 
IgG was used as a model for immune complexes, no binding of these aggregates 
to GEnC was observed (data not shown). Taken together, these data indicate that 
Fig. 2. Binding of nucleosomes to 
glomerular endothelial cells. Binding of 
nucleosomes to GEnC: GEnC in culture 
wells were incubated with nucleosomes, or 
medium alone, washed and subsequently 
incubated with a control monoclonal 
antibody or with a anti-nucleosome 
monoclonal antibody, washed and bound 
antibody was detected with goat anti-mouse 
allophycocyanin as described in Section 
2. Panel (a) shows that there is significant 
binding of nucleosomes to GEnC (dark 
grey profile) as compared to the control 
antibody (open profile) and the cells 
exposed to the goat antibody alone (grey 
profile). The binding of nucleosomes to 
GEnC is dose dependent (panel (b), closed 
symbols) and is reduced when the GEnC 
are pretreated with heparinase (panel (b), 
open symbols). In panel (c) the results are 
shown of the binding of nucleosomes alone 
or nucleosomes in immune complex form to 
GEnC as detected with an anti-nucleosome 
antibody. The results are the mean ± SD of 4 
separate determinations.
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nucleosomes bind directly to GEnC, and not as a result of antibody-dependent 
mechanisms.
C1q binds to human glomerular endothelial cells
It has been described that C1q can directly bind to human umbilical vein endothelial 
cells (38, 39). Therefore, we tested the ability of GEnC for the binding of C1q 
as well (Fig. 3). Detached GEnC were incubated with purified human C1q, and 
bound C1q was detected by a monoclonal mouse anti-human C1q and analyzed 
by FACS. As depicted in Fig. 3a a clear binding of C1q to GEnC occurs. This 
binding is specific and dose-dependent (Fig. 3b). Also in this case we evaluated 
the possible role of HS in mediating direct binding of C1q to GEnC. Removal 
of HS resulted in a decreased binding of C1q to GEnC (Fig. 3b and c), which 
contributed to about 40% of C1q binding (Fig. 3c). In summary, C1q can bind 
directly to GEnC, which in part is mediated by cell surface HS.
Fig. 3. Binding of C1q to glomerular endothelial cells. GEnC in culture wells were 
exposed to 100 µg/ml of C1q or BSA, washed and then bound C1q was detected using 
a mouse monoclonal antibody against C1q (dark line) or a control monoclonal antibody 
(grey profile) as described under Section 2 (panel (a)). The binding of C1q to GEnC 
was dose-dependent (panel (b), closed symbols) and was reduced when the GEnC were 
pre-treated with heparinase (panel (b), open symbols). In panel (c) the binding of a fixed 
concentration of C1q (10 µg/ml) to GEnC either pretreated with heparinase or not is 
depicted for an experiment performed in triplicate (*p < 0.05).
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Binding of C1q to nucleosomes
It has been described that C1q serves as a soluble pattern recognition molecule for 
apoptotic cell debris and that it is implicated in the recognition of lupus antigens, 
including nucleosomes. Exposure of these self-antigens to the acquired immune 
system may lead to the generation of autoantibodies. In this context C1q may 
serve as a target for autoantibodies in SLE as well. It has been suggested that C1q 
bound to apoptotic cells for example via its interaction with nucleosomes leads 
to the exposure of neo-epitopes that are recognized by anti-C1q autoantibodies 
in patients with SLE (40). To investigate whether C1q  is  able to  bind to 
nucleosomes, nucleosomes were coated in 96-well plates and, subsequently, 
incubated with increasing concentrations of C1q. Bound C1q was detected with a 
monoclonal mouse anti-human C1q (Fig. 4a). 
A dose-dependent binding of C1q to nucleosomes was observed. When a 
fixed amount of C1q (10 µg/ml) was incubated in the presence of increasing 
concentrations of potential inhibitors such as DNA and nucleosomes, a dose-
Fig. 4. In vitro interactions of C1q with nucleosomes. Panel (a), ELISA wells were 
coated with increasing concentrations of nucleosomes or BSA, washed and then reacted 
with a fixed concentration of C1q, washed and bound C1q detected with monoclonal 
antibody against C1q. In panel (b) it is shown that the binding of nucleosomes (coated) to 
C1q (10 µg/ml) is inhibited in a dose dependent fashion by nucleosomes and DNA but not 
by BSA. In panel (c), the results of binding of C1q to GEnC are shown. GEnC in culture 
were exposed to BSA or to 10 µg/ml of nucleosomes in triplicate wells, washed and then 
assessed for binding of C1q (100 µg/ml) by FACS as described in Section 2. Results are 
the mean ± 1 SD.
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dependent and decreased binding of C1q to coated nucleosomes was observed 
(Fig. 4b), indicating that C1q binds, at least in part, to nucleosomes via their DNA 
content. A role for the globular heads of C1q in the recognition is suggested as 
the ability of C1q to recognize nucleosomes in ELISA was abrogated after heat-
inactivation of C1q.
As binding of C1q to GEnC also was seen in the absence of nucleosomes (see 
Fig. 3a–c), we wondered whether the binding of C1q to GEnC could be enhanced 
after pre-incubation of these cells with nucleosomes. Indeed, the binding of C1q 
is dramatically enhanced when nucleosomes are already bound to GEnC (Fig. 
4c). Notably, the enhancing effect of nucleosomes in binding of C1q to GEnC 
overrides the contributions of HS mediated binding of nucleosomes and C1q. 
These findings strongly suggest that C1q binds to nucleosomes on the surface of 
GEnC and, thereby, is a potential target for anti-C1q autoantibodies.
Anti-nucleosome and anti-C1q autoantibodies lead to complement 
activation on GEnC
In order to obtain insight in the possible injurious effects of autoantibodies from 
sera of SLE patients on complement activation, GEnC were sensitized with C1q 
alone, nucleosomes alone, the combination of both agents or BSA as a control, 
washed and then incubated with two-fold dilutions of heat inactivated pooled 
human serum (PHS), or heat inactivated serum of a patient containing both 
anti-C1q and anti-DNA autoantibodies (see experimental design in Fig. 6a). 
Thereafter the cells were washed and incubated with a fixed dilution (30%) of 
normal human serum (non-heat treated) as a source of complement. The degree 
of C3 deposition, as a measure for complement activation, was then quantified 
by FACS as described previously (41). BSA-sensitized GEnC incubated with 
dilutions of NHS as a complement source showed only background C3 deposition. 
C1q treated GEnC also exhibited minimal amounts of complement activation that 
was not distinguishable from the BSA controls (Fig. 5b). Nucleosome-sensitized 
GEnC induced a significant increase in C3 deposition and the double sensitization 
with C1q and nucleosomes further increased the amount of C3 deposition on the 
GEnC.
The effect of serum of an SLE patient containing both anti-C1q and anti-DNA 
on BSA-sensitized GEnC was minimal and induced limited C3 deposition on 
the GEnC (Fig. 5c). The effect of SLE serum on C1q-sensitized GEnC was also 
limited as compared to the C1q/nucleosome (double) sensitized cells; however, 
there was significant C3 deposition as compared to the BSA controls. Nucleosome 
sensitized GEnC exposed to SLE serum was significantly enhanced and dependent 
on the dilution of the autoimmune serum reaching plateau levels at dilutions of 
1:4 and 1:2. In summary, the effect of autoimmune serum on GEnC sensitized 
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both with C1q and nucleosomes in complement activation was superior to the 
effect of sensitization with C1q and nucleosomes alone.
To further explore the effects of serum containing only anti-DNA antibodies and 
the combined presence of both anti-C1q and anti-DNA on GEnC, a fixed dilution 
of 1:4 of heat-inactivated sera from normal donors (n = 12),  SLE patients with 
anti-DNA alone (n = 18), and SLE patients having both anti-DNA and anti-C1q 
(n = 21) were tested. The experimental design is shown in Fig. 6a. The sera 
were tested on GEnC sensitized either with BSA alone, C1q alone, nucleosomes 
alone or the combination of C1q and nucleosomes, and finally assessed for C3 
deposition (Fig. 6). GEnC sensitized with C1q and subsequently exposed to 12 
Fig. 5. Sensitization of glomerular 
endothelial cells with nucleosomes and 
C1q leads to complement activation after 
incubation with SLE serum containing 
autoantibodies. Effects of autoantibodies 
against DNA and C1q on GEnC sensitized 
with BSA, C1q, nucleosomes or the 
combination of C1q and nucleosomes. GEnC 
in culture wells, sensitized as indicated in 
panel (b) were first incubated with dilutions 
of heat inactivated pooled human serum and 
then assessed for their capacity to activate the 
complement system in 30% human serum 
(NHS) and then assessed for C3 deposition 
on GEnC by  FACS (panel (a)). In panel 
(b) it is shown that GEnC sensitized with 
nucleosomes support complement activation 
and that sensitization with both C1q and 
nucleosomes leads to better complement 
activation while sensitization with BSA or 
C1q remains negligent. The experiment was 
performed twice and the result of one of the 
two experiments is depicted in (b). In panel 
(c) the cells sensitized as mentioned above 
were first exposed to dilutions of serum from 
a patient with SLE containing both anti-C1q and anti-DNA autoantibodies, washed 
and then further incubated with 30% human serum as a source of complement. It is 
interesting to note that GEnC sensitized with C1q and then reacted with autoantibodies 
(most probably anti-C1q) clearly support complement activation in a dose dependent 
fashion. In a similar way GEnC sensitized with nucleosomes dose dependently support 
complement activation. The degree of complement activation by GEnC sensitized both 
with C1q and nucleosomes is much stronger and seems to be at least additive to that of 
C1q and nucleosomes alone.
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normal sera did not support significant C3 activation as compared to the BSA 
controls. Nucleosome sensitized GEnC exposed to normal sera clearly supported 
complement activation, which was significantly higher than for the BSA and C1q 
sensitized GEnC. GEnC sensitized both with C1q and nucleosomes showed further 
enhanced C3 activation. These findings suggest that binding of nucleosomes to 
GEnC induces C3 activation on GEnC.
The second part of the experiment concerned the effects of SLE serum containing 
either anti-DNA alone or the combination of anti-DNA and anti-C1q. The reason 
for this choice being that there were no SLE sera available having anti-C1q alone.
The effect of SLE sera on BSA sensitized GEnC were not different from that 
found in the normal control sera (Fig. 6b). C1q sensitization followed by exposure 
to anti-DNA containing sera alone did not result in an increase in subsequent C3 
activation. Nucleosome sensitization alone and exposure to anti-DNA containing 
sera clearly resulted in subsequent C3 activation. The combination of sensitization 
of GEnC with both C1q and nucleosomes was significantly increased as compared 
Fig.6. 
Sensitization of glomerular 
endothelial cells with 
nucleosomes and C1q leads 
to complement activation 
after incubation with 
SLE sera containing anti- 
nucleosome and anti-C1q 
antibodies. GEnC  in culture 
wells were first sensitized 
with BSA alone, C1q  alone 
or with nucleosomes together 
with C1q,  washed, and then 
reacted with sera containing no 
antibodies (control), anti-DNA 
antibodies or sera containing 
both anti C1q  and anti-DNA. 
After washing, the cells were 
subjected to complement 
activation in 30% NHS and assessed for C3 deposition by FACS (a). (b) Activation of 
complement and subsequent deposition of C3 on GEnC sensitized with BSA alone (panel 
b–a), C1q alone (panel b–b), nucleosomes alone (panel b–c) and the combination of C1q 
and nucleosomes (panel b–d). The cells were then exposed to a fixed dilution of 1:4 of 
12 sera from normal donors (open bars), sera from 18 SLE patients with anti-DNA alone 
(hatched bars) and 21 sera of SLE patients with both anti-C1q and anti-DNA (dark bars), 
washed and then incubated with 30% human serum as a complement source for 30 min 
at 37˚C and assessed for C3 deposition by FACS. The results are the mean ± SD of C3 
deposition. The horizontal bars indicate the p-value of difference *p < 0.05; **p < 0.02.
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to nucleosome sensitization alone (Fig. 6b).
Next the combined effects of anti-C1q and anti-DNA were analyzed. As before, 
BSA sensitized GEnC and subsequent exposure of these cells to the SLE sera 
containing both anti-C1q and anti-DNA were not different from the results 
presented in Fig. 6b and c. The presence of anti-C1q resulted in a modest but 
significant increase in C3 deposition on the C1q sensitized GEnC, which is also 
clearly enhanced as compared to the effects seen with SLE sera that did not 
contain anti-C1q antibodies. The effects of anti-DNA together with anti-C1q on 
GEnC sensitized both with nucleosomes and C1q was significantly greater than 
the sum of C1q and nucleosome sensitization separately (Fig. 6b–d).
3.6. Pathway of complement activation
In order to obtain insight in the pathway of complement leading to C3 activation 
and C3 deposition on GEnC under different conditions of sensitization, GEnC 
sensitized with BSA alone, C1q alone, nucleosomes alone or the combination of 
the two latter agents, after washing, were exposed to 30% NHS as a complement 
source; 30% NHS containing 5 mM MgEGTA or 30% C1q-depleted serum, and 
assessed for C3 deposition on the GEnC.
As shown in Fig. 7a, BSA or C1q sensitized GEnC did not exhibit significant C3 
deposition. Nucleosome sensitization resulted in clear C3 deposition on GEnC 
which was abrogated in the presence of MgEGTA and also did not occur in 
C1q-depleted serum. GEnC sensitized with both C1q and nucleosomes showed 
relatively more C3 deposition than GEnC sensitized with nucleosomes alone. 
Again this C3 deposition did not occur in MgEGTA or in C1q-depleted serum 
indicating activation of complement mainly via the classical pathway.
Next we explored the pathway of complement activation of the differently 
sensitized GEnC following treatment of the cells with an SLE serum containing 
only anti-DNA antibodies (Fig. 7b). Again BSA or C1q sensitized cells did not 
exhibit significant C3 deposition. Nucleosome sensitized GEnC and further 
opsonisation with anti-DNA showed clear C3 deposition which was absent in 
the presence of MgEGTA or in C1q-deficient serum. GEnC sensitized with both 
C1q and nucleosomes and further opsonised with anti-DNA exhibited a further 
increase in C3 deposition which did not occur in the presence of MgEGTA or in 
C1q-deficient serum.
Finally, the pathway of complement activation was assessed for the differently 
sensitized GEnC but now further opsonised with both anti-C1q and anti-DNA. 
The results depicted in Fig. 7c show that the C1q opsonized GEnC also support 
C3 deposition and that this is also dependent on the classical pathway because the 
C3 deposition on the GEnC did not occur in the presence of MgEGTA or in C1q-
deficient serum. In a similar way the pathway involved in complement activation 
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was established for GEnC sensitized with nucleosomes or the combination of 
nucleosomes and C1q.
In summary, in all conditions where C3 deposition occurs a clear involvement 
of the classical pathway of complement activation is seen. The combined 
sensitization of GEnC by C1q and nucleosomes leads to the highest level of 
complement activation, which is mediated by the classical pathway.
Discussion
Several studies have shown a high association between the occurrence of anti-
C1q autoantibodies and renal involvement in systemic lupus erythematosus 
(17, 18, 20). Also the involvement of anti-DNA and or anti-nucleosome 
autoantibodies in the pathogenesis of renal disease in SLE has been implicated 
(30, 42). Experimental studies in mice and rats support both a role for anti-C1q 
antibodies and anti-DNA antibodies in renal injury, however, neither anti-C1q 
Fig. 7.  
Complement activation on 
glomerular endothelial cells 
sensitized with nucleosomes 
and C1q followed by 
incubation with SLE sera 
containing autoantibodies 
is mediated by the classical 
pathway. GEnC sensitized 
as indicated in Fig. 6 were 
washed and then incubated 
with a heat inactivated normal 
human serum, washed and then 
incubated with normal human 
serum (NHS) or with NHS 
containing MgEGTA or with 
C1q-deficient serum (panel (a)) 
for 30 min at 37˚C and assessed 
for C3 deposition by FACS. The 
results are the mean ± 1 SD of 
triple determinations. In panels 
(b) and (c) the sensitized cells 
were sensitized as indicated, 
washed and then exposed to a 
fixed dilution of 1:4 of SLE serum containing only anti-DNA or containing both anti-
C1q and anti-DNA. Thereafter the degree of C3 activation and deposition on the GEnC 
was quantified. The results indicate that under all the three conditions of exposure with 
antibodies classical pathway mediated C3 deposition occurs.
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nor anti-DNA antibodies alone are able to induce significant renal inflammation 
resulting in significant proteinuria (43, 44). Therefore, it has been postulated that 
for lupus nephritis more than one trigger is required for full blown renal disease.
In the present study we have explored the contribution of anti-C1q autoantibodies 
alone, the effect of anti-DNA alone or the combination of both, in an experimental 
in-vitro setting to assess the potential injurious effects of these autoantibodies 
on glomerular endothelial cells. We have focused on the ability of these 
autoantibodies to activate complement because it has been shown that in SLE 
significant complement activation occurs both in the circulation as well as at the 
tissue level in the kidney itself. 
To approach the questions above, immortalized GEnC were assessed directly for 
the binding of C1q and nucleosomes. We found a direct dose dependent binding 
of C1q to GEnC. This binding of C1q to GEnC occurs via the collagenous part 
of the molecule, as suggested by the inhibition of C1q binding by heat treatment 
of C1q. Part of the direct binding of C1q to GEnC is mediated by heparan sulfate 
at the cell surface. Subsequent incubation of the GEnC sensitized with C1q with 
human serum as a complement source did not support significant complement 
activation on the GEnC.
A very important observation in this study is that nucleosomes can bind directly 
and specifically to GEnC in-vitro. Earlier in-vivo studies in rats (29, 45) have 
suggested that trapping of nucleosomes in the glomerular basement membrane 
occurs when the nucleosomes are present in immune complex form. In the present 
study the binding of nucleosomes to cultured GEnC was assessed both using 
immune complexes and free nucleosomes. There was no significant difference 
between binding of nucleosomes in immune complex form or as free nucleosomes 
to GEnC. Previously we have shown that heparan sulphate is essential in the 
initial binding of nucleosome containing immune complexes (28). We now 
show that binding of nucleosomes to GEnC is in part mediated by HS on the cell 
surface. We did not detect an additional effect of antibodies on the binding of 
nucleosomes to GEnC which is compatible with the fact the GEnC line we used 
does not express Fc gamma receptors. It is interesting to note that the binding of 
nucleosomes to GEnC was able to induce complement activation on the GEnC. 
This activation occurs via the classical pathway of complement. This finding is 
in agreement with the observation that nucleosomes bound to GEnC dramatically 
increased the binding of C1q, which induced C3 activation. 
Based on this set of studies one could reason that the direct binding of C1q to 
GEnC in-vivo is not expected to result in any significant complement-mediated 
renal injury. On the other hand one can reason that deposition of large amounts 
of nucleosomes to the kidney potentially could be harmful. We then asked the 
question whether autoantibodies against C1q and/or nucleosomes could enhance 
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the degree of complement activation on C1q and or nucleosomes bearing GEnC. 
We used heat inactivated serum from patients with SLE as a source of anti-C1q 
and anti-DNA autoantibodies. In general all sera of patients with SLE have 
significant levels of anti-DNA antibodies and only a certain percentage of the 
sera also have anti-C1q autoantibodies in addition to anti-DNA autoantibodies. 
However, we were not able to find sera from SLE patients with anti-C1q without 
anti-DNA. Therefore, we could only assess the combined effect of anti-C1q 
and anti-DNA autoantibodies on cells sensitized with C1q, nucleosomes or a 
combination. The results depicted in Fig. 6 indicate that anti-C1q autoantibodies 
can support activation of complement to a modest extent on GEnC that are 
sensitized with C1q. However, the effect of sensitization with nucleosomes is 
superior. The results further show that the effect of anti-DNA and anti-C1q are 
additive in activation of complement by the classical pathway.
Taken together, our data suggest a more vigorous injurious effect of anti-
nucleosomes in combination with anti-C1q antibodies on glomerular injury, 
which could explain why patients with anti-C1q autoantibodies have a high 
association with renal disease (23, 46). Studies by Trouw et al. (26) have shown 
that C1q is present in glomeruli of normal mice and absent in C1q-/- or RAG-
/- mice. Raising the level of IgG in the circulation of RAG-/- mice by splenic 
cell transfer or infusion of normal IgG resulted in the presence of C1q in the 
glomerulus of these mice. This would indicate that under normal conditions C1q 
is present in the glomerulus presumably caused by the presence of trace amounts 
of IgG in the glomerulus. Whether some part of the C1q in the glomerulus is 
bound to the endothelial cells, however, is not fully clear at the moment. Of course 
these in-vitro findings cannot be extrapolated directly to the in-vivo situation and, 
therefore, further analysis of the combined effects of anti-C1q and anti-DNA in 
in-vivo models of renal injury are required. 
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Abstract
In animal models of anti-GBM disease, a model for goodpastures syndrome, a role 
for the complement system has been demonstrated however the exact mechanisms 
involved remain unclear. In particular a role for the classical pathway (CP) and 
alternative pathway (AP) of complement has been suggested as being involved 
in the development of renal injury in anti-GBM disease. C3 is integral to the AP 
with properdin the only positive regulator promoting AP activation. Properdin 
can act as a stabiliser of the AP C3 convertase or as initiator of AP activation. 
We investigated whether the AP was present at the site of injury and if the AP 
is involved in pathogenesis of the anti-GBM disease. Anti-GBM disease was 
induced in WT, C3-/- and properdin-/- mice, and renal tissue was obtained up to 
96 hours following administration of rabbit anti-GBM. Our results indicated that 
at a time of complement activation in the tissue, properdin KO or C3 KO mice 
were not protected from renal injury based on proteinuria, compared to wild type 
mice. Our findings demonstrated the presence of properdin and C3 deposition 
in the glomeruli of WT mice treated with anti-GBM antibody. Interestingly, we 
could find properdin deposited in the glomeruli of C3 KO mice injected with anti-
GBM, indicating properdin deposition independent of C3. In short, our results 
indicate for the first time in-vivo, that properdin can bind to tissue independent of 
C3 activation, supporting the properdin directed model of activation of the AP.
Introduction
Recently the AP and in particular properdin have been increasing implicated 
in various disease states including arthritis, abdominal aortic aneurysm, renal 
ischemia reperfusion injury, ANCA vasculitides and anti-GBM disease (1-6). One 
interesting model is anti-GBM disease whereby CP activation would mainly be 
expected, with recent findings suggesting a role for AP activation. Anti-glomerular 
basement membrane (GBM) autoantibody mediated glomerulonephritis is a key 
trait of goodpastures syndrome (7). Goodpastures syndrome is characterised by 
the deposition of autoantibodies targeting the GBM followed by complement 
activation (C3 deposition) along the GBM. Furthermore, recent studies in 
patients suffering from anti-GBM disease have demonstrated the presence of 
complement activation products, including alternative pathway components 
such as Ba, in their urine was associated with renal injury (8-10). The binding 
of the autoantibody to the GBM followed by complement activation leading 
to leucocyte infiltration, proteinuria and resulting loss of renal function is one 
mechanism leading to autoimmune injury (11). The antibody targeting of the 
GBM is the site of disease induction and often the main focus when developing 
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animal models to mimic the disease course. The exact pathways and means of 
complement activation remain unclear in patients with anti-GBM disease with 
varying findings observed in murine models of the disease. Several animal models 
are used to mimic the disease state, including the direct model which involves 
targeting of the GBM with a single injection of anti-GBM, or the accelerated 
model whereby heterologous IgG is injected initially followed a week later by 
administration of heterologous anti-GBM antibody (12-15). 
The binding of the antibody to the GBM results in complement activation and 
initiation of renal injury (16, 17). The complement system consists of three 
pathways, classical pathway, lectin pathway and alternative pathway which all 
converge at C3. Activation of the complement system can result in opsonisation, 
generation of chemoattractants such as C3a or assembly of the C5b-9 lytic 
complex (18). A role for the classical pathway (CP) and alternative pathway 
(AP) has been suggested for models of anti-GBM disease (19, 20). Recently 
our group developed an attenuated passive mouse model of anti-GBM, whereby 
involvement of the classical pathway and alternative pathway was suggested 
using C1q-/-, C4-/- and C3-/- deficient mice. C1q-/- and C4-/- deficient mice 
demonstrated similar levels of albuminuria as compared to WT mice, while C3-
/- deficient mice exhibited a marked reduction in albuminuria suggesting a role 
for the AP. The clear deposition of the classical pathway component C1q in the 
glomerulus indicated the deposition of early components of the CP however the 
exact involvement of the AP remained difficult to clarify (4). In humans the AP 
can be initiated by two mechanisms. The “traditional” model of AP involves the 
tickover of C3 to form a C3b like molecule which binds factor B that is cleaved 
by factor D to form the AP C3 convertase (C3bBb). The AP C3 convertase is 
stabilised by properdin five to ten fold, promoting further complement activation 
and C3 activation (21-25). The recently described properdin directed model 
involves initial binding of properdin to an AP activating surface followed by 
binding of C3b, factor B and factor D generating as above an AP C3 convertase 
(22, 26). This recently reported in-vitro finding that properdin can act as initiator 
as well as stabiliser has re-opened the topic on how the AP can become activated 
and involved in various AP mediated diseases.
In short, the role of the AP in-vivo, in models of anti-GBM disease still remains 
unclear with the exact role of various AP components including murine properdin 
still unknown due to lack of reagents for functional or tissue analysis. We 
investigated whether mice deficient in integral AP components were protected 
from renal injury following induction of anti-GBM disease, and whether we could 
detect AP components at the site of injury. In our model, the findings indicated 
that proteinuria proceeded in the absence of AP factors or the complement 
system. Intriguingly, at the same time-point we could demonstrate C3 deposition 
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and properdin binding in glomeruli. Furthermore, properdin binding was evident 
in the glomeruli of C3 deficient mice which received the anti-GBM antibody. 
Taken together, our results indicate that complement deficiency did not inhibit 
proteinuria at a time-point where we observed AP activation in the glomerulus. 
Interestingly, we could demonstrate the novel finding of properdin binding in 
the complete absence of C3, indicating the first findings to our knowledge of the 
properdin directed model in-vivo. 
Materials and Method
Mice
C57BL/6 wild type (WT) mice were purchased from Charles river laboratories. 
The C3-/- mice were a kind gift from Mike Carroll (Harvard Medical School, 
Boston, MA, USA). The properdin-/- (P-/-) mice were kindly provided by Cordula 
Stover (University of Leicester, Leicester, UK). All experiments were approved 
by the Leiden University animal ethical committee and performed according to 
institutional and national guidelines.
Reagents
Rabbit anti rat GBM, cross reactive with mouse GBM, was an in house preparation. 
Monoclonal mouse anti mouse properdin (17.17) was a kind gift from Professor 
Wilhelm Schwaeble (University of Leicester, Leicester, UK). Rabbit anti human 
properdin digoxigenin (DIG) and rabbit anti mouse properdin DIG was generated 
in house. Rat anti mouse C3 was obtained commercially (Cedarlane) and DIG 
labelled mouse anti rat κ mAb kindly provided by Dr. N.A. Bos (Department of 
Histology and Cell Biology, Groningen University, The Netherlands). Sheep anti-
DIG peroxidase was from Roche (Mannheim, Germany). Tyramide fluorescein 
isothiocyanate (FITC) was purchased from NEN Life Science Products (Boston, 
USA). Sheep anti-DIG FITC (Fab) was purchased from Roche Diagnostics. Goat 
anti rabbit IgG Alexa 488 and goat anti rabbit IgG Alexa 568 were obtained from 
Molecular Probes (Leiden, the Netherlands). Creatinine strips for Reflotron were 
obtained from Roche.
Induction of glomerulonephritis
For the model, both male and female age matched (ranging from 7-10 weeks) 
mice (C57BL/6 wild type, C3-/- mice and properdin-/- mice) were injected 
for disease comparison. At day 0, the mice were injected intra-venously with 
rabbit anti-GBM (0.5 mg in 200 µl physiological saline). At 72hrs post injection 
the mice were placed in metabolic cages, with access to food and water, for 
collection of 24hr urine. At 96hrs post injection of anti-GBM antibody the mice 
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were sacrificed by CO2, with kidneys snap frozen for histological analysis and 
blood collected in a complement preserved manner. Similar to above, C57BL/6 
wild type mice were injected with 0.5 mg of control rabbit IgG as a control group 
for urine and tissue analysis.
Albumin and creatinine quantification
Mouse urine was collected over a 24hr period, with experiments performed in 
a manner to take into account circadian rhythm. Following collection from the 
metabolic cages the urine was centrifuged and stored at -20˚C. Albumin in the 
urine was quantified using rocket immune-electrophoresis as per previously 
described (4). Urine creatinine was quantified using creatinine strips for the 
Reflotron Plus system (Roche).
Histological analysis
Kidney sections were sectioned into 3 µm slices using as cryostat for analysis 
of anti-GBM deposition and complement activation. Rabbit IgG was detected 
using goat anti-rabbit IgG Alexa 488. The presence of mouse C3 deposited was 
determined using rat anti-mouse C3, followed by mouse anti-rat κ DIG and sheep 
anti-DIG FITC. Mouse properdin was detected using rabbit anti-mouse properdin 
DIG, followed by sheep anti-DIG peroxidase and tyramide FITC. 
Mouse Properdin ELISA
A sandwich ELISA for properdin was generated by coating mouse anti-mouse 
properdin IgG onto a Nunc 96 well plate. Following coating, the wells were 
blocked with 1% bovine serum albumin (BSA) phosphate buffered saline (PBS). 
A dose response of normal mouse CD-1 serum, purified mouse properdin or 
properdin deficient serum was diluted in PBS, 0.05% Tween 20, 1% BSA (PTB) 
and added to the blocked wells. Properdin was detected using rabbit anti-human 
properdin DIG and sheep anti-DIG peroxidase diluted in PTB. The enzymatic 
reaction was developed using 3-3,5,5-tetramethylbenzidine (TMB). Following 
each incubation step the plate is washed in PBS 0.05% Tween 20. Data is 
expressed as optical density values at 450nm.  
Results
Glomerular renal injury independent of the complement system
Following studies by Otten et al demonstrating a role for the AP in the passive 
anti-GBM model (4), we examined whether the AP is involved in the pathogenesis 
of our model, using proteinuria as readout. We injected anti-GBM in WT B6 
mice, C3 KO mice and properdin KO mice, and collected urine at 72-96hrs for 
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quantification of albumin and creatinine (to normalise for renal function). We 
generated a mouse properdin ELISA to demonstrate deficiency of the properdin 
protein in circulation prior to injecting mice (Fig 1a,b). Our findings indicated 
that there was no significant renal protection observed with a properdin KO or C3 
KO mouse compared to WT mice indicating injury occurred independent of the 
AP or the complement system (Fig 2). While none of the mice died during the 
Figure 1. 
Quantification of mouse 
properdin using sandwich 
ELISA. 
For fig 1a,b a sandwich mouse 
properdin ELISA was used. A 
mouse anti-mouse properdin 
antibody was coated to the 
ELISA plate, followed by a 
blocking step with 1% BSA/
PBS. A dose response of purified 
recombinant mouse properdin 
(Fig 1a) or normal mouse CD-1 
serum or properdin deficient 
serum (P-/-)(Fig 1b) was diluted 
in PBS, 0.05% Tween 20, 1% 
BSA (PTB) and added to the 
blocked wells. Properdin was 
detected using rabbit anti-
human properdin DIG.
Figure 2. 
Renal injury independent of 
the complement system at 72-
96hr urine timepoint. 
Anti-GBM disease was induced 
in WT B6 mice, C3 KO mice 
and properdin KO mice with a 
minimum of 8 mice per group, 
and collected urine at 72-96hrs 
for quantification of albumin 
and creatinine (to normalise for renal function). WT B6 mice (n=5) were injected with 
0.5 mg of control rabbit IgG (Ctrl IgG WT) for the 72-96hr collected urine, and the 
albumin/creatinine ratio calculated for the control group. Our findings indicated that 
there was no significant renal protection (based on one way anova statistical analysis) 
observed with a properdin KO or C3 KO mouse compared to WT mice injected with 
anti-GBM, indicating injury occurred independent of the AP or the complement system.
Properdin binding independent of complement activation in-vivo   •   55
   3
time course of the anti-GBM model, significant renal injury was induced ranging 
from 3.6 to 12.6 with the albumin/creatinine ratio for wild type mice at 72-96hrs 
post injection. Although the injury occurred independent of the AP at 96hrs, we 
observed an increase in circulating properdin levels in WT mice injected with 
anti-GBM using our properdin sandwich ELISA. In particular the blood level of 
properdin increased significantly from 2hrs to 48hrs post injection of anti-GBM 
(Fig 3), possibly due to increased production or availability.
Deposition of AP components including properdin in a murine anti-
GBM model 
Studies by our group in the past have indicated a role for the alternative pathway 
in a passive murine model of anti-GBM disease (4). At the early stage of disease, 
a role for the classical and alternative pathway was observed using C1q and C4 
deficient mice. In the present study, we investigated whether properdin a key 
positive regulator of the AP would be involved in the development of renal injury 
in this model. To investigate the role of the AP in the model we used properdin 
deficient mice and WT B6 mice to examine the role of properdin in our direct 
anti-GBM model. We examined whether we could detect the rabbit anti-GBM 
deposited in the glomeruli and if it induced complement activation at the tissue 
level in the kidney. Indeed the rabbit anti-GBM antibody was deposited in the 
glomeruli together with C3 at the same time-point of 96hrs (Fig 4). Furthermore, 
we demonstrated the presence of mouse properdin in the glomerulus of wild type 
mice injected with the anti-GBM which was not observed to the same degree in 
control IgG injected WT mice (Fig 5). These findings demonstrated that properdin 
a key modulator of the AP is deposited in the anti-GBM setting. With our findings 
indicating the presence of properdin and C3 at approx. 96hrs post injection we 
examined whether properdin binding was dependent upon C3 deposition.
levels for the individual time-points. Observed is a statistical significance between 2hrs 
and 48hrs post injection (*). Statistical analysis performed using one way anova (non 
parametric) Kruskal-Wallis test, with Dunns multi-comparison test (* < 0.05). 
Figure 3. Circulating mouse properdin 
levels in WT mice over time during the 
course of the anti-GBM model. 
Wild type black 6 mice were injected with 
0.5 mg of rabbit anti-GBM and followed 
over time for signs of injury in the urine 
and in the kidney tissue. The mice were 
sacrificed at 2hrs, 6hrs, 24hrs, 48hrs and 
72hrs post injection of the anti-GBM, 
followed by collection of blood. Results are 
graphed as mean + SD of blood properdin 
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Properdin deposition in glomeruli independent of C3
Studies over the recent years have demonstrated that properdin is not only 
an important stabiliser of the AP C3 convertase, but it can also act as pattern 
recognition receptor. Properdin has been shown to interact with necrotic cells, 
apoptotic cells and neutrophil components independent of C3 (22, 27-29). 
The finding that properdin can act as initiator of the AP has renewed interest 
in its role in AP mediated diseases. However, it has been the subject of many 
a healthy debate to whether physiological properdin can bind independent of 
C3. We investigated whether we observed properdin deposition in C3 KO as 
compared to WT B6 or properdin KO mice following injection with rabbit anti-
GBM examining the kidney histologically at 96hrs. Our findings demonstrated 
the presence of properdin in WT mice and its absence in properdin KO mice 
indicating the specificity of the stain, while we observed a strong properdin 
staining in C3 KO mice (Fig 6). 
Figure 4. Rabbit IgG and C3 stain in WT, P-/-, C3-/- mice injected with anti-GBM 
as compared to isotype control injected WT mice. 
Rabbit IgG and C3 deposition performed on kidney sections of WT ,P-/- and C3-/- mice 
injected with anti-GBM compared to WT mice injected with control rabbit IgG (Ctrl 
WT), 96hr post injection (x40 magnification of representative images).
Figure 5. Mouse properdin stain on mice injected with anti-GBM or control IgG. 
The mouse properdin stain was performed on kidney sections of WT mice injected with 
0.5 mg of anti-GBM (WT) or 0.5 mg of control IgG (Ctrl WT) (96hr post injection)(x40 
magnification of representative images). 
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In short, these findings indicate the presence of properdin at the site of injury 
independent of the presence C3. With earlier findings demonstrating properdin 
deposition independent of C3 we investigated possible ligands which properdin 
may be binding. We demonstrated that properdin co-localised with areas of rabbit 
IgG within the glomerulus, however based on the staining pattern properdin 
may be binding other structures than rabbit IgG such as dead or injured cells in 
addition (Fig 7). 
Figure 6. Properdin deposited in C3-/- mice as compared to Properdin-/- and WT 
mice. 
Mouse properdin stain performed on kidneys of WT, P-/- or C3-/- mice injected with 0.5 
mg of anti-GBM 96hrs after injection (x40 magnification of representative images). 
Figure 7. Double staining of rabbit IgG and mouse properdin stain in anti-GBM 
treated kidneys. 
The rabbit IgG stain (red) and mouse properdin stain (green) were performed on kidney 
tissue of WT, P-/- and C3-/- mice injected with 0.5 mg rabbit anti-GBM (96hr post 
injection)(x40 magnification).
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Discussion
Several studies have demonstrated a role for the alternative pathway in various 
diseases including arthritis, abdominal aortic aneurysm, renal ischemia 
reperfusion injury and anti-GBM disease (1-5). Findings by our group in recent 
times, demonstrated that in their anti-GBM model which had a controllable degree 
of renal injury, that the alternative pathway had a role in the pathogenesis of the 
disease. The exact mechanism by which the alternative pathway in conjunction 
with the classical pathway is involved in anti-GBM disease remains unclear (4). 
Until recently, reagents have not been available to detect murine properdin a 
key regulator and amplifier of the alternative pathway, to aid in understanding 
its role in various animal models of AP disease. We generated with the help 
of collaborators a mouse properdin sandwich ELISA and a mouse properdin 
stain to help elucidate the role of this key AP regulator in a mouse model of 
anti-GBM disease. Our findings indicated that deficiency of the AP did not 
attenuate proteinuria, however deposition of properdin and C3 in the glomerulus 
was observed. Intriguingly, properdin deposition in the glomerulus occurred 
independent of C3 based on findings with C3-/- deficient mice, suggesting a 
novel role for properdin independent of C3 in-vivo.
Initially, we demonstrated that the rabbit anti-GBM antibody became deposited 
in the glomeruli (Fig 4) and induced significant renal injury (Fig 2) at 96hrs post 
injection. Furthermore we observed that at this time-point the antibody induced 
C3 deposition in the glomeruli (Fig 4). To elucidate whether the AP is involved 
in the pathogenesis of disease we injected C57BL/6 WT mice, Properdin KO 
mice and C3 KO mice with the anti-GBM antibody and collected urine when we 
observed complement activation in the tissue. Our findings demonstrated that the 
mice deficient in the AP or complement system were not protected from renal 
injury based on proteinuria. However, we observed increased levels of mouse 
properdin in circulation of WT mice over a time course of the anti-GBM disease. 
This may be accounted for by increased synthesis or release by white blood 
cells, another possible mechanism is increased availability of properdin from its 
ligands.
Interestingly, we could demonstrate that properdin became involved in the 
disease course of the model. We illustrated the presence of properdin in WT 
mice injected with the anti-GBM antibody as compared to the properdin deficient 
mouse injected with the same concentration of antibody. With this in mind, 
that properdin is indeed deposited in the glomeruli of anti-GBM treated mice 
we investigated whether properdins presence in the glomeruli is dependent 
upon C3 or is C3 independent. We compared WT mice or C3 KO mice injected 
with anti-GBM and examined histologically for the presence of properdin. We 
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demonstrated that properdin is present in the glomeruli of C3 KO mice, indicating 
that properdin became deposited independent of C3.
These findings indicate that although the AP is present in the glomeruli of anti-
GBM treated mice, the disease progression appears unaffected by deficiency in 
either C3 or properdin both integral members of the AP. Studies from the past, 
have indicated a role for complement in the pathogenesis of anti-GBM disease. In 
particular it has been shown that C3 deficiency in a murine model of anti-GBM is 
protective in contrast to our findings (20). These contrasting findings may be due 
to differences in anti-GBM preparation, concentration of antibody injected or the 
kinetics of the experiment. The murine study supporting a role for complement in 
anti-GBM followed the disease until 24hrs while our studies followed up to 96hrs 
post injection which may explain the observed differences. The previous model 
performed by Otten et al. in our laboratory involved injection of rabbit anti-mouse 
GBM followed by mouse anti-rabbit IgG after six days; indicating a role for the 
AP in the pathogenesis of the disease (4). Our current anti-GBM model induced 
by a single injection of rabbit anti-GBM appeared to progress independent of 
the AP in contrast to the previous model. This conflicting data may be due to 
our current model having more available rabbit IgG deposited along the GBM 
in comparison to the earlier model which will have rabbit IgG initially deposited 
on the GBM followed by attachment of mouse IgG. Properdin may be deposited 
at the tissue level in both models based on the observation of co-localisation 
of properdin with rabbit IgG (Fig 7). Furthermore, properdin may be binding 
other structures, possibly injured cells within the glomeruli based on the diverse 
properdin staining observed. Studies by Banda et al, involving adherent immune 
complexes used in their arthritis model, demonstrated enhanced AP C3 activation 
in the absence of the CP or LP. One hypothesis proposed for this activation was 
that properdin may bind and initiate AP activation on the adherent immune 
complexes (30). Intriguingly, we could demonstrate the presence of properdin 
in the glomeruli of mice with anti-GBM disease, independent of whether C3 
is present in the mouse. This suggests that properdin can indeed act as pattern 
recognition molecule, supporting the properdin directed model (22, 26). To our 
knowledge, this is the first example of properdin recognition independent of C3, 
in-vivo. These findings are of interest in various AP and complement mediated 
diseases, as properdin has demonstrated recently an unexpected role, such as in 
recent studies focusing on C3 glomerulopathy (31-33). The ability of properdin to 
interact independent of C3, expands it possible roles in-vivo. In particular, its role 
in removal of apoptotic material (29, 34) and in neutrophil mediated diseases (6, 
28, 35, 36) can be expanded further for future in-vivo studies using the recently 
available mouse properdin reagents. Future anti-GBM studies investigating the 
effect of anti-GBM disease over time using WT B6 mice, C3 KO, C4 KO and 
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properdin KO mice with different doses and strategies of disease induction are 
imperative. These studies would be integral to understand the role of complement 
dependent and independent injury based on our current knowledge across the 
various anti-GBM models.
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Abstract
Properdin is a member of the alternative pathway of complement. It is unique in 
that it is the only known positive regulator of the complement system. Properdin 
can stabilize and promote complement activation, but in addition is also capable 
of initiating the alternative pathway, making it a unique protein. This chapter 
will focus on the methods required for purifying human properdin and testing its 
functionality.
Introduction
Properdin is a member of the alternative pathway (AP) in the complement system. 
Discovered by Louis Pillemer in 1954, it is named after the latin word ‘perdere’ 
meaning to destroy, as it is the only known positive regulator in the complement 
system (1). It is a highly positively charged protein which can form various 
multimeric structures (2,3). Properdin is encoded for on the X chromosome in 
humans and a properdin deficient state does exist in humans which is associated 
with increased susceptibility to meningococcal disease (4,5). Furthermore, a 
properdin deficient mice has been generated by targeting the mouse properdin 
gene present on the X chromosome, allowing for the investigation of properdins 
capabilities in-vivo (6). A monomeric chain of properdin (53kDa) consists of 
six type 1 thrombospondin repeats (TSR) (7,8). These monomeric subunits can 
form head to tail associations with each other to generate dimeric, trimeric and 
tetrameric properdin structures (2,9). Serum derived properdin exists in three 
states; dimeric, trimeric or tetrameric in an approximate ratio of 1:2:1 respectively 
(10). In contrast to most complement components which are produced by the 
liver, properdin is produced mainly by white blood cells including monocytes, 
lymphocytes and neutrophils (11-13).
Activation of the alternative pathway can occur by two means: 
The traditional view is via binding of C3b to a surface followed by attachment of 
Factor B to the C3b molecule. The Factor B is cleaved by Factor D resulting in 
the formation of alternative pathway C3 convertase, which becomes bound and 
stabilised by properdin, allowing the enzyme to cleave more C3 to C3b (14,15). 
Properdin has a high affinity for C3b allowing for its unique feature in stabilizing 
the C3 convertase prolonging the functionality of the enzyme five to ten fold 
(3,10). More recently a novel mechanism was proposed where the initial event 
is the interaction and binding of properdin to a specific surface. The properdin 
molecule binds hydrolysed C3 or C3b followed by attachment of Factor B. The 
Factor B is cleaved via Factor D producing the AP C3 convertase (16). Both 
mechanisms of AP activation result in the development of a C3 convertase which 
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can generate more C3b promoting further AP activation should it be unregulated. 
The capacity of properdin to act as initiator and stabilizer in the generation of 
AP C3 convertase allows it to amplify and modulate complement activation 
in a unique manner via C3b generation. The illustration that properdin can act 
as initiator as well as stabiliser has led to the investigations into the various 
other ligands, other than C3b, which it may bind. Properdin can bind various 
ligands including zymosan, lipopolysaccharide (LPS), bacteria, necrotic cells 
and apoptotic cells allowing it to act as an anchor for the alternative pathway. 
One study illustrated the ability of properdin to bind zymosan and bacteria such 
as Escherichia coli, acting as a platform for C3 convertase generation (17). 
Another study investigating the ability of properdin to bind LPS coated on a 
plate demonstrated properdins ability to bind LPS and promote AP C3 convertase 
production (6). Studies by Xu et al (18) demonstrated properdins ability to bind 
late apoptotic and necrotic jurkat cells in the absence of C3, this deposited 
properdin acts a platform for C3 convertase generation on the surface. Properdin 
has also been shown to interact with early apoptotic T lymphocytes leading to 
assembly of the AP C3 convertase on the cell surface, demonstrating properdins 
role in the removal of dying cells (19). These intriguing findings of properdins 
ability to interact with various foreign and self antigens have led to a rejuvenation 
of interest in properdins role in various disease states. 
In this chapter, we will describe the methods required for the purification of 
human properdin from serum and to test its functionality in-vitro.
Materials
2.1 Sample Preparation
2.1.1. Normal human serum (approx 550ml)





2.2.2. Polyethyleneglycol 4000 
2.2.3. Sodium chloride (NaCl) 
2.2.4. Tris 
2.2.5. Ethylenediaminetetraacetic acid (EDTA)
2.2.6. DEAE buffer: 25mM Tris, 70mM NaCl, 2mM EDTA (pH 8.0, 6.5mS) 
2.3 Anion exchange purification materials
2.3.1. Fraction collector 
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2.3.2. Pump
2.3.3. Diethylaminoethyl sepharose column (DEAE-seph)
2.3.4. BCA Protein assay 
2.3.5. Human properdin ELISA 
2.4 C3b column preparation and purification materials
2.4.1. Purified human C3
2.4.2. Trypsin
2.4.3. Trypsin Inhibitor Soybean 
2.4.4. Spectra/Por 6 standard RC dialysis tubing MWCO 50 kDa
2.4.5. Sodium hydrogen carbonate (NaHCO3 )
2.4.6. pH meter  
2.4.7. CNBr-activated sepharose
2.4.8. Hydrochloric acid (HCL)
2.4.9. Glassfilter connected to a vacuum system
2.4.10. Sodium acetate (NaAc)
2.4.11. Coupling buffer: 0.1M NaHCO3 , 0.5M NaCl, pH 8.3 
2.4.12. Bead blocking buffer: 0.1M Tris/HCL, 0.5M NaCl pH 8.0
2.4.13. Wash buffer 1: 0.1 M TrisHCL, 0.5M NaCl pH 8.0
2.4.14. Wash buffer 2: 0.1 M NaAc, 0.5M NaCl pH 4.0
2.4.15. Elution buffer: 0.5M NaCl PBS 2mM EDTA (33.5mS)  
2.5 Functional analysis requirements
2.5.1. Maxisorp 96 well ELISA plate
2.5.2. Phosphate buffered saline sterile (PBS)
2.5.3 Albumin from bovine serum (BSA) 
2.5.4 TWEEN 20 
2.5.5. Rabbit anti human properdin antibody 
2.5.6. Goat anti rabbit IgG horseradish peroxidase (HRP) antibody
2.5.7. 2,2’-AZINO-BIS(3-ETHYLBENZTHIAZOLINE-6-         
 SULFONIC ACID) (ABTS)
2.5.8. ELISA blocking buffer: 1%BSA/PBS 
2.5.9. ELISA diluent buffer: PBS Tween (0.05%) 1%BSA
Method of properdin purification and functional 
analysis
The purification begins with normal human serum which is filtered and treated 
with polyethyleneglycol. The precipitated material is then passed through an 
anion exchange column. The fall through is then added to a C3b column for 
Purification and functional analysis of human properdin   •   69
   4
purification of human properdin. 
3.1 Sample preparation
3.1.1. Remove any fibrin or other precipitates by passing the cold human  
 serum (550ml) through glass wool.
3.1.2. Centrifuge the filtered material at 2053 x g for 10 minutes
3.2 Serum purification
3.2.1. Add 5% polyethyleneglycol (PEG) (27.5gram/550ml serum) 4000 to the  
 filtrate, ensuring the mixture is at least 2°C.
3.2.2. Stir for 15 min on ice.
3.2.3. Allow the mixture to stand for 45 min on ice.
3.2.4. Centrifuge the mixture at 7519 x g for 20 min in a refrigerated   
 centrifuge 4°C (Note 4.1). Dissolve the pellet in 100ml DEAE buffer.
3.3 Anion exchange purification of PEG treated serum
3.3.1. Rinse the DEAE-Sepharose (2.5 x 40cm) column in DEAE buffer  
 (Note 4.2).
3.3.2. Centrifuge the sample reconstituted in DEAE buffer at 2053 x g for 10  
 min.
3.3.3. Apply the supernatant to the DEAE-SEPH column connected to the  
 pump and fraction collector, with a flow rate of 1ml/min at 4°C,   
 collecting 10ml fractions using the fraction collector (Note 4.3).
3.3.4. Test every second fraction in a human properdin ELISA, detecting  
 properdin using a specific anti human properdin antibody.
3.4 C3b column preparation and purification of properdin
3.4.1. Purified human C3 (30 mg, pre-warmed to 37°C) is exposed to trypsin  
 1% w/w for 1 min at 37°C to generate C3b and C3a.
3.4.2. This trypsinisation reaction is inhibited by trypsin inhibitor 2% w/w for  
 2 min at 37°C. 
3.4.3. The trypsinised C3 pool is dialysed in PBS overnight at 4°C using a  
 50,000 Da dialysis membrane, to remove the small molecular weight  
 fragments such as C3a.
3.4.4. Dialyse the trypsinised C3 pool in the coupling buffer pH 8.3 overnight  
 at 4 °C.
3.4.5. Suspend 4 grams of activated Sepharose in 50ml of 1mM HCL for 15  
 min at 4 °C.
3.4.6. Filter the Sepharose in a glass filter using a vacuum system, washing  
 with cold 1mM HCL (approx 500ml) followed by washing in the  
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 coupling buffer (approx 500ml).
3.4.7. Remove the washed Sepharose gel from the glass filter and mix in a 1:1  
 volume ratio with the C3b pool in coupling buffer.
3.4.8. Leave the mix to rotate on a roller overnight at 4 °C.
3.4.9. Wash the Sepharose beads in a glass filter using the coupling buffer  
 (approx 500ml), the purified C3b is then coupled to the activated  
 Sepharose beads.
3.4.10. Block any uncoupled groups on the beads using bead blocking buffer  
 pH 8.0 for 2 hours at room temperature.
3.4.11. Wash in a glass filter with wash buffer 1 pH 8.0 (approx 500ml) three  
 times.
3.4.12. Wash in a glass filter with wash buffer 2 pH 4.0 (approx 500ml) three  
 times.
3.4.13. Repeat step 11 & 12 at least three times.
3.4.14. A final wash in a glass filter using 500ml of PBS. 
3.4.15. The filtered Sepharose beads reconstituted in PBS 2 mM EDTA and  
 poured into a column (1.5cm x 15cm).
3.4.16. Pool the ELISA positive properdin fractions following the DEAE  
 purification.
3.4.17. Centrifuge the fractions at 2,053 x g for 10 min.
3.4.18. Apply the supernatant to the C3b column using PBS 2mM EDTA, with  
 a flow rate of 0.2 ml/min (Note 4.4) at 4°C.
3.4.19. Elute the properdin using elution buffer (33.5mS) (Note 4.5).
3.4.20. Test the fractions in a human properdin ELISA, detecting properdin  
 using a specific anti human properdin antibody (see Figure 1).
Figure 1. C3b column fractionation
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3.5 Functional analysis of properdin
3.5.1.  Coat the pre-made human C3b (5 µg/ml) using PBS on an ELISA plate  
 overnight at 4°C.
3.5.2.  Block the wells using ELISA blocking buffer 1hr 37°C.
3.5.3.  Add the purified human properdin (5 µg/ml titrated in doubling   
 dilutions) diluted in ELISA diluent buffer to the coated C3b wells for  
 1hr 37°C.
3.5.4.  Detect the bound properdin using a specific rabbit anti human   
 properdin antibody diluted in ELISA diluent buffer for 1hr 37°C. 
3.5.5.  Use a goat anti rabbit HRP antibody diluted in ELISA diluent buffer for  
 1hr 37°C. 
3.5.6. Colorimetric reaction determined using ABTS at room temperature,  
 with the absorbance measured at 415nm.
Notes 
4.1. Remove the supernatant following centrifugation and keep the pellet.
4.2. Prepare the columns, buffers and equipment in advance. Ensure   
 the equipment is functional and the columns are clean and leak proof.  
 In particular, the pH and mS (conductivity) of the buffers can be   
 temperature sensitive; the buffers should be equilibrated to the required  
 operational temperature.
4.3.  The properdin should be present in the fall through of the DEAE  
 column. The fractions should be tested for properdin but can also be  
 tested for total protein concentration using the BCA protein assay. It is  
 useful to perform a C3 ELISA on fractions so as to rule out any   
 contaminating C3 in properdin fractions.
4.4.  Connect the C3b column to the pump and fraction collector. The  
 properdin will remain bound to the C3b beads within the column.
4.5.  The 0.5M NaCl should be sufficient to elute the properdin from the  
 column; however 1.0M NaCl can also be used. The conductivity (mS),  
 total protein concentration (BCA protein assay) and properdin levels  
 should be ascertained for every second fraction.
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Abstract 
Neutrophils and complement are key members of innate immunity. The 
alternative pathway (AP) of complement consists of C3, factor B, factor D 
and properdin which amplifies the AP activation. The AP has been implicated 
in many neutrophil mediated diseases such as ANCA vasculitis. The exact 
mechanism by which the AP and neutrophil interact remains largely unstudied. 
We investigated the ability of the AP to interact with neutrophil components 
which can be exposed and released upon activation. Our studies focused on 
neutrophil enzymes including myeloperoxidase (MPO), elastase, lysozyme and 
cathepsin G. All enzymes demonstrated an ability to bind properdin compared to 
azurocidin which did not. However, only MPO illustrated a capability to induce 
C3 activation. We demonstrated MPO-mediated AP complement activation as 
it occurred in the presence of MgEGTA compared to the EDTA control. This 
activation resulted in C3 deposition and required properdin to occur. Furthermore, 
we could show that MPO binds properdin directly which then serves as a focus 
for AP activation. In summary, we show that properdin can interact directly with 
neutrophil components. MPO demonstrates the ability to activate the AP which is 
dependent on properdin. Finally, MPO is capable of inducing properdin initiated 
C3 and C5b-9 deposition in-vitro.
Introduction
The complement system consists of three pathways, the classical, lectin and 
alternative pathway. The AP is composed of C3, factor B, factor D and properdin. 
The AP is unique in that it can become autoactivated, transforming C3 to C3H2O 
(C3b like molecule). This activated C3 binds factor B which is then cleaved by 
factor D forming the C3bBb (AP C3 convertase) which generates more C3b. The 
C3bBb is stabilised by properdin, promoting further C3b generation (1). More 
recently, it was discovered that properdin has a pattern recognition capability 
allowing it to bind, and become initiator of the AP. Properdin is then capable of 
binding C3b followed by factor B and factor D generating the stabilised AP C3 
convertase (2, 3). In short, properdin is the only known positive regulator in the 
complement system and can act as initiator of the AP. 
Properdin can recognise various foreign structures such as Neisseria gonorrhoeae, 
Escherichia coli as well as lipopolysaccharide (LPS)(4). Properdin can also bind 
altered self such as apoptotic and necrotic cells. Studies by Xu et al, demonstrated 
that properdin can bind necrotic splenocytes from both wild type and C3 deficient 
mice excluding any role of C3b in the binding of properdin (5). Furthermore, the 
pattern recognition ability of properdin can promote phagocytosis of apoptotic 
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cells (4). This was illustrated by Kemper et al by demonstrating that properdin can 
bind apoptotic T lymphocytes which can then induce AP complement activation. 
Intriguingly, in this study the apoptotic T cells with properdin attached were 
phagocytosed in the absence of any complement activation (6). Properdin can 
also bind to non-apoptotic/necrotic cells such as the surface of viable stimulated 
neutrophils allowing for complement activation which demonstrates overlap 
between the AP and neutrophil mediated processes (7). 
The AP has been implicated in many neutrophil mediated diseases such as 
rheumatoid arthritis, ischemia reperfusion injury and in particular anti-neutrophil 
cytoplasmic antibodies (ANCA)-associated vasculitis. With this in mind, 
exposure of various neutrophil constituents may allow for interaction with the 
alternative pathway of complement. Human neutrophils have demonstrated the 
capability to produce C3, while in mouse studies it has been demonstrated that 
neutrophils can produce factor B, both integral to the alternative pathway (8, 9). 
Moreover, neutrophils store the only positive regulator of complement, properdin 
in their secondary specific granules (10). In contrast, the majority of ANCA 
autoantigens including MPO are stored in the primary azurophilic granules of 
neutrophils. Activation of neutrophils followed by degranulation allows for an 
assortment of neutrophil enzymes to interact with complement factors. Various 
azurophil granule proteins and oxidants have demonstrated the capacity to 
activate complement (11, 12). MPO itself can activate human C5 to generate 
a haemolytic C5-9 (13). Interestingly, neutrophils activated with anti-MPO or 
anti-PR3 IgG released factors capable of activating the complement system (14). 
With this in mind, exposure of various neutrophil constituents may allow for 
interaction with the alternative pathway of complement. We investigated the 
ability of the AP including properdin to interact with these purified constituents 
in-vitro. We show that various neutrophil enzymes can interact with properdin. 
In addition, MPO demonstrates a clear ability to induce AP activation which 
is dependent upon properdin. Intriguingly, MPO illustrated an ability to anchor 
properdin providing a platform for AP C3 and C5b-9 deposition.
Materials and Method
Reagents
Myeloperoxidase was isolated from human neutrophils (15). Commercially 
available myeloperoxidase from Athens research (Georgia, USA) and Cedarlane 
(Ontario, Canada) was also tested. Azurocidin, lysozyme and cathepsin G 
isolated from human neutrophils were from Athens research. Native neutrophil 
elastase tested from AbD serotec (Oxford, UK). Human properdin was isolated 
from serum by anion exchange and size exclusion chromatography (5), or was 
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obtained from commercial source (Quidel, California, USA). The molecular 
characteristics of properdin were investigated by SDS-PAGE (Fig 1). Properdin 
deficient serum was generated in house using zymosan depletion (16). C3 was 
isolated from human serum and treated with trypsin for the generation of C3b 
(17). The rabbit anti-human properdin DIG, mouse anti-human C3 DIG (RFK-
22) are in house reagents, and the mouse anti human C5b-9 DIG (a kind gift 
from Dr. T.E. Mollnes, Bodo, Norway) (18). Mouse anti human factor P #2 was 
supplied by Quidel while the goat anti human factor P was from Complement 
Technology (Texas, USA). Goat anti-mouse immunoglobulins Horseradish 
peroxidase (HRP) and rabbit anti-goat immunoglobulins HRP were purchased 
from Dako (Heverlee, Belgium). Sheep Anti Digoxigenin (DIG) peroxidase 
was from Roche (Mannheim, Germany). For use in ELISA, all antibodies were 
diluted in PBS BSA (1%) Tween-20 (0.05%) (PTB).
Properdin binding to neutrophil components.
The neutrophil enzymes MPO, elastase, azurocidin, lysozyme, cathepsin G or 
bovine serum albumin (BSA) were diluted in phosphate buffered saline (PBS) 
and coated in a NUNC 96-well plate. The plate was blocked using 1% BSA/
PBS for a minimum of 30 minutes incubated at 37°C. Properdin was diluted in 
PTB and added to the wells for 1 hr. Followed by detection of properdin using 
rabbit anti-human properdin-DIG for 1 hr and sheep anti-DIG HRP for 1 hr with 
development using 3-3, 5, 5-tetramethylbenzidine (TMB). The plate is washed in 
PBS Tween-20 (0.05%) between each step. Data are expressed as optical density 
values at 450nm (OD 450nm). Furthermore properdin binding was demonstrated 
using mouse anti-human factor P #2 and goat anti-human factor P respectively. 
The primary antibodies were developed using corresponding goat anti-mouse 
HRP and rabbit anti-goat HRP followed by TMB.  
Complement activation assays.
For the C3 activation assay, a variety of neutrophil constituents or BSA was 
coated on a 96-well plate using PBS. After coating, the plate was blocked using 
1% BSA/PBS and incubated at 37°C for at least 30 minutes. The wells were 
exposed to normal human serum diluted in GVB++ MgEGTA (33.3mM) or 
EDTA (20mM) for 1hr at 37°C. The plate was washed in PBS Tween-20 (0.05%) 
with mouse anti human C3-DIG (RFK-22) added after for 1 hr. Detection was 
completed using sheep anti-DIG HRP for 1hr and TMB. The plate was washed in 
PBS Tween-20 (0.05%) between each step.
The properdin deposition assays involving NHS were performed similar to 
above however detection was performed using rabbit anti-human properdin DIG 
and sheep anti-DIG HRP using TMB as chromogen. All TMB readings were 
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performed at 450nm.
To show that the alternative pathway activation is dependent upon properdin we 
performed the following experiment. MPO was coated at 2.5 µg/ml using PBS 
on a 96 well plate. A blocking step of 1% BSA/PBS was added for a minimum 
of 30 minutes at 37°C following coating. The wells were exposed to a fixed 
concentration of properdin deficient serum with or without properdin or just 
NHS in GVB++ MgEGTA (33.3mM) or EDTA (20mM) for 1 hr. The plate was 
washed in PBS Tween-20 (0.05%). Mouse anti-human C3 DIG was diluted in 
PTB and added to all wells for 1 hr followed by addition of sheep anti-DIG HRP 
in PTB for 1 hr. The enzymatic reaction was developed using TMB with OD 
values measured at 450nm. Studies testing the ability of properdin to initiate 
complement activation were performed on a 96 well plate coated with MPO 
and BSA respectively. All MPO and BSA coated wells were blocked using 1% 
BSA/PBS for at least 30 minutes at 37°C. Increasing concentrations of properdin 
diluted in PTB were added to the individual wells. The wells were washed using 
PBS Tween-20 (0.05%). A fixed concentration of properdin deficient human 
serum diluted in GVB-/- MgEGTA (33.3mM) or GVB-/- EDTA (20mM) was 
then added for 1 hr. The plate was washed using PBS Tween-20 (0.05%) followed 
by addition of mouse anti-human C3 DIG or mouse anti human C5b-9 DIG, both 
were then detected using sheep anti-DIG HRP as mentioned earlier. The assay 
was developed using TMB and read at 450nm.
Properdin-C3b assay
Based on previous studies demonstrating MPO ability to activate complement 
we set out to determine the exact mechanism involved in the AP activation. 
We coated MPO or BSA using PBS onto a 96 well plate. The coated plate was 
incubated with 1% BSA/PBS as a blocking step for a minimum of 30 minutes 
at 37°C. Increasing concentrations of properdin was added to the individual 
wells for 1 hr. The wells were washed using PBS Tween-20 (0.05%) and a fixed 
concentration of human C3b (30 µg/ml) was added to all wells for 1 hr. The C3b 
binding was detected using mouse anti human C3 DIG (RFK-22) and sheep anti-
DIG HRP each incubated for 1 hr respectively. TMB was used as chromogen and 
the plate was read at 450nm.  
Results
Properdin interacts with various components of neutrophil granules
It has been described that properdin may play a role in neutrophil mediated 
diseases such as ANCA vasculitis (4, 19). Properdin is present in secondary 
granules of neutrophils, and after degranulation can act as a pattern recognition 
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molecule (4, 19). Therefore we investigated the ability of properdin to interact 
with a selection of neutrophil components.
We used an ELISA based system and immobilised the following purified 
neutrophil   factors: myeloperoxidase (MPO), elastase, azurocidin, lysozyme, 
proteinase 3 (PR3) and cathepsin-G (Fig 2). Incubation with a fixed concentration 
of purified human properdin (5µg/ml), resulted in a strong binding to MPO, 
Figure 1. Molecular characteristics of properdin. 
Preparations of properdin were analyzed under 
non reducing conditions in a 10% SDS PAGE gel. 
Following electrophoresis, the gel was stained with 
coomassie brilliant blue and destained using methanol. 
The commercial preparation (lane 1) showed dimeric 
properdin, but no presence of aggregates, even when 
high concentrations are loaded (25µg).While in 
another preparation (lane 2, 1µg loaded), aggregates 
were formed following storage and this preparation 
was excluded from testing. 
Figure 2. The interaction between 
neutrophil components and the AP. In panel 
(a), ELISA wells were coated with MPO, 
azurocidin, lysozyme, proteinase 3, cathepsin 
G all at 2 µg/ml respectively. Furthermore, 
elastase was coated at 8 µg/ml with 1% BSA 
coated as negative control. The coated plate 
was washed and 1% BSA/PBS was added 
as a blocking step for at least 30 minutes at 
37°C. The wells were washed and exposed to 
5µg/ml of properdin, followed by detection 
using rabbit anti human properdin. In panel 
(b) MPO, elastase, cathepsin G, proteinase 3 
and lysozyme were coated at 2 µg/ml with 1% 
BSA coated as a control. Following coating, 
the plate was blocked using 1% BSA/PBS 
for a minimum of 30 minutes at 37°C. The 
wells were washed, with 5% NHS diluted in 
GVB ++ MgEGTA then added followed by 
detection using mouse anti human C3. The 
values in panel (b) were measured in triplicate 
and plotted as mean with standard deviation 
(SD).
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intermediate binding lysozyme, cathepsin G, proteinase 3, elastase and a weak 
binding to azurocidin or BSA as a control protein (Fig 2a). 
As properdin is an instrumental protein in the alternative pathway (AP) of 
complement, we addressed whether under similar conditions immobilised 
neutrophil enzymes are capable of activating the AP of complement. After 
addition of a fixed concentration of 5% normal human serum (NHS) in MgEGTA, 
to specifically allow only AP activation, complement activation was measured by 
the deposition of C3. MPO, and to a lesser extent also cathepsin G was capable 
of activating the AP of complement (Fig 2b). Cathepsin G-induced complement 
activation has been demonstrated previously (20).
Properdin binding to MPO
We further concentrated on the novel interaction between properdin and MPO. 
Although initial interaction of properdin with MPO was demonstrated with an 
in-house purified preparation (15), a similar binding was observed with two 
commercial preparations (Fig 3a). 
Figure 3. Properdin binding to MPO. In panel (a) the various MPO preparations were 
coated to the ELISA wells at 0.5 µg/ml with 1% BSA as negative control. The coated 
plate was incubated at 37°C with 1% BSA/PBS for at least 30 minutes as a blocking step. 
Increasing concentrations of properdin were added to the wells followed by detection 
using rabbit anti human properdin. Panel (b) shows MPO coated at various concentrations 
or 1% BSA coated to the wells. All MPO or BSA coated wells had 1% BSA/PBS added 
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Binding of purified human properdin was demonstrated using a polyclonal 
antibody against properdin. Increasing the concentration of properdin, showed 
dose-dependent binding to MPO, which was already clearly observed with 2.5 
µg/ml of properdin, which is within the physiological range (Fig 3a). 
The binding of properdin was also dependent on the concentration of MPO 
immobilised on the plate when a fixed concentration of properdin was added 
(Fig 3b). Similar to panel 3a, a dose-dependent binding of properdin could be 
demonstrated with either a mouse monoclonal directed against properdin (Fig 
3c), or with a goat anti-human properdin polyclonal (Fig 3d). In all cases only 
limited interaction was observed with the control protein BSA.
MPO activates the alternative pathway of complement inducing C3 
deposition.
It has previously been reported that MPO can interact directly with the human 
complement component C5 allowing for the generation of a haemolytic C5b-
9 complex (13). Therefore, we investigated the conditions required for MPO-
mediated complement activation. MPO or BSA were exposed to 5% NHS diluted 
in either MgEGTA or EDTA conditions, followed by detection of bound C3. 
MPO incubated with NHS in MgEGTA demonstrated a strong C3 deposition 
compared to its respective EDTA and BSA controls (Fig 4a). 
Furthermore testing of a titration of NHS diluted in MgEGTA showed that 
the MPO-mediated C3 deposition is dose-dependent compared to the control 
protein (Fig 4b). This suggests that MPO-mediated complement C3 deposition is 
supported under AP conditions.
for a minimum of 30 minutes at 37°C as a blocking agent. Properdin was added at a 
concentration of 0.25 µg/ml followed by detection using rabbit anti human properdin. In 
panel (c) the MPO was coated at 2.5 µg/ml and 1% BSA as negative control, followed 
by a blocking step of all wells with 1% BSA/PBS for a minimum of 30 minutes at 37°C. 
Increasing concentrations of properdin were added to the wells following by detection 
using mouse anti human properdin #2. In panel (d) the MPO was coated at 2.5 µg/ml and 
1% BSA as negative control. The plate was blocked using 1% BSA/PBS and incubated 
at 37°C for at least 30 minutes. A dose response of properdin was added to the wells 
followed by detection using goat anti human properdin.
Immunohistochemistry
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MPO mediated AP activation is dependent on properdin.
From earlier studies it has been reported that properdin is integral in promoting 
AP complement activation (2). To investigate whether properdin had a role in 
the MPO mediated C3 activation, we added 10% NHS in MgEGTA or EDTA 
to immobilised MPO and detected properdin binding. The findings demonstrate 
significant properdin deposition on MPO in the presence of MgEGTA, but 
with diminished signals observed with the EDTA conditions. These findings 
were reaffirmed by comparing NHS and properdin deficient serum under AP 
conditions (Fig 5a). The results illustrate a clear properdin binding in the NHS 
wells as compared to the properdin deficient serum, demonstrating the need for 
properdin for activation in this setting (Fig 5a). Similar results were obtained with 
recombinant mouse MPO using normal mouse serum and properdin deficient 
serum (data not shown).
Taking into account the ability of MPO to activate the AP and inducing both C3 
and properdin deposition, we wanted to elucidate the role of properdin in this C3 
activation. With this in mind, NHS or properdin deficient serum with/without 
properdin was added to MPO. Properdin deficient serum exhibited significantly 
less C3 bound as compared to its NHS control; however the C3 deposition can 
be restored with the addition of properdin to the deficient serum (Fig 5b). To 
investigate the role of properdin further, we added increasing concentrations of 
properdin to 5% properdin deficient serum (MgEGTA) which was then added to 
Immunohistochemistry
Figure 4. MPO activates AP inducing C3 deposition. In panel (a) ELISA wells were 
coated with MPO at 2.5 µg/ml and 1% BSA as negative control. All coated wells were 
incubated with 1% BSA/PBS as a blocking agent for a minimum of 30 minutes at 37°C. 
A fixed concentration of 5% NHS diluted in GVB++ MgEGTA or EDTA was added to 
the wells with detection by mouse anti human C3. The values in panel (a) were measured 
in duplicate and expressed as mean with SD. In panel (b) MPO was coated at 2.5 µg/ml 
and 1% BSA as negative control to ELISA wells. The plate was blocked using 1% BSA/
PBS at 37°C for at least 30 minutes. Increasing concentrations of NHS diluted in GVB++ 
MgEGTA was added to the wells followed by detection using mouse anti human C3. 
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MPO. The C3 deposited on the well is increased with the dose dependent addition 
of properdin to the deficient serum (Fig 5c). In short, these results indicate a 
significant role for properdin in MPO-mediated complement activation. 
Properdin initiates C3 deposition on MPO.
Recently published data have suggested that properdin may act as an initiator of 
the alternative pathway inducing C3 activation (3). Therefore, we coated MPO or 
BSA exposed it to increasing concentrations of properdin or buffer alone. Next, 
the plate was washed and properdin deficient human serum diluted in MgEGTA 
or EDTA was added to all wells, followed by C3 detection. The results showed 
Figure 5. MPO induces AP properdin consumption. In panel (a) MPO was coated 
at 2.5 µg/ml to ELISA wells. Following coating, all MPO coated wells had 1% BSA/
PBS added as a blocking step which incubated at 37°C for a minimum of 30 minutes. 
The wells were washed and exposed to increasing concentrations of NHS or properdin 
deficient serum diluted in GVB++ MgEGTA or EDTA followed by detection using the 
rabbit anti human properdin antibody. In panel (b) ELISA wells were coated with MPO 
at a concentration of 2.5 µg/ml. The wells were washed and incubated with 1% BSA/PBS 
as a blocking agent and incubated at 37°C for at least 30 minutes. A fixed concentration 
of 5% properdin deficient serum was added alone or with 5µg/ml of properdin diluted in 
GVB++ MgEGTA or EDTA. Also, 5% NHS was diluted in GVB++ MgEGTA or EDTA. 
Detection was performed using the monoclonal mouse anti human C3. In panel (c) MPO 
was coated at 2.5 µg/ml to ELISA wells. The wells were blocked using 1% BSA/PBS 
for a minimum of 30 minutes at 37°C. A fixed concentration of 5% properdin deficient 
serum was added alone or with increasing concentrations of properdin diluted in GVB++ 
MgEGTA. The C3 deposited was detected using mouse anti human C3. P = properdin; 
P-  = properdin deficient.
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only background levels of C3 bound in BSA wells, with a slight increase in the 
MPO wells which did not receive properdin. MPO wells supplemented with 
properdin prior to the addition of properdin deficient serum, demonstrated a clear 
dose-dependent increase in C3 deposition as compared to MPO wells unexposed 
to properdin (Fig 6). Similar results were obtained with a different properdin 
batch (data not shown). In summary, the results indicate that properdin may act 
as an initiator of alternative pathway C3 deposition involving MPO. 
Properdin mediated AP generation of C5b-9
Results described above demonstrate a role for properdin in generating AP 
activation up to the C3 level. Therefore, we investigated whether this AP 
activation would lead to further complement activation and generation of C5b-9. 
This was performed similar to our assay for properdin initiated C3 deposition on 
MPO, with detection performed using a mouse monoclonal antibody specific to 
human C5b-9. 
These results show a clear C5b-9 deposition on MPO compared to BSA coated 
wells which had received 5 ug/ml of properdin followed by serum diluted in 
MgEGTA. The C5b-9 was generated in a complement dependent manner as 
illustrated by its inhibition using EDTA. Furthermore, the AP C5b-9 is generated 
in a dose dependent manner when increasing concentrations of properdin were 
added before addition of properdin deficient serum (Fig 7).
Figure 6. Properdin initiated 
C3 deposition on MPO. 
ELISA wells were coated with 
MPO (1 µg/ml) or 1% BSA 
diluted in PBS. All coated wells 
were blocked using 1% BSA/
PBS and incubated at 37°C for 
at least 30 minutes. The wells 
were exposed to increasing 
concentrations of properdin 
diluted in PTB. The wells were 
washed using PBS Tween and 
5% properdin deficient serum 
diluted in GVB-/- MgEGTA (33.3mM) or EDTA (20 mM) added. C3 deposition was 
determined using mouse anti human C3 DIG and sheep anti-DIG HRP.
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Properdin directed C3b deposition on MPO
Our results indicated a role for MPO in activating the AP of complement, with 
properdin remaining key for this activation. With a previous study demonstrating 
that MPO can induce complement activation (13), we examined the exact 
mechanism involved in our studies using purified components. MPO and BSA 
were coated followed by the addition of increasing concentrations of properdin. 
All wells were exposed to 30µg/ml of C3b followed by detection of C3 deposition. 
The results demonstrate a clear binding of C3b which is dependent on the presence 
of properdin for binding to MPO (Fig 8).
Figure 7. Properdin mediated 
AP generation of C5b-9.
Wells were coated with MPO 
at a concentration of 2.5 µg/
ml or 1% BSA diluted in PBS. 
The coated plate had 1% BSA/
PBS added as a blocking step 
which was incubated at 37°C 
for a minimum of 30 minutes. 
A dose response of properdin 
(5µg/ml) diluted in PTB was 
added to the wells followed 
by addition of 5% properdin 
deficient serum diluted in GVB-/- MgEGTA (33.3mM) or EDTA (20 mM). C5b-9 was 
detected using a monoclonal antibody (AE-11) specific to the neoepitope of the MAC 
complex.
Figure 8. MPO directly 
binds properdin allowing 
for C3b attachment. ELISA 
wells were coated with 0.5 
µg/ml of MPO or 1% BSA 
diluted in PBS. All coated 
wells were incubated at 
37°C with 1% BSA/PBS 
as a blocking step for at 
least 30 minutes. Increasing 
concentrations of properdin 
diluted in PTB were added 
to the wells. Next all wells 
were exposed to a fixed 
concentration of human C3b (30µg/ml) diluted in PTB followed by detection using 
mouse anti human C3.
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Discussion
Several studies have demonstrated a role for the alternative pathway in neutrophil-
mediated diseases. Activated neutrophils and the release of soluble mediators 
have increasingly become the focus of research in this field. In particular in 
ANCA, TNF-stimulated neutrophils, as well as neutrophil extracellular traps 
(NETS), have been postulated as sources of immune activation in the disease 
(21, 22). Enzymes stored within the granules of neutrophils were shown to 
activate complement C5 with oxidants also illustrating similar capabilities (11-
13). Intriguingly, ANCA activated neutrophils themselves release factors capable 
of activating the complement system (14). This led us to address the question 
whether neutrophil components may be involved in the alternative pathway 
activation, and by what possible mechanism it may become activated.
Initially, we focused on properdin and its interplay with neutrophil components, 
as it promotes AP activation. We found that properdin was capable of binding to 
MPO, elastase, cathepsin G and lysozyme but not azurocidin. With these results 
in mind, we wanted to assess the ability of these enzymes which bound properdin 
to activate alternative pathway C3 deposition. Interestingly, only MPO appeared 
capable of inducing significant C3 deposition. It is intriguing to see that not all 
properdin binding enzymes such as proteinase 3, elastase and lysozyme could 
activate complement, suggesting a mode of possibly regulating properdin. To 
ensure our results were reproducible we altered the MPO, properdin and antibody 
detection systems and attained similar results.
After demonstrating that MPO can mediate AP C3 deposition, we focused on the 
exact conditions and whether the process is complement dependent. Our results 
showed clear complement activation in MgEGTA but not in EDTA conditions 
indicating that activation is dependent on the AP of complement. In addition, we 
illustrated that during AP activation on MPO, properdin becomes deposited on 
the antigen in a dose dependent manner. To address the importance of properdin 
in this AP induced C3 deposition we tested the ability of properdin deficient 
serum to induce activation as compared to NHS. The results show that properdin-
deficient serum lacked the ability to induce AP activation as compared to NHS. 
However, this activation could be restored by the addition of properdin to the 
properdin-deficient serum, and restoration of activation occurred in a dose-
dependent manner. Properdin has two known distinct roles in the complement 
field. It can stabilise the AP C3 convertase and act as a pattern recognition 
molecule inducing AP activation (2, 4). We evaluated the ability of properdin to 
interact with MPO initially, followed by exposure to properdin deficient serum as 
a source of complement factors. Our results demonstrated that MPO was capable 
of inducing properdin mediated C3 and C5b-9 deposition, as compared to the 
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control. 
These results indicate a new role for MPO in activating the complement system. 
In addition, this data demonstrates that MPO and the other neutrophil granule 
components demonstrate a pleiotropic range of capabilities in regulating 
complement. It would be interesting to take into account the role of autoantibodies 
to these autoantigens, such as to whether it would enhance AP activation. 
Furthermore, MPO and other enzymes such as elastase are instrumental in the 
process of NETS which may possess capabilities to control AP activation. A 
recent study by Camous et al reinforced the link between neutrophils and the 
AP. Their interesting findings showed that normal activated neutrophils could 
bind properdin released during activation, and subsequently induced AP C3 
convertase generation, indicating another link between the AP and the neutrophil 
(7). The diverse mechanism of AP activation involving the activated neutrophil, 
acting as a source of properdin and a platform for AP activation using enzymes 
such as MPO demonstrates the complex and varied interactions at work. Recent 
publications in the field of ANCA vasculitis, demonstrated the presence of AP 
components at the site of damage, as well as AP activation in the circulation of 
patients with active ANCA vasculitis (23, 24). These findings were reinforced by 
a mouse  model of MPO ANCA vasculitis using various complement deficient 
mice, which demonstrated that the AP is involved in the pathogenesis of the 
condition (14). Our findings are all in-vitro but are comparable with data in-vivo 
(human and mice in ANCA vasculitis); however it will be important to test the 
principles in-vivo in the setting of neutrophil immune and autoimmune mediated 
diseases. 
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Abstract
Properdin is a key positive regulator of the alternative pathway (AP), which can 
bind necrotic cells as well as viable proximal tubular epithelial cells (PTEC), 
independent of complement activation. The AP of complement can become 
activated on the surface of PTEC, with properdin instrumental in anchoring to the 
cell and activating the AP. Studies have indicated that in circulation there is an 
inhibitor of properdin, which exact molecule inhibits properdin is unknown. We 
investigated whether we could inhibit properdin binding to PTEC and necrotic 
cells in-vitro, and whether it would have downstream effects on complement 
activation. We demonstrate that pre-incubation of properdin with normal human 
serum, inhibits properdin binding to viable PTEC. We identified that monomeric 
CRP (mCRP) can bind properdin in solution inhibiting its ability to bind viable 
PTEC cells while pentameric CRP (pCRP) exhibited no such effect. In addition, 
mCRP inhibits properdin directed C3 and C5b-9 deposition on viable HK2. 
mCRP inhibitory ability was not unique for viable cells but could also inhibit 
properdin binding to necrotic Jurkat cells. In summary, we demonstrate a novel 
finding that mCRP is an inhibitor of properdin in both binding to necrotic cell and 
viable cells, regulating C3 and C5b-9 deposition on the cell surface.  
Introduction
Properdin is known as the only positive regulator in the complement system. It 
stabilises the short lived AP C3 convertase (C3bBb) by approximately five to ten 
fold (1). In recent years, it was discovered that properdins role extends beyond its 
ability to act as stabiliser, it can also act as pattern recognition molecule. Properdin 
can recognise pathogenic stimuli including LPS and bacteria, promoting C3 
deposition (2, 3). Furthermore, properdin can bind viable mammalian cells such 
as neutrophils or altered-self including necrotic or apoptotic cells independent of 
complement activation. Studies demonstrating the diverse role of properdin led to 
a re-evaluation of its role in various alternative pathway (AP) activated settings. 
Proximal tubular epithelial cells (PTEC) are capable of activating the AP of 
complement on its surface in-vitro (4-6). Furthermore, complement activation 
has been detected on the apical surface of renal tubules, as was observed for 
nephrotic patients with C3 deposition along the brush border (6). To re-enforce 
these findings that complement plays a role in renal injury, C6 deficient rats 
were protected from damage in a puromycin induced nephrotic model and in 
a remnant kidney model (7, 8). Also, an in-vivo model of proteinuric renal 
disease demonstrated that targeting complement inhibitory components to the 
tubules preserved renal function (9). With earlier findings demonstrating that 
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AP activation occurred on PTEC, studies in our laboratory by Gaarkeuken et al 
demonstrated an integral role for properdin in mediating AP activation on PTEC, 
with deposition of properdin observed on the tubule luminal surface of biopsies 
from patients with proteinuric renal disease (10). Heparan sulphate on the surface 
of PTEC acted as binding sites for properdin, binding which can be inhibited by 
heparinoids (11, 12). In addition, properdinuria was associated with complement 
activation products in the urine and worse renal outcome in patients with at least 
1g/day of proteinuria including diabetic nephropathy and glomerular disease 
cases (13). 
The AP can be activated by the spontaneous hydrolysis of C3 forming C3(H2O). 
This C3(H2O) associates with factor B in the presence of Mg2+. The factor B 
attached to C3(H2O) is cleaved by factor D with the resulting C3(H2O)Bb complex 
(C3 convertase) stabilised by properdin. The stabilised C3 convertase can cleave 
additional fluid phase C3, allowing for the generation of the amplification loop 
(1, 14-17). Recently, another mode of AP activation was identified termed 
the properdin-directed model. This mechanism is dependent on the pattern 
recognition ability of properdin to initially recognise and bind its target surface. 
Once properdin has bound the target surface it can bind C3b followed by factor 
B and Mg2+, which is cleaved by factor D to form the fully stabilised and active 
AP C3 convertase (3, 15). 
Currently there is limited data available on modes of properdin regulation. It has 
been demonstrated that human serum can inhibit the ability of properdin to interact 
with platelets, however the exact mechanism is still unclear (18). Intriguingly, 
during an acute phase response properdin levels decrease in circulation in contrast 
to various other serum proteins, such as C-reactive protein (CRP), which increase 
(19). These two findings indicate the possibility that a protein which is increased 
in serum during an acute phase response may regulate properdin. One such 
protein often used as a marker of an acute phase response is CRP. The normal 
physiological range for CRP is 70-29,000 µg/l with an interquartile range of 340-
1700 µg/l (20). CRP in circulation can increase 10,000 fold following an acute 
phase response with its production in hepatocytes regulated by IL-6. CRP is a 
member of the pentraxin family, consisting of five monomeric (23kDa) subunits 
forming a pentameric structure pCRP (19). Interestingly, pCRP can dissociate 
into monomeric CRP (mCRP) on the surface of activated platelets, apoptotic 
monocytes and apoptotic T cells. The mechanism of dissociation is dependent 
upon lysophosphatidylcholine exposure (21). 
We investigated whether CRP could affect the ability of properdin to bind PTEC 
and to induce AP activation. Our findings demonstrate that mCRP directly 
interacts with properdin in solution, inhibiting its ability to bind PTEC or necrotic 
Jurkat cells, in contrast to pCRP which had no inhibitory effect. Furthermore, 
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mCRP inhibited properdin-directed C3 deposition and C5b-9 generation on 
viable PTEC, demonstrating its novel role in regulating properdin.  
Materials and Method
Reagents
Properdin was obtained from Quidel (San Diego, Calif., USA). Pentameric 
C-reactive protein was obtained from human plasma (Sigma Aldrich) and 
recombinant monomeric CRP a gift from Larry A. Potempa (Roosevelt University, 
Illinois, USA). The immortalised renal PTEC human kidney-2 (HK-2) cells were 
a kind gift obtained from Prof M. Ryan, University College Dublin, Ireland, 
cultured as previously described (10). Jurkat cells were cultured as previously 
described (22). Properdin deficient human serum was generated in house using 
zymosan depletion (23). Mouse anti human factor P #1 obtained from Quidel. 
The mouse anti-human C3 (RFK-22) antibody is an in-house reagent (10) and 
the mouse anti-human C5b-9 (AE-11) was a kind gift from T.E Mollnes (Bodo, 
Norway). Goat anti-mouse IgG Alexa 647 and goat anti mouse IgG Alexa 488 
were obtained from Molecular Probes (Leiden, the Netherlands). Propidium 
iodide (PI) was from Molecular Probes. Rabbit anti human CRP  and digoxigenin 
(DIG) labelled rabbit anti-human properdin are both in-house reagents. Sheep 
anti-DIG peroxidase was from Roche (Mannheim, Germany).
Properdin binding to cells 
For flow cytometry, HK2 cells were trypsinised and aliquoted into respective 
wells. Necrotic Jurkat cells were harvested and aliquoted into respective wells. 
Necrotic Jurkat cells were generated by heat treating at 56˚C for a minimum of 
30 minutes as per previously described (22). A fixed concentration of human 
properdin (5µg/ml or 10 µg/ml, both within the normal serum physiological 
range) or medium alone is pre-incubated in the presence or absence of NHS or 
pCRP or mCRP for a minimum of 30 minutes at 4˚C. The cells were washed 
using their respective medium and exposed to their respective pre-incubated mix 
for 60 minutes at 4˚C. Following the properdin incubation the wells were washed 
twice using flow buffer (PBS with 1% Bovine serum albumin and 0.02% Sodium 
azide). The cells are then exposed to mouse anti-human factor P#1 (1 µg/ml) 
specific for human properdin diluted in flow buffer for 30 minutes at 4˚C. After 
30 minutes the cells are washed and goat anti mouse Alexa 647 in flow buffer, 
is added for 30 minutes at 4˚C. The cells are washed in flow buffer, and cell 
viability assessed using propidium iodide, added just before measuring in the 
flow cytometer. 
For fluorescent microscopy, the HK2 cells were cultured on a 48 well culture 
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plate. Properdin (20 µg/ml) was pre-incubated in the presence or absence of 
pCRP (20 µg/ml) or mCRP (20 µg/ml) for a minimum of 30 minutes at 4˚C. The 
pre-incubated mix is then added to the HK2 cells for 60 minutes at 4˚C. After 
washing the cells, mouse anti human factor P#1 (4 µg/ml) or mouse IgG control 
(4 µg/ml) is added for 60 minutes at 4˚C. Finally, goat anti mouse Alexa 488 is 
added for 45 minutes at 4˚C. 
Properdin-CRP Sandwich ELISA
A rabbit polyclonal anti-human CRP was coated to a Nunc 96 well plate using 
a carbonate buffer pH 9.6. The wells were washed using PBS 0.05% Tween and 
blocked using PBS 1% bovine serum albumin for a minimum of 30 minutes 
at 37˚C. A fixed concentration of human properdin (0.5 µg/ml) or HK2 cell 
medium alone (control) is pre-incubated in the presence or absence of increasing 
concentrations of pCRP or mCRP for a minimum of 30 minutes at 4˚C (as per cell 
based assay). The plate is washed in PBS 0.05% Tween and the pre-incubated 
mix is added to its respective well for 60 minutes at 37˚C. After the properdin-
CRP step the plate is washed using PBS 0.05% Tween. Properdin was detected 
using rabbit anti human properdin-DIG and anti-DIG peroxidase for 60 minutes 
at 37˚C respectively using PBS 0.05% Tween-20 and 1% BSA (PTB) as diluent 
buffer. The enzymatic reaction was developed using 3-3,5,5-tetramethylbenzidine 
(TMB). The plate was washed in PBS Tween-20 (0.05%) between each step. 
Data are expressed as optical density values at 450nm. 
C3b-CRP Sandwich ELISA
In a similar manner to the aforementioned ELISA, a rabbit polyclonal targeting 
human CRP was coated to a Nunc 96 well plate using a carbonate buffer pH 9.6. 
The wells were washed using PBS 0.05% Tween and blocked using PBS 1% 
bovine serum albumin for a minimum of 30 minutes at 37˚C. A fixed concentration 
of human properdin (3 µg/ml) or HK2 cell medium alone is pre-incubated with 
a fixed concentration of mCRP (3 µg/ml) or HK2 cell medium for a minimum 
of 30 minutes at 4˚C. Following the properdin-mCRP pre-incubation, increasing 
concentrations of trypsinised C3b diluted in HK2 cell medium is added for 30 
minutes at 4˚C. The plate is washed in PBS 0.05% Tween and the pre-incubated 
properdin-mCRP-C3b mix is added to its respective well for 60 minutes at 37˚C. 
Afterwards, the plate is washed using PBS 0.05% Tween. C3b was detected 
using mouse anti human C3-DIG and anti-DIG peroxidase for 60 minutes at 37˚C 
respectively using PBS 0.05% Tween-20 and 1% BSA (PTB) as diluent buffer. 
The enzymatic reaction was developed using 3-3,5,5-tetramethylbenzidine 
(TMB). The plate was washed in PBS Tween-20 (0.05%) between each step. 
Data are expressed as optical density values at 450nm.  
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Complement Activation Assays
For the C3 activation assay, the HK2 cells were harvested and aliquoted. A fixed 
concentration of human properdin (10 µg/ml) or medium alone is pre-incubated 
in the presence or absence of pCRP or mCRP for a minimum of 30 minutes at 
4˚C. The cells were washed using medium and exposed to their pre-incubated 
mix for 60 minutes at 4˚C. Following the properdin incubation the wells were 
washed twice using cell medium. A fixed concentration of properdin deficient 
serum (5%) diluted in HK2 medium with MgEGTA (10mM) was added to the 
HK2 cells for a minimum of 30 minutes at 37˚C. Following the serum incubation 
the wells were washed twice using flow buffer. C3 deposition was detected using 
a monoclonal specific for C3 (RFK-22) diluted in flow buffer and incubated on 
the cells for 30 minutes at 4˚C. After 30 minutes the cells are washed twice and 
goat anti mouse Alexa 647 in flow buffer, is added for 30 minutes at 4˚C. The 
cells are washed in flow buffer, and cell viability assessed by propidium iodide 
added just before measuring in the flow cytometer.
For the C5b-9 deposition assay, the protocol is similar to the aforementioned C3 
activation assay. HK2 cells were washed using their culture medium. A fixed 
concentration of human properdin (10 µg/ml) or medium alone is pre-incubated 
in the presence or absence of pCRP or mCRP for a minimum of 30 minutes at 
4˚C. The pre-incubated properdin-CRP mix is added to its respective cells for a 
minimum of 60 minutes at 4˚C. After washing a fixed concentration of normal 
human serum (NHS, 10%) diluted in HK2 medium with MgEGTA (10mM) was 
added to the cells for 120 minutes at 37˚C. Following the serum incubation the 
wells were washed twice using flow buffer. C5b-9 detected using a monoclonal 
specifically targeting the neo-epitope (AE-11, 1 µg/ml), which was diluted in flow 
buffer and incubated for 30 minutes at 4˚C. Following incubation of the primary 
antibody the cells are washed twice with flow buffer. Add goat anti-mouse IgG 
Alexa 647 diluted in flow buffer and incubate for 30 minutes at 4˚C. The cells are 
washed in flow buffer, and cell viability assessed by propidium iodide. 
Results
Properdin binding to HK2 cells is inhibited by normal human serum
Recently we have demonstrated the ability of properdin to bind viable HK2 cells, 
thereby acting as a focal point for complement activation (10). HK2 cells were 
incubated with physiological concentrations of properdin (5 µg/ml), and after 
gating on the viable cell population (Fig 1a), showed a strong and homogenous 
staining for properdin (Fig 1b). In line with a previous report (13), binding of 
properdin could be inhibited in a dose-dependent manner when properdin was 
pre-incubated with normal human serum (Fig 1b, 1c).
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CRP as an inhibitor of properdin binding to viable HK2 cells
Based on the demonstration that the acute phase protein CRP can interact with 
various complement proteins (24), we investigated whether CRP could interfere 
with properdin binding. Initially, properdin was pre-incubated in the presence or 
absence of pentameric CRP (pCRP) or monomeric CRP (mCRP), followed by 
addition to HK2 cells. Fluorescent microscopy showed that properdin deposition 
on HK2 cells cultured on a plate was inhibited by pre-incubation with mCRP 
(Fig 2a). In contrast, properdin binding appeared unaffected by the addition of 
similar concentrations of pCRP (Fig 2a). To further quantify this, we performed 
flow cytometry on PI-negative viable HK2 cells. The properdin binding could 
be specifically inhibited by mCRP, but not by pCRP (Fig 2b,c,d). Increasing 
mCRP concentrations showed a dose-dependent inhibition of properdin binding, 
whereas pCRP even showed an increased properdin binding at the highest 
concentrations (Fig 2e). This data indicates both qualitatively and quantitatively 
Figure 1. NHS inhibits properdin binding to viable HK2 cells. 
Properdin was pre-incubated in the presence or absence of NHS and added to HK2 cells, 
followed by detection of properdin binding. The PI negative HK2 cells (panel a) were 
analysed by flow cytometry for properdin binding. In panel b the medium alone condition 
(open) was compared with properdin (5 µg/ml) alone (filled in) and the pre-incubation of 
20% NHS with properdin (5 µg/ml)(dash line) on viable cells. Furthermore, increasing 
concentrations of NHS were incubated with properdin (5 µg/ml)(panel c), data is mean 
and SD of duplicate measurements.
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that preincubation with mCRP, but not pCRP, can inhibit properdin binding to 
HK2 cells. Furthermore, the higher concentrations of pCRP increased properdin 
binding to HK2 cells.
Figure 2. CRP as in inhibitor of properdin binding to HK2 cells. 
In panel a, properdin (20 µg/ml) was pre-incubated in the presence or absence of mCRP 
(20 µg/ml) or pCRP (20 µg/ml) for 30 minutes which was then added to the HK2 cells 
followed by properdin or control staining. Panel b,c demonstrate flow cytometry staining 
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mCRP complexes with human properdin in solution
Previous studies have demonstrated that both pentameric and monomeric CRP 
can interact with various complement proteins (24, 25). To investigate whether 
pCRP or mCRP can interact with properdin in solution, we used an ELISA system. 
Properdin (0.5 µg/ml) was pre-incubated in the presence or absence of increasing 
concentrations mCRP or pCRP. This pre-incubated mix was added to an ELISA 
plate coated with a polyclonal anti-human CRP antibody, followed by detection 
using a specific polyclonal antibody targeting properdin. The results showed that 
properdin could complex with mCRP in a dose response, while this could not be 
demonstrated with pCRP or the individual components alone (Fig 3a).
for properdin on viable HK2 cells, exposed to a pre-incubation of properdin (5 µg/ml) in 
the presence or absence of  pCRP (15 µg/ml) or mCRP (15 µg/ml). In panel b, cells were 
exposed to medium alone (open) or properdin pre-incubated in the presence of pCRP 
(dash line) or medium (filled in) was added. In panel c, cells were exposed to medium 
alone (open) or properdin pre-incubated in the presence of mCRP (dash line) or medium 
(filled in) was added. The ability of mCRP (15 µg/ml) to inhibit properdin (5 µg/ml) 
binding is clearly demonstrated in panel d as compared to medium or pCRP (15 µg/ml) 
added to properdin, dash line is mean of medium alone, data is mean + SD of duplicate 
measurements. In panel e, increasing concentrations of mCRP or pCRP was added to 
properdin, followed by detection of properdin binding to the HK2 cells.
Figure 3. mCRP complexes 
with human properdin in 
solution. 
In panel a, ELISA wells were 
coated with rabbit anti human 
CRP followed by blocking 
with 1% BSA/PBS. A fixed 
concentration of properdin 
(0.5 µg/ml) was pre-incubated 
with medium, or increasing 
concentrations mCRP or 
pCRP for 30 minutes, which 
is then added to the ELISA 
plate, followed by detection of 
properdin binding, data is mean 
+ SD of duplicate measurements. 
Similar to above in panel b, 
ELISA wells were coated with 
rabbit anti human CRP followed 
by blocking with 1% BSA/PBS. 
A fixed concentration of human 
properdin (3 µg/ml) or medium alone was pre-incubated with a fixed concentration of 
mCRP (3 µg/ml) or medium for a minimum of 30 minutes. Following the properdin-
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Similar to above, in panel b, a fixed concentration of human properdin (3 µg/ml) 
was pre-incubated in presence or absence of a fixed concentration of mCRP (3 µg/
ml), followed by the addition of increasing concentrations of human trypsinised 
C3b. The pre-incubated mix was added to an ELISA plate which was coated 
with rabbit anti human CRP, followed by detection of bound human C3. This 
data demonstrated that the mCRP-properdin complex is still capable of binding 
purified C3b (Fig 3b). In summary, this indicates that mCRP could regulate 
properdin binding, by complexing with properdin in solution.
Properdin directed C3 deposition on viable HK2 cells is inhibited by 
mCRP
We previously showed that properdin can bind HK2 cells inducing C3 deposition 
on the cell surface (10). To elucidate the effect of CRP on this properdin-
directed C3 deposition, we pre-incubated properdin with or without increasing 
concentrations of mCRP or pCRP and exposed it to HK2 cells. The cells were 
washed and a fixed concentration of properdin deficient serum added followed 
by detection of C3 deposited using a monoclonal antibody. Properdin clearly 
directed C3 activation on the surface of the viable HK2 cells as compared to the 
condition exposed to serum alone (Fig 4a). 
Figure 4. Properdin directed C3 deposition on HK2 cells is inhibited by mCRP. 
Panel a,b demonstrate flow cytometry staining for C3 deposition on viable HK2 cells, 
exposed to a pre-incubation of properdin (10 µg/ml) in the presence or absence of  pCRP 
mCRP pre-incubation, increasing concentrations of human trypsinised C3b diluted in 
HK2 cell medium is added for 30 minutes after which it is added to the plate, followed 
by detection of human C3 bound.
CRP as an inhibitor of properdin   •   101
   6
pCRP was incapable of inhibiting properdin directed C3 deposition (Fig 4a), 
whereas mCRP clearly inhibited complement activation (Fig 4b). Increasing 
concentrations of mCRP strongly inhibited C3 deposition almost returning to 
levels of serum alone, while pCRP did not effect C3 deposition (Fig 4c). This 
indicates that mCRP can modulate properdin directed C3 deposition on viable 
HK2 cells.
mCRP inhibits properdin directed C5b-9 generation on viable HK2 
cells
Previous studies in patients with kidney disease demonstrated the presence of 
properdin in their urine which was associated with higher levels of urinary soluble 
C5b-9 and worse renal function (13). Properdin bound to HK2 cells can induce 
generation of C5b-9 on its surface as previously shown (10). We investigated 
whether the ability of mCRP to inhibit properdin directed C3 deposition would 
effect C5b-9 generation (Fig 5). The experiment was performed as similar to 
(5 µg/ml) or mCRP (5 µg/ml), followed by the addition of 5% properdin deficient serum 
as a source of complement. In panel a, cells were exposed to medium alone (open) 
or properdin pre-incubated in the presence of pCRP (dash line) or medium (filled in) 
was added. In panel b, cells were exposed to medium alone (open) or properdin pre-
incubated in the presence of mCRP (dash line) or medium (filled in) was added. In panel 
c, C3 deposition was quantified after increasing amounts of mCRP or pCRP were pre-
incubated with properdin (10 µg/ml), dash line is medium alone.
Figure 5. mCRP inhibits properdin directed C5b-9 generation on viable HK2 cells.
Panel a,b demonstrate flow cytometry staining for C5b-9 deposition on viable HK2 
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above, and gated on PI negative HK2 cells for analysis. We observed that the 
addition of properdin alone prior to the serum step (filled in) induced C5b-9 
generation on viable HK2 cells as compared to serum alone condition (open), 
with no significant effect observed with pCRP (dashed line)(Fig 5a). 
mCRP in similar conditions inhibited the properdin directed C5b-9 deposition as 
observed in the overlay (Fig 5b). This inhibition was observed with increasing 
concentrations of mCRP with the presence of pCRP unaffecting C5b-9 generation 
on viable HK2 cells (Fig 5c). In short, mCRP can inhibit properdin directed AP 
C3 deposition and C5b-9 generation.
Properdin binding to necrotic Jurkat cell is impaired by mCRP
Properdin has been shown to act as a pattern recognition molecule and can bind 
altered-self such as necrotic cells (22). To investigate whether our findings with 
mCRP acting as an inhibitor of properdin binding was unique for viable HK2 cells 
or more generally applicable, we investigated whether it would control properdin 
binding to necrotic Jurkat cells. Jurkat cells were made necrotic by treating them 
at 56 ˚C, resulting in a homogenous population of PI positive cells (Fig 6a).
The strong binding of properdin to necrotic cells could not be inhibited by pCRP 
(Fig 6b), but was strongly inhibited after pre-incubation of properdin with mCRP 
(Fig 6c). This inhibition was specific and dose-dependent and maximal inhibition 
was already obtained with 10 µg/ml of mCRP (Fig 6d,e). In summary, mCRP can 
inhibit properdin binding to viable HK2 cells and necrotic Jurkat cells. 
cells, exposed to a pre-incubation of properdin (10 µg/ml) in the presence or absence of 
pCRP (10 µg/ml) or mCRP (10 µg/ml), followed by the addition of 10% normal human 
serum as a source of complement. In panel a, cells were exposed to medium alone (open) 
or properdin pre-incubated in the presence of pCRP (dash line) or medium (filled in) 
was added. In panel b, cells were exposed to medium alone (open) or properdin pre-
incubated in the presence of mCRP (dash line) or medium (filled in) was added. In panel 
c, C5b-9 deposition was quantified, when increasing amounts of mCRP or pCRP were 
pre-incubated with properdin (10 µg/ml), dash line is medium alone, afterwards all were 
treated with 10% normal human serum.
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Discussion
Our data demonstrates that mCRP can bind properdin in solution inhibiting 
properdin binding and properdin directed AP activation on PTEC. The ability of 
mCRP to inhibit properdin was not unique to PTEC as properdin binding was also 
inhibited with necrotic Jurkat cells. The levels of properdin assayed were within 
the normal physiological level of properdin in circulation which is approximately 
25 µg/ml (26). The level of 3.3 µg/ml mCRP induced significant inhibition of 
properdin binding. One could hypothesise that this may be a mechanism by which 
properdin decreases in circulation during an acute phase response (19). 
Figure 6. Properdin binding to necrotic Jurkat cells is impaired by mCRP. 
Panel b,c demonstrate flow cytometry staining for properdin binding on PI positive Jurkat 
cells (panel a), exposed to a pre-incubation of properdin (10 µg/ml) in the presence or 
absence of  pCRP (10 µg/ml) or mCRP (10 µg/ml). In panel b, cells were exposed to 
medium alone (open) or properdin pre-incubated in the presence of pCRP (dash line) or 
medium (filled in) was added. In panel c, cells were exposed to medium alone (open) or 
properdin pre-incubated in the presence of mCRP (dash line) or medium (filled in) was 
added. In panel d, properdin binding was quantified when mCRP or pCRP (10 µg/ml) 
was added to properdin (10 µg/ml), dash line is medium alone, data are mean + SD of 
duplicate measurements. In panel e, increasing concentrations of mCRP or pCRP were 
pre-incubated with properdin followed by addition to necrotic cells, dash line is medium 
alone, data are mean + SD of duplicate measurements.
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Previous in-vitro studies have demonstrated that complement activation occurs 
on PTEC, which is mediated by the AP (4-6). This mechanism is believed to 
be involved in proteinuria induced renal injury (27). In particular the exposure 
of the apical membrane of PTEC to atypically filtered complement components 
can result in activation of complement possibly due to reduced expression of 
regulators on the surface, however this requires further investigation due to 
conflicting observations (28, 29). Properdin can bind PTEC by interacting with 
heparan sulphates, acting as a platform for complement activation inducing C3 
and C5b-9 deposition (10, 11). Interestingly, in patients with diabetic chronic 
kidney disease, biopsies revealed a tubular mCRP staining in the kidney, which 
is the same location observed for properdin staining in biopsies of proteinuric 
patients (10, 30). This data is suggestive that mCRP may be allowed to interact 
with properdin however it could also possibly bind factor H which has also been 
shown to bind PTEC (12). This would be of interest to study in kidney disease 
patients with proteinuria, staining for the co-localisation of factor H or properdin 
with mCRP to see how it relates to tubular injury.   
Traditionally, native CRP (pCRP) is associated with its ability to induce classical 
pathway activation by binding of a single C1q to two CRP molecules (31). 
Interestingly, pCRP activates early classical pathway components (C4, C2) but 
has limited terminal pathway activity (32). The ability of pCRP to dissociate 
forming mCRP may explain the pleiotropic range of capabilities of CRP. pCRP 
can undergo dissociation to mCRP by means of chemical treatment or a new 
biological mechanism involving lysophosphatidylcholine, as observed on 
activated platelets or apoptotic monocytes and T cells (21). The conversion of 
pCRP to mCRP results in the generation of neo-epitopes with a range of new 
biological functions (33). However, the two forms of CRP differ functionally as 
much a structurally. In contrast to pCRP, mCRP promotes neutrophil survival 
due to its anti-apoptotic activity and it also binds CD16 on human neutrophils 
(34, 35). In thrombus development pCRP appears to have no role while mCRP 
enhances platelet deposition (36). For endothelial progenitor cells mCRP induced 
a pro-inflammatory response, in particular interferon responsive genes, with 
pCRP exhibiting no such response (37). With regard to complement, complement 
factor H-related protein 4 binds pCRP but not mCRP (25). Furthermore, mCRP 
has been demonstrated in previous studies to interact with other complement 
proteins including C4bp, FH and FHL-1 protein indicating its diverse role in the 
complement system (38). The ability of mCRP to interact with FH and promote C3 
inactivation is intriguing as both properdin and factor H bind heparan sulphates in 
PTEC (12, 24). This may suggest a means by which mCRP can aid in regulating 
AP activation on PTEC, by interacting with FH promoting C3 inactivation and 
inhibiting properdin directed complement activation. The unique capability of a 
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fragment of CRP in solution to inhibit properdin and downstream AP activation, 
compared to its multi-complex pentameric structure demonstrates the pleiotropic 
capabilities of this molecule. In particular one could speculate that a possible 
mechanism by which CRP produces limited terminal pathway activation is due to 
regulation of the AP at both the FH-C3 level and controlling of properdin directed 
complement activation. 
These findings would be of particular interest in the clearance of apoptotic or 
necrotic cells whereby properdin has been shown to bind, and pCRP has been 
shown to dissociate to mCRP by means of apoptotic cell surface. Furthermore, the 
properdin-mCRP complex may have a role in the neutrophil field. In particular, 
we recently demonstrated that properdin can interact with myeloperoxidase 
(MPO) modulating AP activation (39), with MPO also capable of binding mCRP 
inhibiting its binding of FH and C1q (40). This area encompassing apoptotic 
cells, neutrophil constituents and complement requires further investigation in 
the future as it may yield findings of interest for neutrophil mediated diseases 
with a complement arm such as ANCA vasculitides. This ability of mCRP to 
control properdin directed complement activation will be of particular interest 
for future studies in the proteinuric renal disease setting and in the clearance of 
apoptotic material.   
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Abstract
Dendritic cells (DCs) and complement are both key members of the innate 
immune system, and are critical for immunogenic as well as regulatory functions 
of adaptive immunity. Recent experimental mouse models have shown that 
production of alternative pathway (AP) components by DCs strongly affects their 
functional capacity to activate and regulate T cell responses. In this study we 
investigated the production and regulation of properdin (FP) and factor H (FH) 
both integral regulators of the AP, by both human monocyte-derived DCs and 
tolerogenic DCs (tolDCs). Both FP and FH were expressed and produced by DCs, 
as shown by Q-PCR, intracellular staining, Western blotting and ELISA, with 
significantly higher levels of both AP components produced by tolDCs. Upon 
activation with IFNγ both cells increased FH production, while simultaneously 
decreasing production of FP. This was unique for IFNγ as LPS and IFNα or IFNβ 
did not demonstrate this dual regulation. IL-27, a member of the IL-12 family 
which elicits features of IFNγ stimulation, did increase FH, but production of FP 
remained unaffected. The functional capacity of FP and FH produced by DCs and 
tolDCs was confirmed by their ability to bind C3b and the capacity of FP to bind 
to necrotic cells. Inhibition of FH production by DCs through siRNA, resulted in a 
greater ability to induce allogenic CD4 T cell proliferation. In contrast, inhibition 
of FP production by DCs led to a significantly reduced allostimulatory capacity. 
In summary this study shows that production of FP and FH by DCs, differentially 
regulates the T cell stimulatory capacity of these cells, and that the local cytokine 
environment can profoundly affect the production of FP and FH by DCs.
Introduction 
Dendritic cells (DCs) and the complement system are both integral members 
of the innate immune system (1, 2). The complement system is composed 
of three distinct pathways-classical, lectin and alternative. Together these 
pathways serve as key mediators of the innate immune response, involved in 
defending the host from pathogens, removing immune complexes and facilitating 
efficient phagocytosis of apoptotic cells (2, 3). A key role of complement in the 
humoral arm of the adaptive immune response has been demonstrated through 
experimental depletion of complement resulting in poorer antibody responses, and 
opsonisation with complement fragments which profoundly lowers the amount of 
antigen needed to induce antibody production (4, 5). Recently, there has been an 
increasing body of evidence demonstrating that complement may function more 
broadly as a link between innate and adaptive immunity. This includes murine 
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studies which have demonstrated a role for the AP in the DC: T cell synapse (6-
8). Both APC and T cells have been shown to increase C3a and C5a receptor on 
their surface, while a surface regulator, decay accelerating factor, has been shown 
to be decreased, allowing for further complement activation (9, 10). 
The AP is unique in that it can become auto activated via C3 hydrolysis generating 
a C3b like molecule which can bind covalently to an activating surface recruiting 
factor B, which is then cleaved by factor D generating a C3 convertase (C3bBb). 
This C3 convertase can convert further C3 to C3b, with stabilisation of the enzyme 
by properdin (FP) allowing for propagation of the AP activation (11). Regulation 
of the AP is key, with FP promoting AP activation and negative regulators such as 
factor H (FH), limiting the availability of C3b, or acting as a co-factor for factor 
I, which degrades C3b. This delicate balance between activators and inhibitors 
of the AP is crucial for controlling complement activation (12). The majority 
of complement proteins are produced by the liver, although white blood cells 
including DCs can also act as a local source of certain complement proteins (13). 
The source of FP is largely restricted to white cells, including neutrophils (14, 
15). Factor H is most abundantly expressed in the liver, but also here extra hepatic 
production has been described, which includes mesangial cells, endothelial cells 
and fibroblasts (16-19). This suggests that local cell populations, either resident 
or infiltrating, can significantly contribute to the overall complement activation at 
a particular site of inflammation.
DCs are distinct among other cells in the immune system as they are uniquely 
equipped to respond to a host of innate stimuli while also adapting and tailoring 
their functions in response to the local cytokine environment. This had led to 
the understanding that DCs are not just immunogenic but that tolerogenic DCs 
also exist. These tolDCs are characterised by differences in cytokine production 
and expression of co-stimulatory molecules, which has a direct impact on the 
strength and quality of their T cell stimulatory capacities (20). Previous studies 
have demonstrated by RT-PCR that DCs can express many components of the 
complement system (21, 22), however protein data to support this has been 
limited. Furthermore there is only limited data available on the regulation of AP 
component production by DCs or particularly tolDC populations. Local production 
of complement components such as C3 by APCs at the site of inflammation or 
immunological synapse can be instrumental in the immune response (8). With the 
demonstration that local AP activation at the interface of APC and T cells plays 
a key role in the regulation of T cell responses (23), regulation of the AP in the 
local environment will be key in controlling the strength of the T cell response. 
Therefore, we investigated the regulation of two integral modulating factors of 
the AP, FP and FH. Combined both molecules have the ability to influence the 
balance of the AP towards activation or regulation.
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In this study, we demonstrate that DCs are a source of FP and FH and that 
tolDCs are superior producers of both components. We observed a differential 
regulation of FP and FH, whereby IFNγ profoundly inhibited FP in both cell 
types, while simultaneously increasing production of FH. This distinct dual 
effect was found to be unique for type II IFN. IL-27 did significantly enhance 
FH levels in DC supernatants. Importantly, RNA interference of FH in DCs 
increased their allostimulatory capacity, while siRNA targeting of FP decreased 
T cell proliferation. Taken together, our data suggests that the local cellular and 
cytokine microenvironment are crucial for overall complement regulation and 
thereby T cell immunity.
Materials and Methods
Cell culture and Reagents 
Human monocytes were isolated from buffy coats obtained from healthy donors 
using Ficoll density gradient centrifugation followed by positive selection using 
anti-CD14 MACS microbeads (Miltenyi Biotech GmBH, Bergisch Gladbach, 
Germany). DCs were generated and cultured in RPMI 1640 supplemented with 
10% heat inactivated fetal calf serum (FCS), 90 U/mL penicillin, and 90 μg/
mL streptomycin (Gibco/Life technologies, Breda, The Netherlands), 5 ng/mL 
GM-CSF and 10 ng/mL IL-4 (Biosource Europe, Belgium), as described before. 
Tolerogenic DC (tolDCs) were generated by addition of Dexamethasone (10−6M 
Dex) (Pharmacy, L.U.M.C., Leiden, the Netherlands) only at the start of culture 
(day 0) (24). Cultures were refreshed with medium containing cytokines on day 
3. For stimulation experiments, immature DCs were harvested on day 6, washed 
and seeded accordingly, followed by addition of 200 ng/ml LPS (E.Coli EH100 
Enzo, Belgium), 100 ng/ml each of IFNγ, IFNα, IFNβ (Peprotech) or 100 ng/
ml IL-27 (R&D). Neutrophils were isolated as previously described (25), briefly 
blood from healthy donors was collected using ACD tubes (BD Vacutainer). 
Neutrophils were isolated by Ficoll-Paque and Dextran T-500 gradients (Sigma 
Aldrich). The preparation contained greater than 90% neutrophils as confirmed 
by flow cytometry using CD16 (R&D Systems), CD11b (BD Biosciences), and 
CD66b (AbD Serotec) antibodies. 
Flow Cytometry
For intracellular staining, cells were stimulated overnight, with the addition of 
Brefeldin-A (10 µg/ml) for the last 5 hrs of culture. The cells were then harvested, 
washed and fixed in PBS containing 4% formaldehyde and 1% heat inactivated 
FCS, washed with PBS containing 1% BSA and permeabilised with perm buffer 
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(PBS, 0.5 % saponin, 0.1% BSA) for 10 mins. Cells were stained with primary 
antibodies including anti-FP (Quidel) and anti-FH (Hycult Biotech, Uden, The 
Netherlands) for 30 mins at 4°C in perm buffer followed by goat anti mouse 
Ig APC conjugated secondary antibody. Isotype matched control antibodies 
were used to determine the level of background staining. The fluorescence was 
measured on a FACS Calibur flow cytometer, and data were analyzed with Flow 
Jo and Cell Quest Software. 
mRNA isolation, cDNA synthesis, and RT-PCR
Cells were harvested and mRNA was isolated from DCs using an Rneasy kit 
according to the manufacturer’s instructions (Qiagen, Hilden, Germany). DNA 
was digested using the on-column RNase-free DNase set. cDNA was synthesised 
using a reverse transcription system kit (Promega) following the manufacturer’s 
guidelines and stored at −20°C until analysis. Specific primers for human 
Properdin, Factor H, IFNγR1, IFNγR2, gp130 and WSX-1 (Table I) were designed 
using the computer software Oligo explorer and synthesised at Biolegio. Primer 
specificity was tested by homology search with the human genome (basic local 
alignment search tool or BLAST; National Center for Biotechnology Information) 
and later confirmed by electrophoresis through 2% agarose gels containing 
ethidium bromide followed by visualisation under UV light. GAPDH was used 
as an endogenous reference gene. For each sample, the relative abundance of 
target mRNA was calculated from the obtained Ct values for the target gene and 
expressed relative to the endogenous reference gene GAPDH.
DC-T cell co-culture
Allogeneic CD4+ T cells were isolated from buffy coats by negative selection 
using the MACS CD4+ T Cell Isolation Kit II (Miltenyi Biotec). DCs from 
all conditions were harvested after 24hrs, washed, and plated in 96-well round 
bottom plates at a starting ratio of 1:40 with 100,000 T cells/well. Cells were 
Table I: Real Time PCR Oligonucleotide sequences.
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cultured for 5 days and supernatant was harvested to measure IFNγ production by 
means of ELISA. Proliferation was assessed by the addition of 3[H]-thymidine 
(0, 5 µCi/well) (24).
Western Blot
DCs were plated at 1 × 106 cells/ml, and stimulated at indicated time points 
with either IFNγ or IL-27. Cells were harvested, washed in ice-cold phosphate-
buffered saline and lysed in medium stringency lysis buffer for 30 minutes. The 
lysates were centrifuged at 13,000 rpm and the supernatants were harvested. 
Protein concentration was determined by a Pierce assay and 30ug was loaded 
per lane. The samples were boiled for 5 min in 1x loading buffer under reducing 
conditions, and SDS-PAGE analysis was performed. Blots were probed for 
p-STAT1, total STAT 1 (both Cell signaling technologies), Properdin (Quidel) 
and factor H (Santa Cruz biotech). Anti β-actin (Abcam, Cambridge, UK) was 
used as a loading control. Blots were stripped using western blot stripping buffer 
(Thermo Scientific, Illinois, USA).
Confocal microscopy
Cells were cultured on 8 well chamber slides (Nunc) and stimulated overnight 
with IFNγ followed by Brefeldin-A for the last 5 hours of culture. The slides 
were subsequently washed and fixed in PBS containing 4% formaldehyde, 1% 
heat inactivated FCS followed by washing with PBS containing 1% BSA and 
permeabilised with perm buffer (PBS, 0.5 % saponin, 0.1% BSA) for 10 mins. 
The DCs were then stained using purified anti-FP or anti-FH followed by goat 
anti-mouse IgG Alexa 488. Hoechst was used for nuclear staining. Stains were 
visualised using Leica TCS SP5 or Zeiss LSM710 NLO.
Complement binding assays
For determination of properdin function, necrotic cells were exposed to supernatant 
of DC or tolDC for 1 hour at 4°C, followed by detection of properdin binding by 
flow cytometry and microscopy. Purified human C3b was coated overnight on a 96 
well Nunc plate followed by exposure to DC or tolDC supernatants and detection 
of properdin binding with rabbit anti human FP. To determine specificity of the 
assay tolDC sups were FP depleted by incubating with anti-properdin pre-coupled 
A/G beads overnight at 4°C. Both depleted and control non-depleted tolDC 
supernatant was assessed for ability to bind C3b as above. For determination of 
Factor H binding, DCs were either unstimulated or stimulated with IFNγ prior to 
supernatant exposure to coated human C3b, followed by detection by mouse anti 
factor H (Abcam).
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Cytokine and Complement production
DCs or neutrophils were plated at 1x106/ml in RPMI and treated as per mentioned 
earlier. Cell culture supernatants were harvested after indicated time points and 
frozen at −20°C until analysis. Subsequently they were tested for the presence 
of IL-12p40 and IL-10 by ELISA (Biolegend, Sanquin respectively) according 
to manufacturer’s instructions, or properdin and FH using in-house specific 
sandwich ELISAs (26, 27) Cell culture medium with 10% FCS unexposed to 
cells was negative in all complement assays used. 
RNA interference
DCs were transfected with 50 nM siRNA through the use of the transfection reagent 
Lipofectamine 2000 (Life Technologies) and were used for experiments 24hr 
after transfection. The following SMARTpool siRNAs were used (Dharmacon): 
CFP, CFH and nontargeting siRNA as a control. Silencing of expression was 
verified by FP and FH ELISA.
Statistical analysis
Statistical analysis was performed with Graph Pad Prism (Graph Pad Software, 
San Diego, CA) using a one-tailed t-test. P-values ≤ 0.05 were considered 
statistically significant.
Results
TolDCs display elevated levels of properdin and FH 
To investigate the ability of DCs to produce properdin (FP) and factor H (FH), 
we first assessed by RT-PCR if FP and FH were expressed in both DC and tolDC 
populations. We demonstrate that DCs and tolDCs expressed both factors, and 
that tolDCs showed more than 10 fold higher transcription of both FP and FH 
compared to DCs (Fig 1A, B). Western blotting was performed to analyse protein 
expression. Under reducing conditions for FP an expected band of approx. 55kDa 
was found, with no discernible changes noted with IFNγ stimulation over time (Fig 
1C). The same cell lysates were assessed for the presence of FH, showing a band 
of approx. 155kDa in lysates of tolDCs (Fig 1D). In this case, expression of FH 
clearly increased over time with IFNγ stimulation (Fig 1D). We further assessed 
FP and FH production within DCs and tolDCs using intracellular microscopy. 
Using this method we could demonstrate expression of FP and FH protein in 
both DCs and tolDCs (Fig 1E). Incubation with IFNγ reduced the presence of FP, 
whereas at the same time it appeared to increase the expression of FH. 
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To further quantify these observations, we performed intracellular flow cytometry, 
and confirmed these opposing effects of IFNγ on FP and FH expression (Fig 1F). 
Figure 1. Expression and production of properdin and FH by human DC and tolDC.
Dendritic cells were harvested after 6 days of culture after which mRNA was isolated 
followed by cDNA synthesis. The transcript levels of (A) properdin (B) Factor H were 
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IFNγ, but not LPS, exerts opposing effects on the production of FP 
and FH by DC and tolDC
To further assess the differences in transcriptional expression and differential 
regulation of FP and FH protein, we performed ELISAs on various cell culture 
supernatants. In line with Q-PCR data (Fig 1A, B), we found that tolDCs produced 
significantly more FP and FH compared to DCs (Fig 2A, B). For comparison, 
supernatants from neutrophils, a widely accepted source of FP, were shown to 
produce levels of FP similar to DCs, but with only minimal production of FH. 
To investigate whether the differential regulation of FP and FH was a general 
feature of mature DCs or was activation dependent, we compared stimulation 
with either IFNγ or LPS. Both stimuli induced the typical cytokine profile, with 
DCs producing high IL-12 and low IL-10, and tolDCs producing no IL-12 but 
high levels of IL-10 (Fig 2C, D). In view of the large differences in FP and 
FH production (Fig 2A, B), we calculated the relative change upon stimulation 
for each donor measured, with the immature/medium state set at 100%. In both 
DC and tolDC we observed that FP production was significantly reduced in the 
presence of IFNγ (Fig 2E, F). This effect was not observed with LPS stimulation 
where no clear regulation was noted. Regulation of FH demonstrated the opposite 
effect, where both cell types showed a significant increase in FH production 
upon treatment with IFNγ (Fig 2G, H). Also here, despite the strong induction of 
cytokine production (Fig 2C, D), LPS did not show any effect on the production 
of FH. 
determined by RT-PCR. GAPDH mRNA expression from the same samples was used 
as an endogenous reference gene (relative mRNA expression). Data shown is mean ± 
SD of 8 independent experiments. DCs and tolDCs were either untreated or stimulated 
for indicated time points with IFNγ. Cells were harvested, lysed and samples were 
loaded on 10% SDS gel followed by transfer to nitrocellulose membranes. Blots were 
probed with antibodies directed against either (C) properdin or (D) Factor H. Blots 
shown are representative of 2 independent experiments. (E) DCs were cultured on 8 
well chamber slides and either untreated or stimulated with IFNγ for 16 hours followed 
by incubation with Brefeldin A for the last 5 hours of culture. The cells were then fixed 
and permeabilised, followed by incubation with anti-FP or anti-FH and detection with 
GaM-Alexa488. (F) DCs were either untreated or stimulated with IFNγ for 16 hours 
followed by incubation with Brefeldin A for the last 5 hours of culture. The cells were 
then fixed and permeabilised, followed by incubation with purified anti-FP or anti-FH 
followed by detection by flow cytometry with GaM-APC. Data shown is mean ± SD of 
3 independent experiments.
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Figure 2. IFNγ exerts opposing effects on the production of FP and FH by DC and 
tolDC.
DCs were harvested on day 6 and re-plated for another 24 hours. (A) FP and (B) FH 
production was measured using ELISA. Data shown is mean ± SD of 8-24 independent 
experiments. Dendritic cells were harvested after 6 days of culture and stimulated with 
IFNγ or LPS. After 24 hours the supernatants were harvested and (C) IL-12p40 and (D) 
IL-10 was measured. Data shown is the mean ±SD of 4 independent experiments. Cells 
were stimulated for 24 hours after which (E, F) FP and (G, H) FH was determined by 
ELISA. Levels upon stimulation were expressed as a percentage relative to medium 
values (relative change). Data shown is mean ± SD of 12-28 independent experiments. 
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TolDCs express elevated levels of IFNγR, IL-27R and STAT-1
We observed that IFNγ displayed its most striking differences regarding FP and 
FH when incubated with tolDCs (Fig 1E). IL-27 is a member of the IL-12 family 
of cytokines, but possesses some effector properties in line with IFNγ stimulation 
(28, 29). We investigated the level of expression of both IFNγR and IL-27R on 
DC and tolDCs, and found that tolDCs express higher levels of both IFNγR1 and 
R2, together making the IFNγ receptor (Fig 3A). In addition, both DC and tolDCs 
expressed the IL-27R, with tolDCs expressing significantly higher levels of both 
gp130 and WSX-1, together generating the IL-27R (Fig 3B). 
Both IFNγ and IL-27 are known to mediate their downstream functions largely 
through phosphorylation of STAT-1. We observed a strong and prolonged 
phosphorylation of STAT-1 in tolDCs upon stimulation with both IFNγ and IL-
27, while in comparison; DCs had a much lower and transient level of p-STAT-1. 
Interestingly, total STAT-1 levels were elevated in tolDCs compared to DCs 
despite the loading control being similar amongst all conditions analysed (Fig 
3C).
Figure 3. TolDCs express elevated levels of IFNγ R, IL-27R and STAT-1.
Dendritic cells were harvested after 6 days of culture after which mRNA was isolated 
followed by cDNA synthesis. The transcript levels of (A) IFNγR (B) IL-27R were 
determined by RT-PCR. GAPDH mRNA expression from the same samples was used 
as an endogenous reference gene (relative mRNA expression). Data shown is mean ± 
SD of 9 independent experiments. DCs and tolDCs were either untreated or stimulated 
for indicated time points with IFNγ or IL-27. Samples were loaded on 10% SDS gel 
followed by transfer to nitrocellulose membranes. Blots were probed with antibodies 
directed against either (C) total or phosphorylated STAT-1. 
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Type I IFNs do not possess the same opposing properties as IFNγ, 
while IL-27 specifically increases FH  
We addressed whether IL-27 could, like IFN-γ, also possess dual roles in regulating 
alternative pathway components in DCs. In addition to IL-27 stimulation we used 
type I IFNs (IFN α and β) to discern whether FP and FH regulation was unique 
for type II IFN (IFNγ) or was more widely regulated across the IFN family. We 
observed that both DCs and tolDCs demonstrated reduced levels of FP upon IFNγ 
stimulation. IFN-α but not IFN-β did significantly reduce FP levels in tolDC 
supernatants, while no regulation of FP was observed in DC with type I IFN 
(Fig 4 A,C). In contrast, IL-27 did not demonstrate any clear ability to regulate 
FP production. The levels of FH remained unchanged in both DC and tolDCs 
stimulated with either IFNα or IFNβ but were significantly up-regulated upon 
IL-27 and IFNγ stimulation respectively (Fig 4 B, D). 
DC derived FP and FH exhibit traditional functional characteristics 
A key characteristic of serum derived FH is its ability to bind C3b, so we assessed 
whether FH found in DC supernatants can also demonstrate functional activity by 
Figure 4. Type I IFNs decrease FP production but do not increase FH, while IL-27 
specifically increases FH.  
Dendritic cells were harvested after 6 days of culture and stimulated with IFNγ, IFNβ, 
IFNα or IL-27. After 48 hours the supernatants were harvested and (A, C) FP and 
(B, D) FH was measured by sandwich ELISA. Data shown is the mean ±SD of 8-13 
independent experiments.
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binding C3b. Although we found minimal binding in immature DC supernatants 
the binding was enhanced in the supernatants from IFNγ stimulated DCs. This 
binding was more pronounced in supernatants of IFNγ-stimulated tolDCs (Fig 5A). 
We assessed the ability of FP derived from DCs and tolDCs to bind its traditional 
ligand C3b and found that while the amount produced by DCs might be too little for 
detection, FP derived from tolDCs showed a strong and dose-dependent binding 
to C3b (Fig 5B). To confirm the specificity of this assay we show that binding is 
inhibited upon depletion of FP using pre-coupled anti-properdin beads (Fig 5C).
Recent evidence suggests that FP possesses additional functions aside from C3b 
binding and may act as an independent recognition molecule for necrotic and 
Figure 5. DC derived FP and FH exhibit traditional functional characteristics. 
Dendritic cells were harvested after 6 days of culture and either untreated or stimulated 
with IFNγ. After 48 hours the supernatants were harvested and incubated on a 96-well 
ELISA plate coated with C3b, followed by detection of (A) FH and (B) FP. (C) To 
determine the specificity of FP binding the same C3b binding assay was performed with 
tolDCs supernatants either untreated or depleted of FP using pre-coupled anti-properdin 
beads. Data shown is representative of 3 independent experiments. (D) Necrotic cells 
were generated and incubated with 48 hour supernatants from immature DC/tolDC, 
followed by detection of FP binding by fluorescent microscopy. (F) The same experiment 
was performed followed by detection of FP binding by flow cytometry and calculated by 
MFI DC supernatant / MFI Medium alone.
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apoptotic cells. Necrotic cells were generated as previously described (30), and 
incubated with DC or tolDC conditioned supernatant followed by detection of FP 
binding. Using fluorescent microscopy, FP binding was detected on necrotic cells 
exposed to DC supernatant and this binding was even more evident on necrotic 
cells exposed to tolDC supernatants (Fig 5D). This binding to necrotic cells 
was confirmed by flow cytometric analysis (Fig 5E), and quantification across 
a number of donors showed that tolDC supernatants demonstrated significantly 
higher levels of FP binding to necrotic cells compared to supernatant of DCs (Fig 
5F).
Inhibition of FP in DCs decreases allogenic T cell proliferation, while 
inhibition of FH enhances the allostimulatory capacity of DCs 
In light of the recent evidence that AP components may play a role in the 
allostimulatory capacity of DCs, we investigated whether silencing of FP or FH in 
human DCs could alter T cell activation in an allogenic setting. We successfully 
and specifically silenced FP and FH in both immature and IFNγ-stimulated DCs 
by up to 60% on average (Fig 6A, F). Cells treated with siRNA were harvested 
and co-cultured with allogenic total CD4 T cells at indicated ratios for 5 days. 
Proliferation was determined by 3[H]-thymidine incorporation. We observed that 
silencing of FP in DCs significantly hampered their ability to induce allogenic T 
cell proliferation compared with DCs with non-targeted siRNA (Fig 6B). This 
inhibition of proliferation was even more pronounced when FP silencing was 
combined with IFNγ stimulation (Fig 6C). The silencing procedure by itself did 
not affect the T cell stimulatory capacity. The reduced proliferation upon FP 
silencing was significant for different individual experiments (Fig 6D). In these 
co-cultures, IFNγ production was relatively low, but showed a trend for reduced 
production in IFNγ-activated, FP-silenced DC (Fig 6E).  
Similar experiments were performed using DCs treated with siRNA targeting 
FH. These cells induced significantly more T cell proliferation compared to non-
target (non) treated DCs (Fig 6G). This was also observed, but to a lesser degree, 
with DCs activated with IFNγ (Fig 6H). Both immature and IFNγ-stimulated 
DCs silenced for FH exhibited more T cell proliferation, in particular at a ratio 
of 1:40 (Fig 6I). We assessed the production of IFNγ in T cell supernatants and 
found that immature DCs silenced for FH induced more IFNγ production. In line 
with our proliferation data the stimulatory effect of silencing FH was less potent 
when the DCs were first activated with IFNγ (Fig 6J). Taken together loss of FH 
induced more T cell proliferation while loss of FP decreased T cell proliferation, 
suggesting that the local complement activation is important in regulating DC: T 
cell responses. 
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Figure 6. Inhibition of FP in DCs decreases the allostimulatory capacity of DCs 
while inhibition of FH enhances allogenic T cell proliferation.
DCs were either non treated, or treated with siRNA targeting FP or non-specific (non) 
target. After 24 hours of culture, with or without IFNγ activation, supernatants were 
harvested and FP was measured by ELISA (A). DCs with either FP or control silencing, 
without (B) or with IFNγ (C) stimulation were co-cultured with allogenic CD4+ T 
cells at indicated ratios. T cell proliferation was determined at day 5 of culture by 3[H] 
incorporation. Data shown are the mean ±SD of triplicate cultures. The mean ±SD of 
proliferation (D) and IFNγ production (E) at the 1:40 ratio of 3 independent experiments 
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Discussion
Dendritic cells are a heterogeneous population of professional antigen presenting 
cells responsible for both the initiation of immunity and immunological 
tolerance. Recent murine studies have suggested that complement activation 
is a key determinant in the ability of APCs to direct T cell responses. In this 
study we show that production of FP and FH by DCs is subject to regulation by 
IFNγ and IL-27 and that modulation of these regulators of the AP determines the 
potency of the T cell response. This implicates the local cellular and cytokine 
microenvironment as crucial mediators of overall complement regulation and 
subsequent T cell activation.
Several exciting studies over the last decade have introduced complement as a 
system that actively plays a role in regulating T cell immunity. By generating 
bone marrow APCs from C3-/- (31, 32), factor B-/-, factor D-/-, C3aR-/- (33) 
and C5aR-/- (34) mice, various groups demonstrated that DCs require local 
complement activation in order to become fully competent APCs. To date these 
studies have mainly focused on rodent models, however DCs from C3 deficient 
individuals (35) were also shown to have impaired DC differentiation. More 
recently, a role of C3a and C5a derived from human DC in T cell proliferation has 
been demonstrated in-vitro and in a humanized mouse model (8). Further work 
on human DCs and the contribution of other complement factors has remained 
finite with mostly transcriptional analysis and limited protein data. 
We focused on monocyte-derived DCs and tolerogenic DCs and showed that 
both cells produced FP and FH in an immature state with tolDCs expressing 
much higher levels of both components. Some studies have demonstrated gene 
expression of FP and FH in plasmacytoid DCs (21). Although we did not perform 
PCR analysis on pDCs, we did test cellular supernatants and did not find any 
detectable levels of both components analysed in this study (data not shown). 
Several complement components have been shown to possess GAS and ISRE 
elements in their promoters (36, 37), so we assessed the ability of IFNγ to regulate 
FP and FH. Interestingly, IFNγ possessed opposing roles by decreasing FP 
of cells silenced for FP is shown. DCs were either non treated, or treated with siRNA 
targeting FH or non-specific (non) target. After 24 hours of culture, with or without 
IFNγ activation, supernatants were harvested and FH was measured by ELISA (F). 
DCs with either FH or control silencing, without (G) or with IFNγ (H) stimulation were 
co-cultured with allogenic CD4+ T cells at indicated ratios. T cell proliferation was 
determined at day 5 of culture by 3[H] incorporation. Data shown are the mean ±SD of 
triplicate cultures. The mean ±SD of proliferation (I) and IFNγ production (J) at the 1:40 
ratio of 3 independent experiments of cells silenced for FH is shown. 
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production, while increasing FH. Decrease of FP upon IFNγ stimulation has been 
observed in primary monocytes and THP-1 cell lines (38), but to our knowledge 
this is the first report of this dual effect on FH and FP in human DCs. IFNγ is the 
only member of the type II IFNs so we questioned whether the regulation of FP 
and FH was unique for this specific member, or was a broader feature of the IFN 
family, including type I IFNs. IFNα and IFNβ behaved comparably in terms of 
FP and FH regulation and did not possess the same regulatory properties of IFNγ. 
The IL-12 family has been gaining attention as a key regulator of immunity and 
immunological tolerance (39, 40), and one family member, IL-27 has been shown 
to exert some functions typically seen with IFNγ stimulation (28, 29, 41, 42). 
Interestingly IL-27 stimulation of DCs did increase production of FH but did not 
influence FP production again stressing the uniqueness of IFNγ in its differential 
regulation of these two opposing molecules of the complement system. 
We observed in our study considerable variation using LPS stimulation, with 
no clear regulation of FP or FH evident across a number of donors, despite its 
ability to induce IL-12p40 and IL-10 production. This fluctuating effect of LPS 
on FP production was not observed for FH. There are some conflicting reports 
regarding the ability of LPS to regulate FP. While it has been shown that LPS can 
up regulate FP in monocytic cells lines (38), decreased transcriptional expression 
has been observed in murine BMDCs (33). Conversely again up-regulation of FP 
mRNA has been seen in human DCs (21). This may be explained by different 
strains of LPS used in sets of experiments. 
We performed western blot analysis to confirm that FP and FH possessed the 
expected molecular structure. FP demonstrated an expected band at approx. 
55kDa under reducing conditions. While we did observe a band of approx. 
155kDa for FH in tolDC lysates no clear band was evident in DC lysates. Other 
studies demonstrating FH in DCs have focused on DC supernatants (21) and it 
may be that our detection method was not sensitive enough to detect FH in DC 
cell lysates. Notably we did observe two smaller bands of approx. 30-35kDa 
(data not shown). Further work is needed to determine if these molecules are FH 
like or related proteins and what role they might play in DC biology, although a 
role in phagocytosis has been demonstrated previously (43). Functionally both 
FP and FH were active in the traditional complement assessment by binding to 
C3b. In recent years FP has been shown to act as a recognition molecule (11, 44, 
45) with the ability to bind to, amongst others, apoptotic (46) and necrotic cells 
(30). We found that FP from DCs could bind necrotic cells though we did not test 
whether this was independent of complement activation. 
We have shown that cytokines can profoundly and differentially regulate the 
opposing regulators of the AP, FP and FH. IFNγ stimulation of DCs also changes 
many phenotypical features of DCs including up-regulating co-stimulatory 
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molecules such as CD80 and CD86. In order to establish whether simply 
shifting the balance of production of FP and FH could alter the allostimulatory 
capabilities of DCs we silenced FP or FH in DCs and co-cultured these cells with 
allogenic CD4 T cells. We found that inhibition of FH led to a significant increase 
in T cell proliferation while inhibition of FP led to decreased proliferation. DCs 
silenced for FP and pre-matured with IFNγ were even further hampered in their 
allostimulatory capacity, likely because of the combined silenced by siRNA 
and decreased FP production by IFNγ. Further work is needed to fully establish 
whether the diverging T cell proliferation is a direct effect of FP and FH on the T 
cells or a consequence of altered local complement activation. 
Taken together our results demonstrate a novel role for FP and FH production by 
DCs to be a key regulator of  T cell activation. Both molecules can be influenced 
by IFNγ whereas only FH is increased by IL-27, indicating that the local cellular 
and cytokine environment can potentially influence the local complement 
activation and in turn local T cell responses.
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8.1 The Complement system over time
The term “complement” was coined by Paul Ehrlich, to describe the ability of these 
heat labile proteins to complement humoral immunity, supporting its bactericidal 
role (1). Although the naming has not changed since its inception, it portrays 
the complement system as a limited “fringe” player in the immune response. 
Historically, the complement system will always be remembered as an anti-
bacterial specific arm of our innate immunity; however complementologists over 
the last few decades have illustrated the dynamic role the complement system has 
in our bodies. The central roles of the complement system include host defense 
against pathogens, clearance of apoptotic material and immune complexes, and 
regulation of the adaptive immune response (2, 3). The complement system is a 
collection of 30 or more serum proteins, with a collection of various complement 
proteins generally required to fulfil its role. Noteworthy, is the fact that over 
recent years various functions of complement proteins have been discovered, 
independent of complement activation, as observed with properdin and factor 
H (4, 5). The new and emerging functions of complement proteins demonstrates 
the pleiotropic capabilities of this unappreciated system. The aforementioned 
central roles of complement in clearance of apoptotic, necrotic material or 
immune complexes and its role in the adaptive immune response emphasises 
the close association between complement and autoimmunity (6). In this thesis 
we investigate the role of the complement system in particular the CP and AP 
in autoimmunity and immune-homeostasis. We focus on novel emerging roles 
of regulation and activation of the AP and possible roles it may play in disease 
states.
8.2 Complement and autoimmunity
Complement is associated with various autoimmune diseases including SLE, 
ANCA vasculitides and anti-GBM disease (7, 8). The role of complement in 
autoimmunity is believed to be linked to the waste disposal hypothesis or the 
ability of complement to modulate the adaptive immune response. Failure in 
clearance of apoptotic material in the body, as proposed in the waste disposal 
hypothesis, precludes maintenance of self-tolerance, as observed with C1q 
deficient individuals who are at greater risk of developing autoimmune diseases. 
The ability of complement to control the adaptive immune response, as illustrated 
with C3 activation acting as an adjuvant lowering the threshold for B cell 
activation, may also support an autoimmune disease setting whereby autoreactive 
B cells are resident (2, 6). 
Initially we focused on the role of complement in SLE, a setting whereby exposure 
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of autoantigens and presence of autoantibodies can modulate the disease course. 
In chapter 2 we demonstrate that glomerular endothelial cells, a cell targeted in 
the disease, can bind nucleosomes, one of the autoantigens in SLE, as well as 
the complement factor C1q. These cell-bound autoantigens can be targeted by 
monoclonal or polyclonal autoantibodies including anti-nuclear autoantibodies 
from serum of patients with SLE. The binding of anti-C1q autoantibodies and anti-
nucleosome autoantibodies mediates an additive effect on complement activation. 
Our in-vitro studies revealed that complement activation on these endothelial cells 
was dependent upon the classical pathway. The findings demonstrate the close 
relationship between classical pathway components, such as C1q and anti-C1q 
autoantibodies, and the role they may play in the development of lupus nephritis.
Over the years, the AP of complement has increasingly become implicated in the 
pathogenesis of autoimmune diseases, as observed with ANCA vasculitides and 
goodpastures syndrome (9, 10). The exact role of the AP in these disease settings 
may be multi-faceted; due to the increasing array of possibilities by which the AP 
may become activated or regulated. The well-known capability of the AP to act as 
an amplification loop for the complement system is an obvious avenue by which 
the AP can become an integral player in complement mediated autoimmune 
injury. The ability of the AP to deposit 107 C3b molecules in less than five 
minutes clearly demonstrates the speed by which this pathway can overcome the 
homeostatic situation, indicating the need for it to be tightly regulated (11-15). 
In-vivo models of such autoimmune diseases can aid in elucidating the role 
of the AP, in particular with the introduction of complement deficient mice. 
Consequently, in chapter 3 we investigated the role of the AP in a mouse model 
of anti-GBM disease. Previous studies had indicated a role for the AP in this 
antibody-induced renal injury, with limited data available on the exact mechanism 
involved (16). Taking the principle that the AP has a role in anti-GBM disease 
we induced a similar model of anti-GBM disease in WT, properdin-/- and C3-
/- mice. As expected, administration of anti-GBM antibodies induced significant 
proteinuria and complement activation. However, in this model deficiency in 
either properdin or C3 did not significantly ameliorate the disease, indicating 
that damage at the indicated time-point was complement independent. Previous 
studies have indicated a pathogenic role for polymorphonuclear granulocytes 
in mouse models of anti-GBM disease. The influx of granulocytes into the 
glomerulus and the presence of Fc receptors were integral to the development 
of albuminuria (17). This mechanism may explain our findings whereby 
albuminuria persisted independent of complement. Through the generation of 
an in-house mouse properdin ELISA and an immuno-fluorescent staining for 
mouse properdin we have been able to demonstrate the presence of properdin 
in the anti-GBM model. Interestingly, our results demonstrated the presence of 
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mouse properdin in WT mice which was absent in properdin-/- mice (deficient 
for properdin in serum) injected with the anti-GBM. Furthermore, properdin was 
deposited in glomeruli of C3-/- mice injected with anti-GBM antibody indicating 
that properdin had bound independent of C3. To our knowledge, this is the first 
time that properdin, a key stabiliser of the AP C3 convertase and promoter of the 
AP has been shown to bind independent of C3 in-vivo. The use of key diagnostic 
tools including a sandwich ELISA for mouse properdin and a histological stain 
for mouse properdin can expand our knowledge base for the role of properdin in 
mouse models of disease, in particular those using complement deficient mice. 
Noteworthy we observed a significant increase in circulating properdin levels 
over the time course of anti-GBM, suggestive of increased synthesis which has 
not been observed in previous murine studies, allowing us to compare the murine 
model in more in-depth to the human situation. The finding in-vivo that properdin 
can become deposited at the site of injury independent of activated C3, one of 
its principle ligands, supports in-vitro findings that human properdin can act as a 
pattern recognition molecule (5, 18). 
8.3 Properdin-directed model of the alternative  
pathway
Properdin is unique in that it is the only known positive regulator of the 
complement system, and a key member of the oldest of all complement pathways 
the alternative pathway. Since, its discovery by Louis Pillemer, 60 years ago, it 
has had a controversial beginning resulting in a stunted properdin research field 
until recently (19). The “traditional” model of AP activation by C3 “tickover” 
and assembling of the resulting C3 convertase, which is stabilised 5-10 fold by 
properdin demonstrates its key function in regulating the AP (20, 21). Recent 
studies, re-affirmed by various other groups, have demonstrated a second mode 
of AP activation in the human complement setting (5, 12, 22-24). This new 
properdin-directed model of activation whereby properdin acts as an initiator of 
the AP, providing anchorage as a focal point for C3 convertase assembly on an 
activating surface. The ability of properdin to act as a focal point, has led to 
a renewal of investigations into properdin binding surfaces and whether it can 
support AP activation. Properdin has been shown to bind to platelets, viable 
cells or necrotic cells and apoptotic cells expanding the roles of this previously 
ignored protein (12, 22-26). The functional repertoire of properdin has expanded 
to include roles in pattern recognition, lipid metabolism and phagocytosis (12, 
22, 27).
In chapter 4 we describe a method of purifying human properdin, while in 
chapter 5 we investigate the ability of human properdin to act as pattern 
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recognition molecule in-vitro. Properdin is a serum derived protein, which in 
contrast to most complement proteins is synthesised extra-hepatically, for 
instance by white blood cells such as neutrophils. In circulation properdin exists 
as dimers, trimers, tetramers and pentamers with a normal plasma level of 25 µg/
ml observed in humans (28-33). The AP has been implicated in various neutrophil 
mediated diseases including ANCA vasculitides, where neutrophil enzymes are 
the autoantigenic targets. The exact mechanism by which the AP is involved 
in ANCA vasculitides remains unclear, with AP activation demonstrated in the 
circulation of patients with active ANCA vasculitides and at the site of injury (7, 
9, 34-37). Activation of neutrophils, resulting in degranulation, allows various 
neutrophil enzymes to interact with complement factors. We demonstrated that 
various neutrophil enzymes, including the principal ANCA autoantigens, are 
capable of binding properdin in-vitro. Properdin bound to lysozyme, cathepsin 
G, elastase, proteinase 3 and in particular myeloperoxidase (MPO). Furthermore, 
MPO exposed to serum is capable of inducing AP C3 deposition, which was 
significantly reduced with properdin-deficient serum. More in-depth analysis 
revealed that binding of properdin to MPO supported AP C3 deposition and 
increased generation of C5b-9. The findings indicated a new role for MPO in 
activating the complement system and illustrate its ability to support properdin-
directed complement activation. Interestingly, various neutrophil enzymes bound 
to properdin without the ability to activate complement (as shown for MPO), 
suggesting an additional mechanism of regulating properdin in the context of 
neutrophil degranulation.
8.4 Alternative pathway modulators: emerging roles 
and their regulation 
The ability of properdin to act as a pattern recognition molecule, providing a focal 
point for complement activation on either viable PTEC or necrotic cells, is an area 
which is still relatively unexplored. Under normal conditions, properdin is not 
filtered by the glomerulus and as such is not able to reach the apical membrane 
of PTEC. However, if the permeability of the glomerulus becomes compromised, 
properdin will leak through, allowing it to bind PTEC, as demonstrated in kidney 
biopsies of patients with proteinuria (25). Furthermore, the presence of properdin 
in the urine, properdinuria, is associated with increased complement activation 
and worse renal function (38). 
Since properdin is known as the only positive regulator in the complement 
system, this could lead to the impression that properdin remains completely 
unopposed and unregulated. Currently, there is limited data available with regard 
to the presence of molecules negatively regulating the function of properdin. 
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However it does seem rational that a system such as the complement system, 
which is heavily regulated at various junctions, would have a regulator for the 
only positive modulator of the system. Properdin exhibits a unique trait compared 
to most complement proteins during an acute phase response. While the majority 
of complement components such as C2, C3, C4, and C5 increase during an acute 
phase response, levels of properdin decrease (39). This decrease in circulating 
properdin levels could be due to consumption, reduced production or due to a 
negative regulator of properdin, which may be increased during an acute phase 
response. Although still speculation, recent results have indicated that indeed an 
inhibitor of properdin binding exists in normal human serum (23).
We focused on the regulation of properdin binding to PTEC (Chapter 6), where 
it acts a focal point for complement activation resulting in terminal pathway 
activation. We investigated whether properdin binding could be inhibited by 
normal human serum, possibly confirming the existence of an inhibitor. Our 
data showed that human serum inhibited in a dose dependent manner the ability 
of properdin to bind to PTEC. With the findings of Pepys in mind (39) we 
investigated whether an acute phase protein may be a candidate inhibitor. Our 
studies focused on C-reactive protein (CRP), both the conventional pentameric 
CRP and the dissociated form, monomeric CRP (40). We demonstrated that 
specifically monomeric CRP could inhibit properdin binding to viable PTEC, 
whereas pentameric CRP did not exhibit such activity. Interestingly, monomeric 
CRP could in solution form a complex with properdin, while its larger pentameric 
form was unable to do so. The ability of monomeric CRP to inhibit properdin 
binding to PTEC, impeded properdin-directed C3 deposition and C5b-9 
generation on these cells. More importantly, this inhibitory feature of monomeric 
CRP was not unique for the binding of properdin to PTEC, since it also prohibited 
properdin binding to necrotic Jurkat cells. These findings indicate that properdin 
is capable of binding to a dissociated form of pentameric CRP in solution, further 
expanding its capability to bind various other ligands independent of C3. This 
was re-enforced by the observation that properdin binding to PTEC was inhibited 
by human serum deficient in C3 (Fig 1)(O`Flynn, unpublished). Taken together, 
it suggests that within the architecture of the expansive acute phase response 
there is a negative feedback loop to control alternative pathway activation by 
controlling its only stabiliser and initiator. This may be of particular interest in 
the field of platelet activation and apoptotic cell clearance whereby a mechanism 
of dissociation of the pentameric CRP to monomeric CRP has been described 
(40).
The distinct ability of the alternative pathway to become auto-activated makes 
it increasingly susceptible to the role of AP regulators. Properdin promoting AP 
activation is counter-acted by factor H, the most prominent AP negative 
General discussion   •   137
   8
regulator. This delicate balance between promoters and inhibitors is often ignored 
and under-estimated in most settings of AP research. Researchers often prefer to 
focus on a single regulator leading to an in-balance in the studies, resulting in a 
dogma that only a single regulator is important in that AP research setting. This 
can be clearly observed in complement system diagrams whereby one or both 
AP regulators are ignored. The clear ability of properdin to act as initiator and 
stabiliser of the AP C3 convertase (C3bBb) is in stark contrast to factor H. 
Factor H limits the availability of C3b or acts as co-factor for factor I which 
degrades C3b. Factor H is similar to most complement components as it is mainly 
produced by the liver with limited data available on extra-hepatic sources, in 
contrast to properdin which is largely restricted to white blood cells (18, 41). 
Data on production and regulation of both properdin and factor H by primary 
cells is limited, mainly focusing on messenger RNA and even less details on 
levels of protein produced. The ability of white cells to act as a local source of 
complement factors including regulators enables the local or infiltrating white 
cells to modulate the immunological response at the site of injury. In chapter 
7 we examined whether primary human dendritic cells (DC), a potent antigen 
presenting cell, can produce both properdin and factor H and if so by what 
means can it be regulated? Indeed, monocyte derived DC or tolerogenic (tol) 
DC produce properdin and factor H, with tol DC producing significantly more of 
both AP regulators. In particular the unique capability of IFNγ to tip the delicate 
balance of the AP towards negative regulation. The quantity of both properdin 
and factor H produced is quiet limited compared to the levels observed for both 
in circulation, however local production can put it to potent use in a site of 
Figure 1: C3 deficient human serum inhibits properdin binding to HK2 cells. Pre-
incubation of increasing concentrations of NHS or C3 deficient human serum inhibits 
properdin (5 µg/ml) binding in a dose dependent manner to viable HK2 cells. Properdin 
binding detected using a monoclonal antibody to properdin.
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inflammation or at the immunological synapse. Over recent years, studies have 
revealed a role for the AP in the interface between APC and T cells, and showed 
the capacity of local complement activation to modulate T cell responses (42-44). 
However, the demonstration of a key role for AP activation in the APC-T cell 
synapse did not take into account any role for either properdin or factor H. Our 
studies (chapter 7) demonstrated the constitutive capability of DC to produce 
properdin and factor H, with significantly higher levels of both AP components 
produced by tolDCs. Upon activation with IFNγ both cell types increased FH 
production, while simultaneously decreasing production of FP. This was unique 
for IFNγ as LPS and IFNα or IFNβ did not demonstrate this dual regulation. 
IL-27, a member of the IL-12 family which elicits features of IFNγ stimulation, 
did increase FH, but production of FP remained unaffected. This prompted us 
to investigate if either DC-derived regulators of the AP had a role in the APC 
T cell synapse. Therefore we silenced production of properdin or factor H in 
DCs, and investigated the impact on allogenic T cell activation. Interestingly, 
silencing of DC factor H resulted in increased T cell proliferation. In contrast, 
RNA interference of DC-derived properdin diminished their allostimulatory 
capability. Cumulatively, these results indicate the importance of both AP 
regulators, guiding the AP towards activation or regulation. Noteworthy, is the 
capability of both DC derived regulators even at relatively low levels to induce 
opposing effects on the T cell population in the surroundings. This emerging role 
of properdin and factor H in the immunological synapse illustrates the benefit of 
analysing both regulators production, regulation and functionality. The findings 
re-instate the AP as a key modulator at the interface between DC and T cells, 
affecting downstream T cell capabilities.
 
8.5 Future directions
This thesis is focused on the role of the complement system in healthy and 
autoimmune settings. In particular, we focused on the classical pathway and the 
alternative pathway, with the latter having received less attention in-vivo, partly 
due to lack of reagents. The final part of this discussion will revolve around the 
open questions and future research lines which may benefit our understanding of 
the AP and its emerging roles. In chapter 3, we re-affirm the proposed properdin-
directed model in-vivo, which was only possible due to the generation of novel 
antibodies for detecting mouse properdin. The immunofluorescent staining and 
sandwich ELISA for mouse properdin will be of particular interest in mouse 
models of neutrophil mediated diseases including ANCA vasculitides which is 
driven by AP activation. The ability to demonstrate consumption or increased 
production of properdin in circulation may aid in assessing the balance of the AP. 
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Furthermore, the ELISA may prove instrumental in characterising the possible 
variations between mouse and human, as to which cells are capable of producing 
properdin and how this production is regulated. The histological stain for mouse 
properdin was key to demonstrate deposition of properdin independent of C3, 
which may be particular useful in various other murine disease models or in 
development whereby a proposed role for properdin had been postulated (45). 
The capacity of properdin to bind various neutrophil enzymes and its involvement 
in phagocytosis independent of C3 could be tested histologically in an in-vivo 
mouse model. The ability of properdin to become deposited in the absence of 
C3 in-vivo re-enforces in-vitro data obtained for humans which to some degree 
has been disregarded. The properdin research field has become stagnated due 
to the ability of properdin to aggregate upon improper storage and the risk of 
contaminating C3. In the past, both issues generally have been left unaddressed 
in manuscripts, leading to disregard for the pattern recognition capabilities 
of properdin in the complement field. In chapter 5 our results indicated that 
properdin binding to neutrophil enzymes occurred in the absence of aggregated 
properdin or any detectable C3. These findings confirm that properdin is indeed 
a pattern recognition molecule and can induce properdin-directed complement 
activation. Intriguingly, properdin bound various neutrophil enzymes such as 
proteinase 3 without inducing complement activation, suggesting a possible 
role in regulating properdin function. This may be an interesting avenue of 
investigation, as properdin has been shown to bind a normal activated neutrophil 
surface by an unknown mechanism independent of C3. Also, neutrophil 
extracellular traps (NETs) consisting of chromatin fibres, have been shown to 
act as a potent source of ANCA autoantigen including MPO and elastase. The 
ability to induce clearance of NETs may be modulated by the ability of MPO 
and elastase to anchor properdin with/without resulting complement activation. 
The understanding from this research line may be of particular interest in ANCA 
vasculitides and SLE, where NETs are believed to have a pathophysiological 
role (46, 47). We hypothesise that depending on the ligand that properdin binds 
initially, will determine the fate of complement activation. One could suggest 
that binding of a ligand to properdins C3b binding domain (TSR 4,5) may act as 
a modulator of AP activation, by affecting AP regulation.
The novel ability of monomeric CRP to interact in solution with properdin 
(Chapter 6) and to prevent properdin-directed complement activation is certainly 
an open research field. Firstly, activated platelets and apoptotic bodies have been 
shown to generate monomeric CRP (40). In parallel the same structures have 
demonstrated the ability to bind properdin (22, 23). It would be tempting to 
speculate that the generation of monomeric CRP by dying cells may be a means 
to prevent uncontrolled complement activation in the surrounding tissue, by 
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preventing properdin-mediated complement activation allowing for C1q mediated 
apoptotic cell clearance. However it is likely that the situation is more complex, as 
monomeric CRP has been shown to bind various complement proteins (48). This 
would suggest that it may depend on which complement pathway pre-dominates 
the local area of inflammation or disease setting. The ability of IL-6 to induce 
complement component and CRP production could speculatively suggest an 
archaic means of negatively regulating any uncontrolled complement activation 
by dissociation of the increased available CRP.
The focus in chapter 7 is the delicate balance between factor H and properdin, 
all of which is dependent on its sites of production and regulation. Previous 
studies have demonstrated by RT-PCR that DCs can express many components 
of the complement system (29, 49), however protein data to support this has been 
limited. Furthermore there is only limited data available on the regulation of AP 
component production by DCs or particularly tolDC populations. This avenue of 
investigation focusing on regulation would be particularly interesting for white 
blood cells or stromal cells. It would aid in generating a complement profile for 
respective cells which can infiltrate a tissue acting as local source of complement 
or those resident in certain organs such as in immune privileged sites. Properdin 
production has primarily been linked to white blood cells, however there is little 
data available on the isoforms of properdin which are produced by various white 
cells including neutrophils. We believe this is of particular interest due to the 
increased potency of larger isoforms of the molecule (50). Additionally, the 
factor H family is ever expanding and we believe characterisation of the factor 
H members produced by white cells may be instrumental due to the pleiotropic 
range of capabilities that exists within the family. We observed two smaller 
bands of factor H being produced constitutively, which demonstrates that DC 
alone produce more than just the conventional 150kDa full length protein (Fig 2)
(O`Flynn, Dixon unpublished). The observed bands were located at approx. 34kDa 
and 30kDa. This could lead to the hypothesis that the 34kDa may be indicative 
of factor-H-like protein 1 (FHL1), which has an approximate size of  42 kDa (4). 
Figure 2: Factor H present in dendritic cells. DC or tol DC stimulated with IL-27 over 
time up to 24hrs and probed for the presence of factor H and β-actin.
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The other 30kDa band may be another member of the expanding factor H family 
such as the factor H related proteins (51) or as yet an unidentified protein. The 
bands appear to be present in both DC and tolDC without stimulation, with IL-27 
inducing some apparent increases within the cell. These findings require further 
investigation regarding characterisation of both bands and probing for the relevant 
factor H family members using specific monoclonal antibodies. Interestingly, 
FHL1 has been shown to have a role in cell attachment (4), it would be intriguing 
to investigate its role in DC adhesion during steady state or activation.  
Local production of complement components such as C3 by APCs at the site of 
inflammation or immunological synapse has been shown to be instrumental in 
the immune response (42). With the demonstration that local AP activation at the 
interface of APC and T cells plays a key role in the regulation of T cell responses 
(52), regulation of the AP in the local environment will be key in controlling 
the strength of the T cell response. Combined both properdin and FH have the 
ability to influence the balance of the AP towards activation or regulation. The 
novel emerging role of both regulators in the APC T cell synapse is of particular 
interest, as they have previously been ignored in this setting. It would be 
interesting to investigate in more detail the functional characteristics of the T cells 
induced upon silencing of the respective DC regulators, including their respective 
cytokine profile. As we have seen earlier with IFNγ, the cytokine environment 
can dramatically affect production of both regulators by DC, the resulting T cell 
cytokines may alter the AP balance within the local environment. In particular 
an open avenue of investigation is what the role of properdin or factor H derived 
from T cells may play in the immunological synapse and whether T cell cytokines 
such as IFNγ may regulate its production. 
The ability of the complement system to recognise foreign or noxious antigens 
inducing an acquired immune response has been illustrated over the years. The 
ability of C3d to act as an adjuvant in lowering the threshold for a B cell to 
induce this response was instrumental in demonstrating the role of complement 
in the adaptive immune response (2). The ability to activate B cells, inducing 
proliferation and expansion, requires antigen stimuli and T cell help (CD40 ligand 
stimulation) (53). Obviously the pathway of complement activation leading to C3 
activation can depend on what antigenic biochemical structures is recognised i.e 
mannan or DNA resulting in antibody production. One could hypothesise that 
since the AP can become easily auto-activated and induce such quick deposition 
of C3b on a surface it would be an intriguing mechanism to investigate in the B 
cell-T cell synapse involved in the adaptive immune response to certain antigen. 
With regulation being a key feature in the AP, assessing the role of lymphocyte 
derived regulators such as properdin or factor H in the synapse of B cell-T cell 
interactions would be particularly interesting.
142   •  Chapter 8 
8.6 Conclusions
Our studies primarily encompassed the alternative pathway focusing mainly on 
regulation by factor H and properdin. Herein, we demonstrated that properdin has 
a wider repertoire of functions than only stabilising the C3 convertase. Our in-vivo 
results supported the ability of properdin to act as a pattern  recognition molecule 
independent of C3b. Our in-vitro data illustrated that properdin can bind various 
new ligands supporting the properdin-directed model, and the existence of a novel 
inhibitor of properdin and the resulting complement activation. DC exhibited the 
ability to act as a potent source of both regulators and the unique effect of IFNγ 
stimulation on modulating of their production. The unexplored importance of DC 
derived factor H and properdin was illustrated by their opposing effects on T cell 
immunity, thereby highlighting their novel role in modulating the T cell immune 
response. 
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Nederlandse samenvatting
Onder normale fysiologische omstandigheden is ons lichaam beschermd door ons 
immuunsysteem tegen aanvallen van micro-organismen, zoals bacteriën, virussen 
en parasieten. Het immuunsysteem bestaat uit ons natuurlijk immuunsysteem en 
het verworven immuunsysteem. 
Bij onze geboorte zijn we vooral afhankelijk van ons natuurlijk immuunsysteem 
geholpen door antilichamen die wij via de navelstreng krijgen van onze moeder. 
Deze antilichamen zijn vooral gericht tegen pathogenen die in de omgeving te 
vinden zijn. Op deze wijze zijn we in de eerste maanden van ons leven goed 
beschermd voor aanvallen van buiten. In de loop van de tijd bouwen we onze 
eigen verworven afweer op.
Bij autoimmuniteit kan het individu ook een immuniteit opbouwen dat gericht 
is tegen onderdelen van het individu zelf. Deze immuunreactie kan uiteindelijk 
leiden tot schade aan weefsel en ziekte veroorzaken zoals bij gesystematiseerde 
Lupus Erythematosus (SLE), waarbij oa. antilichamen worden gemaakt tegen de 
glomerulus basaal membraan (GBM) van de nieren en tegen het cytoplasma van 
neutrofielen. Dit kan leiden tot ontsteking in nieren en andere bloedvaten.
Het immuunsysteem wordt opgebouwd door een groot aantal verschillende 
cellen zoals T cellen, B cellen, macrofagen, neutrofielen en dendritische 
cellen. Daarnaast zijn er verschillende eiwitten zoals die welke zorgen voor de 
bloedstolling of voor de directe natuurlijk afweer, complement.
Het complement systeem is een zeer belangrijke pijler van onze natuurlijke 
afweer en het speelt ook een essentiële rol bij de inductie en versterking van de 
verworven afweer. Het complement systeem is onder normale omstandigheden 
niet geactiveerd. Activatie van het complement systeem kan plaats vinden via 
drie verschillende routes nl. de klassieke-(CP), de alternatieve-(AP) en de lectine-
(LP) route. Elk van deze routes wordt geactiveerd na specifieke herkenning 
van liganden die voor komen op bijvoorbeeld bacteriën, virussen en antigeen-
antilichaam complexen. De klassieke route wordt geactiveerd na herkenning 
van een pathogeen of antigeen-antilichaam complex door C1q. Bij de LP 
zijn mannose bindend eiwit (MBL) en Ficolines betrokken terwijl bij de AP 
properdine een belangrijke rol speelt als herkenningsmolecuul. Als herkenning 
door complement optreedt, bijvoorbeeld op een pathogeen, dan kan dit door 
activatie van het complement systeem leiden tot schade en tenslotte eliminatie. Als 
complement activatie geïnduceerd wordt door bijvoorbeeld autoantilichamen dan 
zal dit complement juist schade van eigen weefsel veroorzaken. Om overmatige 
complement activatie in de hand te houden wordt het activatieproces in bedwang 
gehouden door verschillende complement remmers zoals factor H en factor I.
In hoofdstuk 2 hebben wij de rol van complement onderzocht bij SLE. Eerder 
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onderzoek van onze onderzoeksgroep heeft aangetoond dat een percentage van 
patiënten met SLE autoantilichamen maken tegen C1q. Het bleek dat patiënten 
met anti-C1q antilichamen vaker te kampen hebben met nierontstekingen (Lupus 
Nefritis). Tijdens Lupus Nefritis is er vooral schade aan nierendotheelcellen. 
Wij vonden in ons onderzoek dat C1q via specifieke receptoren in-vitro kan 
binden aan endotheelcellen. Als er autoantilichamen tegen C1q aanwezig zijn, 
kunnen deze antilichamen via het C1q binden aan het endotheel en verdere 
complement geïnduceerde schade aan de cellen veroorzaken. Bij SLE worden 
ook autoantilichamen gevonden tegen DNA en nucleosomen. Wij vonden in ons 
onderzoek dat er meer schade aan endotheel kan optreden als autoantilichamen 
tegen C1q en nucleosomen tegelijkertijd aanwezig zijn. Deze resultaten wijzen 
bij autoimmuun-aandoeningen op een gecoördineerde samenwerking tussen 
autoantilichamen gericht tegen verschillende eigen antigenen en complement.
In hoofdstuk 3 werd de rol van properdine onderzocht in een experimenteel 
model van antilichaam gemedieerde nierziekte. Van oudsher is aangetoond dat 
properdine een positieve regulator is van de alternatieve C3 convertase. Recent 
is echter ook aangetoond dat properdine net als C1q en MBL direct bepaalde 
liganden op bijvoorbeeld bacteriën of beschadigd eigen weefsel kan herkennen en 
de AP activeren. Bij antilichaam-geïnduceerde ontstekingen speelt de klassieke 
route van complement een essentiële rol. Echter in verschillende experimentele 
modellen is gevonden dat ook de AP betrokken is bij de voortgang van de ziekte. 
In tegenstelling tot wat wij hadden verwacht vonden wij niet minder nierschade 
in een antilichaam-geïnduceerde nierontsteking in properdine knockout muizen. 
Een mogelijke verklaring is dat de hoeveelheid antilichaam die toegediend is 
zodanig hoog was dat er geen additief effect van complement waarneembaar 
is. Dit is in overeenstemming met de vondst dat onder vergelijkbare condities 
ook in C3 knockout muizen geen belangrijk verschil met wildtype muizen werd 
gevonden. De bevinding is in tegenstelling tot een eerder model van antilichaam-
geïnduceerde nierziekte waarbij een mildere vorm van nierziekte werd opgewekt.
Recent onderzoek bij patiënten met een ANCA-gemedieerde vasculitis hebben 
duidelijk gemaakt dat complement en vooral de AP geactiveerd is in nieren 
van deze patiënten. De vraag die wij in hoofdstuk 4 hebben gesteld is of er 
een directe herkenning is door properdine van de autoantigenen die bij ANCA-
gemedieerde nierziekten betrokken zijn en of properdine op die wijze kan 
bijdragen tot complement-geïnduceerde ontsteking. Inderdaad vonden wij dat 
myeloperoxidase (MPO), een belangrijk autoantigeen, properdine bindt en op 
die manier directe activatie van de AP van complement op gang brengt. Dit is 
een belangrijke vondst want het verklaart niet alleen de betrokkenheid van de 
AP bij deze vorm van ziekte maar verschaft ook een inzicht op welke wijze 
eigen antigenen die beschikbaar komen bij ontstekingen herkend kunnen worden 
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door onze eigen natuurlijk afweer en leiden tot versterkte ontsteking. Tevens 
verschaffen deze vondsten een inzicht hoe MPO als platform kan functioneren 
bij schade geïnduceerd door neutrofiele granulocyten.
Zoals eerder genoemd is properdine de enige positieve regulator van het 
complement systeem. Dit bewerkstelligt properdine door de stabiliteit van de 
alternatieve C3 convertase te verhogen. Dit heeft als voordeel dat de mate van 
complement activatie op bijvoorbeeld pathogenen versterkt wordt en kan leiden tot 
schade aan deze pathogenen. Aan de andere kant zou properdine bij autoimmuniteit 
juist kunnen zorgen voor meer weefselschade. Om de functie van properdine 
verder te kunnen bestuderen is in hoofdstuk 5 in detail de methode beschreven 
hoe properdine geïsoleerd kan worden uit menselijk serum. In hoofdstuk 6 
laten we zien dat weefselschade in een in-vitro model van schade aan niercellen 
wordt beperkt door ‘C-reactive protein’ (CRP). Eerder onderzoek binnen ons 
laboratorium heeft laten zien dat proximale tubulus cellen (PTEC) properdine 
binden via heparansulfaat op deze cellen en complement schade induceren. In 
dit hoofdstuk laten we zien dat CRP een complex aangaat met properdine en de 
binding van properdine aan PTEC blokkeert. Een gelijksoortige vondst werd ook 
met apoptotische cellen waargenomen. Dit zou kunnen betekenen dat CRP de 
mate van properdine gerelateerde schade in-vivo zou kunnen beperken.
Zoals bekend spelen dendritische cellen een cruciale rol bij de presentatie 
van antigenen bij de inductie van de verworven afweer. Van deze cellen is 
eerder aangetoond dat ze verschillende complementfactoren produceren. Uit 
verschillende studies is komen vast te staan dat deze complementfactoren een 
belangrijke rol spelen bij de herkenning van antigeen door dendritische cellen. 
In hoofdstuk 7 hebben wij de vraag gesteld of properdine en factor H worden 
geproduceerd door DC en zogenaamde tolerogene DC. Van tolerogene DCs wordt 
gedacht dat zij de verworven immuniteit ten voordele van het individu reguleren. 
Inderdaad werd gevonden dat zowel DCs als tolDCs factor H en properdine 
produceren. Stimulatie van de cellen met interferon (IFN)-gamma liet een 
verhoogde productie van factor H door beide cellen zien terwijl de productie van 
properdine juist verlaagd was. Deze bevinding was uniek voor IFN-gamma want 
stimulatie met LPS of IFN-alfa vertoonde dit effect niet. Door gebruik te maken 
van remming van productie van properdine of factor H op celniveau konden wij 
de tegengestelde functies van factor H en properdine verder bevestigen. Deze 
studies tonen aan dat properdine en factor H een regulerende rol hebben in de 
functie van DCs.
Samenvattend: in dit proefschrift hebben wij verschillende aspecten van 
complement bestudeerd die van belang zijn bij autoimmuunziekten. Ook hebben 
wij inzicht verkregen hoe properdinefunctie op weefselniveau geregeld wordt 
door CRP. Tenslotte hebben wij inzicht verkregen hoe MPO als platform voor 
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alternatieve route activatie via properdine kan induceren.
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Summary
In a normal situation your body is protected from insults (viruses, bacteria and 
parasites) by the immune system. The immune system consists of a powerful set 
of tools which function to protect the host and maintain the normal physiological 
state. In autoimmunity, the immune system attacks the body itself inducing 
damage, generally due to a combination of genetic and environmental factors. 
The damage induced by autoimmunity can result in various illnesses known as 
autoimmune diseases. Systemic lupus erythematosus (SLE), anti-glomerular 
basement membrane (GBM) and anti-neutrophil cytoplasmic antibody (ANCA) 
vasculitides are examples of autoimmune diseases all of which can target the 
kidney. 
The immune system is an intricate collection of cells and proteins which interact 
to form a potent tool for the body. The cells of the immune system include white 
blood cells such as dendritic cells and neutrophils, while the proteins vary from 
antibodies and clotting factors to the complement system. If the body is damaged 
(cut) and becomes infected (by bacteria), the site of injury becomes the focal point 
of cells and proteins of the immune system to help resolve and heal the damaged 
site. Resolution of the injury by the immune system is typically achieved when 
the key signs of inflammation e.g swelling, pain, redness and heat are removed 
from the site of injury.
The complement system is a key member of the immune system. The system is a 
collection of proteins found in circulation which have a role in removing infections 
or injured/dying cells. The complement system is divided into three pathways the 
classical pathway (CP), lectin pathway (LP) and alternative pathway (AP). The 
CP is activated by the initiator protein C1q while the LP generally requires the 
protein mannan binding lectin (MBL) to act as a recognition molecule for LP 
activation. The alternative pathway is the oldest of the pathways and can become 
auto-activated should it be left uncontrolled. It consists of various proteins 
including complement C3, factor B, factor D and properdin. The AP can become 
activated in seconds allowing it to act as a potent pathway in the complement 
system. Due to its swift capability in becoming activated, the AP requires tight 
regulation. Properdin promotes AP activation by stabilising the pathway, while 
factor H inhibits AP activation, allowing both proteins to regulate the level of 
complement activation.
In chapter 2, we investigated the role the complement system plays in lupus 
nephritis, the renal manifestations in SLE. Earlier studies from our department 
have shown that anti-C1q antibodies are strongly associated with renal disease in 
patients with SLE. During lupus nephritis, the endothelial cells are the principle 
target. We investigated how autoantigens targeted during SLE, e.g C1q, interact 
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with the cells and whether it supports complement activation. The autoantibodies 
bound to the endothelial cells and supported CP complement activation, suggesting 
a mechanism of damage in lupus nephritis. The findings demonstrate the close 
relationship between classical pathway components, such as C1q and anti-C1q 
autoantibodies, which may play a role in the development of lupus nephritis. 
Properdin is a key member of the AP, with its traditional function stabilising the 
AP by binding activated C3. In recent years a novel role for properdin has been 
proposed whereby it acts as a pattern recognition molecule, initiating the AP 
thereby expanding its possible roles in disease states. The AP has been implicated 
in various renal autoimmune diseases including ANCA vasculitides and anti-
GBM disease. Both diseases have an autoantibody component which would 
suggest CP activation. However the AP is also implicated in both diseases but 
the exact mechanism is unknown. In chapter 3, we investigated the role of the 
AP, in particular properdin, in an in-vivo model of anti-GBM disease. We found 
that deficiency of properdin or C3 in-vivo did not protect from renal damage as 
compared to the normal control. We demonstrated that properdin levels increased 
in circulation during the disease time course, while properdin was also deposited 
at the site of injury in the kidney. Interestingly, properdin was deposited in the 
kidney independent of C3, suggesting that also here properdin can act as a pattern 
recognition molecule. This is to our knowledge the first proof of properdin binding 
independent of C3 in-vivo, supporting the earlier proposed ability of properdin to 
act as a pattern recognition molecule.
The AP is intricately implicated in neutrophil mediated diseases including ANCA 
vasculitides, but its exact role in the disease is still unclear. In chapter 4 we isolated 
human properdin which in chapter 5 we used to investigate its interaction with 
neutrophil components and the capacity to direct AP activation. The neutrophil 
enzymes myeloperoxidase (MPO) and proteinase 3 (PR3) are the main targets in 
ANCA vasculitides. Properdin bound to lysozyme, cathepsin G, elastase, PR3 and 
in particular MPO. MPO exposed to serum is capable of inducing C3 deposition, 
which was significantly reduced with properdin-deficient serum. More in-depth 
analysis revealed that binding of properdin to MPO supported AP-mediated 
C3 deposition and increased generation of C5b-9, indicating AP activation. 
The results indicated a new role for MPO in activating the complement system 
and illustrate its ability to support properdin-directed complement activation. 
Interestingly, various neutrophil enzymes bound to properdin without the ability 
to activate complement (as shown for MPO), suggesting additional mechanisms 
of regulating properdin in the context of neutrophil degranulation.
As mentioned earlier, properdin may act as a stabiliser or initiator of the AP. In 
recent years, properdin has been shown to bind proximal tubular epithelial cells 
(PTEC) in the kidney following injury to the organ. Furthermore, in-vitro data 
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demonstrated that properdin can bind to the cells initially and act as an initiator 
for AP activation on its cell surface. Recent studies from various groups have 
indicated that an inhibitor of properdin may exist in-vivo, however the exact 
identity of the molecule remains unknown. In chapter 6, we investigated whether 
properdin binding could be inhibited by normal human serum, possibly confirming 
the existence of an inhibitor. Our data showed that human serum inhibited the 
ability of properdin to bind to PTEC. Our studies focused on C-reactive protein 
(CRP), both the pentameric CRP and the dissociated form, monomeric CRP. 
We demonstrated that specifically monomeric CRP could inhibit properdin 
binding to viable PTEC, whereas pentameric CRP did not exhibit such activity. 
Interestingly, monomeric CRP could in solution form a complex with properdin, 
while its larger pentameric form was unable to do so. The ability of monomeric 
CRP to inhibit properdin binding to PTEC, impeded properdin-directed C3 
deposition and C5b-9 generation on these cells. More importantly, this inhibitory 
feature of monomeric CRP was not unique for the binding of properdin to PTEC, 
since it also prohibited properdin binding to necrotic Jurkat cells. These findings 
indicate that properdin is capable of binding to a dissociated form of pentameric 
CRP in solution, further expanding its capability to bind various other ligands 
independent of C3. Moreover, the binding of monomeric CRP to properdin and 
inhibition of properdin-directed AP activation reveals a novel role for CRP in 
regulating complement activation.
Properdin can exist in various forms including dimers, trimers, tetramers as well 
as pentamers and is found in the bloodstream at a concentration of approximately 
25µg/ml. Typically most complement components are produced by the liver, with 
certain components such as C1q or properdin produced by white blood cells. The 
white blood cells can act as potent reservoirs of complement components at the 
site of damage or insult. The ability of the AP to become autoactivated makes it 
increasingly susceptible to the AP regulators, properdin and factor H.  Activation 
of the AP by properdin is counter-acted by factor H, the most prominent negative 
regulator of the AP. Our aim in chapter 7 was to investigate whether human 
monocyte derived dendritic cells (DC) or tolerogenic (tolDC) can act as a source 
of properdin and factor H, and whether this production can be modulated. Our 
studies demonstrated the constitutive capability of DC to produce properdin and 
factor H, with higher levels of both AP components produced by tolDCs. Upon 
activation with IFNγ both cell types showed an increased FH production, while 
simultaneously decreasing the production of properdin. This was unique for 
IFNγ as LPS and IFNα or IFNβ did not demonstrate this dual regulation. IL-27, a 
member of the IL-12 family which elicits features of IFNγ, did increase production 
of FH, but FP remained unaffected. This prompted us to investigate if either 
DC-derived regulators of the AP had a role in the DC T cell synapse. Therefore 
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we silenced production of properdin or factor H in DCs, and investigated the 
impact on allogenic T cell activation. Interestingly, silencing of factor H in DC 
resulted in an increased T cell proliferation. In contrast, silencing of properdin 
in DC diminished their allostimulatory capability. Cumulatively, these results 
indicate the importance of both AP regulators, guiding the AP towards activation 
or regulation. 
Our studies mainly encompassed the alternative pathway focussing on regulation 
by factor H and properdin. We demonstrated that properdin has a wider repertoire 
of functions than only stabilising AP activation. Our in-vivo results supported 
the ability of properdin to act as a pattern recognition molecule independent 
of activated C3. Our in-vitro data illustrated that properdin can bind various 
new ligands supporting the properdin-directed model of AP activation, and the 
existence of a novel inhibitor of properdin to control complement activation. 
DC exhibited the ability to act as a potent source of both AP regulators and 
the unique effect of IFNγ stimulation on modulation of their production. The 
unexplored importance of DC derived factor H and properdin was illustrated by 
their opposing effects on T cell immunity.
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Athchoimre
Go hiondúil tugann corás díolúine an duine cosaint don chorp ó ghalair éagsula, 
mar shampla, víorais, baictéir agus séadáin. Tá uirlísí éifeachtacha ag an corás 
diolúine a chosnaíonn an óstach agus a choimeádann an staid fisiceach go normálta. 
San uathadhíonacht, ionsaíonn an corás díoluine an colainn feín, rud a dhéanann 
damáiste, de gnáth de bhárr comhcheangal idir factoír timpeallachta agus factoír 
gineolaíochta. De thoradh an dochar sin a spreagann an corás díolúine, bíonn galair 
a ghlaoitear galair uathadhíonachta orthu. Samplaí de na galair uathadhíonachta 
sin a dhéanann ionsaí ar an duán is ea: lupus erythemitosus eagraithe, scannán 
íochtarach frithghlomearúl (GBM) agus frithchoirpín féadánacha frithneódrúfil 
ciotaplasmacha (ANCA).
Is bailiúchán chasta de chealla agus protéin an córas diolúine a dhéanann 
comhcheangal chun mílís cumagach don cholann a chruthú. I measc cealla an 
chóras díolúine tá cealla bána fola, mar cealla dendritic agus neutrophil agus na 
proitéin a chomhlánaíonn an córas leis na frithchoirp agus na factoír téachtáin. Má 
dhéantar dochar don chorp agus má bhíonn galrú ann (tré bhacteír) díríonn cealla 
agus protein an chóras diolúine an gortú go hiondúil nuair atá na comharthaí 
tábhachtacha athlasadh le feiceáil mar shampla, borradh, pian, teas agus deargú 
imithe ó ionad an ghortú.
Is baill an-thábhachtach an córas comhlánú den córas diolúine. Is bailúchain 
proitéin an córas comhlánú a oibríonn chun galair agus cealla gortaithe agus 
cealla atá ag dul in éag a thógáil amach ón gcolann. Tá an córas comhlánú roinnte 
i dtrí cosán, an cosán claisiceach (CP), an cosán lectin (LP) agus an malairt cosán 
(AP). Gníomhaítear an cosán claisiceach trí an tosaitheoir proitéin C1q agus 
gníomhaítear an cosán lectin trí MBL. Is é an malairt cosán an cosán is aosta 
agus is féidir é a uath ghníomhú mura cuirtear é fari smacht. Tá proitéin eagsúla 
ann, an comhlánú C3, factoír B, factoír D agus properdin curtha san áireamh. Is 
feidir an malairt cosán a ghníomhadh i soicind mar cosán éifeachtach sa chóras 
comhlánú. Dá bhrí sin caithfear rialachaín daingear a choinneáil air. Costaíonn 
properdin gníomhú AP trí an cosán a dhaingniú, stopann factoír H gníomhú AP a 
ligeann don dhá phroitéin gníomhú an comhlánú a rialadh.
I gcaibidil 2 rinnemar imscrudú ar an ról atá ag an corás chomhlánú i lupus 
nephritis, ar na taispeantais dúanách i SLE. I staidéir níos luaithe as an rannóg seo 
tá sé leírithe go bhfuil baint laidir idir frithcomhlachtaí frith-C1q le galair dúanach 
in othair le SLE. Le linn lupus nephritis is iad na cealla endothelial an príomh 
sprioc. Rinneamar imscrudú ar conas a idirghníomhaíonn antaigíní-uathoibríoch 
spriochdhírithe le linn SLE, mar shampla C1q, leis na cealla agus cibé an 
dtacaíonn sé le gníomhachtaithe comhlánú. Déanann na antaigíní-uathoibríoch, a 
cheangal ar na cealla endothelial le tacaíocht CP, gníomhachtaithe comhlánú rud 
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a thugann le tuiscint go bhfuil meicníocht damáiste i lupus nephritis. Leíríonn na 
torthaí seo an gaol dlúth idir comhpháirteanna cosáin clasaiceach, mar shampla 
C1q agus frith-C1q antasubstaintí-uathoibríoch, gur feídir ról a imirt i bhforbairt 
lupus nephritis.
Tá properdin ina bhaill tábhachtach den AP, a bhfuil an feidhm thraidisiúnta aige 
an AP a chobhsú trí AP gníomhachtaithe a cheanglú. Sna blianta beaga anuas, 
tá ról úr do properdin molta ina gníomhaíonn sé mar móilín a aithníonn patrúin, 
agus a chuireann tús leis an AP, rud a leathnaíonn an ról is feídir a bheith aige i 
stáit galair. Tá baint ag an AP le galair auto-imdhíonachta duánach éagsúla lena 
n-áiritear vasculitides ANCA agus galair frith-GBM. Tá comhphaírt uathoibríoch-
antasubstainte ag an dá galair rud a thugann le fios go bhfuil gníomhachtaithe 
CP ann. Comh maith le sin tá an AP i bhfeidhm freisin sa dá galair, ach nach 
bhfuil aithne cruinn ar an mheicníocht fós. I gcaibidil 3 rinnemar imscrúdú ar 
an ról atá ag an AP, properdin go haírithei múnla in-vivo de ghalar frith-GBM. 
Fuaireamar amach nár chosain easnamh de properdin nó C3 in-vivo damáiste 
duánach i gcomparaíd leis an gnáth rialú. Leírigh muid gur mhéadaigh na leibhéil 
properdin i gcúrsaíocht le linn chúrsa ama an ghalair, cé go raibh properdin i 
dtaisce ag an suíomh díobhála sa duáin. Suimiúil go leór, bhí properdin i dtaisce 
sa duáin neamhspleach ar C3, rud a thugann le tuiscint gur féidir le properdin 
ghíomhú mar móilín a aithníonn patrúin. Seo an chéad cruthúnas, comh fada 
agus is eol duinn, go gceanglaíonn properdin neamhspleach ar C3 in-vivo. Rúd 
a thugann tacaíocht leis an cumas, atá molta níos luaithe, atá ag properdin chun 
gníomhú mar móilín a aithníonn patrúin.
Tá an AP gafa go hachrannach i ngalair idirgabhálta neutrophil lena n-áiritear 
vasculitides ANCA, ach go bhfuil ról beacht an galair fós doiloír. I gcaibidil 4 bhí 
properdin daonna scoite again agus a bhí á usáid again i gcaibidil 5 chun imscrúdú 
a dhéanamh ar idirghníomhaíocht le comhpháirteanna neutrophil agus an cumas 
chun AP gníomhachtaithe a ordú. Is iad na heinsímí neutrophil myeloperoxidase 
(MPO) agus proteinase 3 (PR3) na príomh spriocanna i vasculitides ANCA. Tá 
properdin ceangailte go lysozyme, cathepsin-G, elastase, PR3 agus go háirithe 
MPO. Nuair atá MPO nochtaiste le serum is feídir leí taisce C3 a thosnú, rud a bhí 
laghdaithe go mór le serum easnamhach properdin. Thug anailís níos doimhne 
faoi deara gur chuidigh ceangailt properdin le MPO, AP idirgabhálta le taisce C3 
agus gur mhéadaigh sé gininint de C5b-9, ag tabhairt faoi deara gníomhachtaithe 
AP. Tugann na torthaí le tuiscint go bhfuil ról nua ag MPO i gníomhú an córas 
comhlánú, agus léiríonn a chumas chun cuidin le gníomhú properdin dírithe 
comhlánú. Suimiúl go leor tá einsímí neutrophil ceangailte le properdin gan an 
cumas acu an comhlánú a ghníomhú  (mar a taispeánadh le MPO), ag cur in 
iúl níos mó meicníochtaí chun properdin a rialú i gcomhthéacs degranulation 
neutrophil.
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Mar a luadh cheana, is féidir le properdin a ghníomhadh nar cobhsaitheoir nó 
tosaitheoir den AP. Le déanaí, taispeánadh gur cheangail properdin le cealla 
proximal tubular epithelial (PTEC) ins an duáin i ndiaidh gortú den organ. 
Chomh maith le sin thaispeáin sonraí in-vitro gur feídir le properdin ceangailte 
lena cealla sa chéad áit agus gníomhadh mar tosaitheoir do gníomhachtaithe AP 
ar dhromchla den cheall. Thaispeáin staideár ó ghrupaí éagsúla le déanaí gur 
féidir le coscaitheoir de properdin a bheith láithreach in-vivo, ach mar sin féin níl 
eolas fós ar céannacht dearfa den móilín. I gcaibidil 6 rinnemar inscrúdú ar feídir 
ceangailt properdin a choscadh le serum normálta an dhuine, chun a dheimhniú 
b`fhéidir go bhfuil coscaitheoir ann. Thaispeáin ár sonraí gur chuir serum ar 
dhuine cosc ar chumas properdin ceangailt le PTEC. Bhí ár staideár dírithe 
ar proiteín C reactive (CRP), an pentameric CRP agus an fhoirm dhealaithe, 
monomeric CRP. Thaispeáneamar go háirithe gur féidir le monomeric CRP cosc 
a chur ar cheangailt properdin do PTEC inmharthana, ach mar sin féin nár chuir 
pentameric CRP gníomhú mar sin in iúl. Go suimiúl, i bhfoirm lacht is feídir 
monomeric CRP compleásc a dheánamh le properdin, mair nár feídir leis an 
bhforim níos mó pentameric é sin a dhéanamh. Chuir an cumas atá ag monomeric 
CRP cosc a chur le properdin ceangailt le PTEC, bac ar properdin dírithe taisce 
C3 agus giniúmt C5b-9 ar na cealla seo. Níos tábhachtaí níl an tréith coscaithe seo 
de monomeric CRP uathúil i leith ceangailt de properdin le PTEC, os rud é gur 
chuir sé cosc ar properdin ceangailt le cealla jurkat necrotic. Léiríonn na torthaí 
seo gur féidir le properdin ceangailt le foirm dealaithe de pentameric CRP mair 
atá sé tomtha i lacht, ag leathanú a cumas chun ceangailt le ligands áirithe eile 
neamhspleách ar C3. Níos mó na sin, taispeánann an ceangailt atá ag monomeric 
CRP le properdin agus an cosc ar properdin dírithe AP gníomhachtaithe ról faoi 
leith do CRP i rialú gníomhachtaithe comhlánú.
Is féidir le properdin maireachtáil i bhfoirmeacha áirithe lena n-áirítear dimers, 
trimers, tetramers chomh maith le as pentamers agus atá le fáil i sruth na fola 
ag tiúchan de thart ar 25µg/ml. De ghnáth is comhphairteanna chomhlánú a 
thairgtear ag an ae, ach go bhfuil comhphairteanna áirithe mar C1q nó properdin 
tairgthe ag na cealla bána fola. Is féidir leis na cealla bána fola gníomhú mar 
taiscumair cumhachtach de na comhphairteanna comhlánú ag láthair an damáiste 
nó gortú. Déanann cumas an AP a bheith uathoibríoch é níos so-ghabhálaí do na 
rialtóirí AP, properdin agus fachtóir H (FH). Déananna fachtóir H frithghníomh ar 
gníomhú an AP le properdin, an rialtóir diúltach is suntaisí den AP. Is é an aidhm 
a bhí again i gcaibidil 7 ná imscrúdú a dhéanamh ar cibé an féidir cealla dendritic 
(DC) monocyte daonna nó tolerogenic (tolDC) gníomhú mar fhoinse properdin 
agus fachtóir H, agus cibé an féidir an tairgeadh seo a mhodhnú. Thaispeáin ár 
gcuid staidéar an cumas comhpháirteach de DC, properdin agus fachtoir H a 
thairgeadh, le leibhéal níos airde ag an dá comhpháirteanna AP tairgthe le tolDC. 
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Nuair atá said gníomhaithe le IFNγ thaispeáin an dhá saghas cealla tairgeadh 
méadaithe de FH, ach san am chéanna ag déanamh laghdú ar tairgeadh properdin. 
Bhí sé se ar leith do IFNγ mar mór thaispeáin LPS agus IFNα nó IFNβ an rialú 
dúbailta seo. Rinne IL-27, baille den chlann IL-12 a thaispeánann treithe IFNγ, 
tairgeadh de FH a mhéadú, ach ní dhearna sé aon difríocht do properdin. Spreag 
sé seo muid chun inscrúdú a dhéanamh chun fáil amach an raibh ról ag rialitheoirí 
DC bunaithe den AP ag an sionapsa cille DC-T. Dá bhrí sin chiúnaíomar tairgeadh 
de properdin nó fachtóir H ins na DC, agus rinnemar inscrudú ar a thionchar 
ar gníomhachtaithé na cealla T allogenic. Suimiúl go leor, rinne an ciúnadh de 
fachtóir H in DC méadú ar lánú na cealla T. I gcodarsnacht, rinne an ciúnadh 
an properdin in DC laghdú ar a gcumas allostimulatory. Go carnach, leíríonn na 
torthaí seo an tábhacht a bhaineann leis an dhá rialaitheoirí AP ag treorú an AP i 
dtreo gníomhachtú nó rialachán.
Ins an staideár cuimsitheach a rinnemar, bhíomar dírithe ar an gcosán malartach 
a bhí dírithe ar rialachán fachtóir H agus properdin. Thaispeánamar go bhfuil stór 
níos leithe de feidhmeanna ná chobhsú gníomhachtaithe AP. Chuidigh ár dtorthaí 
in-vivo an cumas atá ag properdin chun gmómhadh mar moilín aithniúchán 
patrúin, neamhspleách ar C3 gníomhachtaithe. Thaispeáin ár sonraí in-vitro gur 
féidir le properdin ceangailt le ligands eágsúla nua ag cuidiú le samhail properdin 
dírithe de, AP gníomhachtaithe, agus go bhfuil coscaitheoir úr de properdin ann 
chun gníomhachtaithe comhlánú a smachtadh. Thaispeáin DC  go bhfuil cumas 
aige gníomhadh mar foinse láidir de dá rialaitheoir AP agus an éifeacht uathúil de 
spreagadh IFNγ ar mhodhnú a thairgeadh. Go dtí seo ní raibh taiscealadh deánta 
ar thábhacht DC dírithe, fachtóir H agus properdin mar a léiriú ag a tionchar 
contrálta ar diolúine cealla T.
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List of abbreviations
AAV  ANCA associated vasculitides
ABTS  2,2`-Azino-Bis(3-Ethylbenzthiazoline-6-Sulfonic acid)
AI  Autoimmune
ANCA  Anti-neutrophil cytoplasmic antibody
AP  Alternative pathway
APC  Antigen presenting cell
C3aR  C3a receptor
C4bp  C4 binding protein
C5aR  C5a receptor
CP  Classical pathway
CPM  Counts per minute
CR-1  Complement receptor-1
Ctrl  Control
DAF  Decay accelerating factor




FH  Factor H
FHL-1  Factor H like protein-1
FHR  Factor H related proteins
FITC  Flourescein isothiocyanate
FP  Properdin
GAS  Gamma-interferon-activation sites
GBM  Glomerular basement membrane
GEnC  Glomerular endothelial cell
HK-2  Human kidney-2
HRP  Horseradish peroxidase
HUVS  Hypocomplementemic urticarial vasculitis
IFN  Interferon
IgG  Immunoglobulin G
ISRE  Interferon-stimulated response element
KO  Knock out
LN  Lupus nephritis
LP  Lectin pathway
LPS  Lipopolysaccharide
mAb  Monoclonal antibody
MAC  Membrane attack complex
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MASP  MBL associated serine protease
MBL  Mannan binding lectin
MCP  Membrane co-factor protein
mCRP  Monomeric C-reactive protein
MPO  Myeloperoxidase
NETs  Neutrophil extracellular traps
NHS  Normal human serum
OD  Optical density
pCRP  Pentameric C-reactive protein
PEG  Polyethyleneglycol
PI  Propidium Iodide
PR3  Proteinase 3
PTEC  Proximal tubular epithelial cell
siRNA  Silencing RNA
SLE  Systemic lupus erythematosus
TMB  3-3,5,5-tetramethylbenzidine
TNF  Tumour necrosis factor
tolDC  Tolerogenic Dendritic cell
TSR  Thrombospondin repeats
VWA  von Willebrand factor type-A
WT  Wild Type
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